Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus

ABSTRACT

The invention describes formulations that include either metformin, sulfonylurea or a biguanide-sulfonylurea combination as one active ingredient in addition to specific, other active ingredients. The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of the included biguanide (metformin) and/or sulfonylurea in the prevention and treatment of insulin resistance and diabetes mellitus. The carefully chosen additional active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and those adverse incidences associated with the concurrent use of metformin and/or the sulfonylureas. When clinically administered, the invention will provide therapeutic levels of metformin and of a sulfonylurea, alone or in combination, and broaden their usefulness. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is related to U.S. provisional patentapplications nos. 60/278,296, filed Mar. 22, 2001, 60/278,270, alsofiled Mar. 22, 2001, and 60/278,271, also filed Mar. 22, 2001, all threeof which are incorporated herein by reference in their entirety. Thepresent application claims benefits from all three such provisionalpatent applications for all purposes legally capable of being servedthereby.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] This invention is in the field of pharmacology, and relates tomulti-component formulations, which contain metformin, a sulfonylurea ora combination of both, in concert with one or more other activeingredients, for use in the pharmacological treatment of insulinresistance and type 2 diabetes mellitus.

[0004] 2. Description of the Prior Art

[0005] Insulin resistance and non-insulin-dependent diabetes areprevalent in up to 35% of the population depending upon the age andnature of the subset. In the United States alone, 16 million people havetype 2 diabetes and 13 million have impaired glucose tolerance. In facttype 2 diabetes has reached epidemic proportions worldwide. By 2025, anestimated 300 million people will have diabetes, most of who willinhabit China, India, and the United States. Because of an aging andincreasingly sedentary, obese population with changing, unhealthy diets,insulin resistance is also increasing alarmingly (it is already two tothree times more prevalent than type 2 diabetes). This apparent increasein the prevalence of insulin resistance and type 2 diabetes occurs inall ethnic populations, but especially in those that have migrated fromtheir native lands to more urbanized and westernized regions of theworld.

[0006] Insulin resistance and type 2 diabetes exist not merely as partof the aging process, but also as a process that advances aging.Diabetes affects metabolism in totality: carbohydrate, lipid andprotein. Its causes and its management are very, very complex andstrikingly nonlinear.

[0007] Patients with diabetes of all types have considerable morbidityand mortality from microvascular (retinopathy, neuropathy, nephropathy)and macrovascular (heart attacks, stroke, peripheral vascular disease)pathology, all of which carry an enormous cost. For example: a)Proliferative retinopathy (the leading cause of blindness in the UnitedStates) and/or macular edema occur in about 50% of patients with type 2diabetes, as do peripheral and/or autonomic neuropathy. b) The incidenceof diabetic renal disease is 10% to 50% depending on ethnicity. c)Diabetics have heart attacks, strokes and peripheral vascular disease atabout triple the rate of non-diabetics. The cost of treating diabetesand its complications exceeds $100 billion annually. In addition tothese dreadful data, insulin resistance (a prelude to type 2 diabetes inabout 50% of those effected) with its associated hypertension,coagulopathy, dyslipidemia and obesity substantially adds to thesemorbidity, mortality and cost statistics.

[0008] There are two clinical forms of diabetes, each with a differentpathogenesis: type 1, insulin dependent diabetes mellitus and type 2,non-insulin dependent diabetes mellitus. The latter represents 90% ofall diabetics. In type 2 diabetes, cellular resistance to the functionaleffectiveness of insulin results in above normal levels of insulinsecretion. When this compensatory increase of insulin production cannotbe maintained, and/or when cellular insulin resistance increasesfurther, blood sugar rises, lipid and protein metabolism are disturbed,and the insidious processes of vascular complications of long-termdiabetes begin.

[0009] The fasting hyperglycemia of type 2 diabetes exists in thepresence of hyperinsulinemia; this reflects the presence of insulinresistance in the liver with resultant glycogenolysis andgluconeogenesis. In addition to the impaired insulin suppression ofhepatic glucose production, a decrease of insulin-mediated glucoseuptake by muscle cells contributes (about 50%) to the resultanthyperglycemia.

[0010] After ingestion of glucose, the maintenance of normal blood sugartherefore depends upon: 1) stimulation of insulin secretion; 2)insulin-mediated suppression of hepatic glycogenolytic and gluconeogenicglucose production, and 3) insulin-mediated glucose uptake by muscle.Although hyperglycemia has an independent, direct effect in suppressinghepatic gluconeogenesis and stimulating muscle glucose uptake, theseeffects are modest compared to those of insulin and are inadequate tocompensate for the countering effects of insulin resistance.

[0011] The congeries of micro and macro pathologies fromhyperinsulinemia and/or hyperglycemia have as causative mechanisms: freeradical damage, nonenzymatic protein glycation, lipoproteindisturbances, disturbances of physiological NO effects, reducedsynthesis of heparan sulfate and disorders of sorbitol and myoinositolmetabolism.

[0012] Free radical generation and induced nitric oxide synthase (iNOS)production secondary to the hyperglycemia of type 2 diabetes can lead topancreatic β-cell destruction, and the production of diagnosticenzymatic indicators characteristic of type 1 diabetes. This fact hasintroduced the term “type 1.5 diabetes”. In this scenario, β-cells arenot only “exhausted” by the progression of pathology from insulinresistance to type 2 diabetes, but may also undergo destruction inducedby chronic hyperglycemia.

[0013] Hypertension, dyslipidemia, coagulopathy, obesity and developmentof type 2 diabetes—all of which may follow chronic insulinresistance—are largely preventable, as are the eventual diabetic micro-and macrovascular complications. In those patients with insulinresistance who do progress to type 2 diabetes, successful treatmentrequires maintenance of blood glucose at a normal preprandial level (orat a postprandial level below 180 dl) and a hemoglobin A1c level below7.0%. This degree of glucose control is often not consistentlyattainable over long periods of time.

[0014] Likewise, good glycemic control avoids the impaired synthesis ofthe basement membrane proteoglycan, heparan sulfate, which accompanieshyperglycemia. Heparan sulfate is an essential component of the basementmembrane of many cells. Most importantly, it supports many of the normalfunctions of endothelial cells by maintaining the integrity of thebasement membrane and its anionic charge, both of which are critical inmaintaining physiologic membrane impermeability: It is the predominantglycosaminoglycan produced by the glomerular epithelial cells.Microproteinuria, due to its inadequacy in the glomerular basementmembrane, is one of the earliest, most consistent early signs ofdiabetes, and diabetic nephropathy is invariably associated withprogressive proteinuria. Reductions of heparan sulfate in the basementmembrane of retinal and renal capillaries also leads to the increasedcapillary permeability that occurs at both sites significantlycontributing to diabetic retinopathy and nephropathy .

[0015] Glucose tolerance declines with age because of: 1) increased cellreceptor resistance to insulin; 2) intracellular post receptordisturbances and 3) diminished pancreatic islet β-cell sensitivity toinsulin and glucose. Insulin resistance, with secondary hyperinsulinemiaand/or hyperglycemia, contributes to many disorders associated withaging, i.e., hypertension, obesity, atherosclerosis, lipidabnormalities, coagulopathies and chronic metabolic perturbationsincluding type 2 diabetes.

[0016] Although insulin resistance and type 2 diabetes each have aninherited pathogenic component, they both are substantially influencedby inappropriate diet and inadequate exercise.

[0017] In aging, as in diabetes, elevated circulating glucose reactsnonenzymatically with proteins and nucleic acids to form productsthat: 1) disturb the functionality of the cellular phospholipidmembrane; 2) diminish tissue elasticity and 3) secondary to free radicalformation, increase lipid peroxidation.

[0018] The ingestion of sugars, fats, and sodium has been linked toinsulin resistance, while caloric restriction, exercise, ingestion ofchromium, vanadium, magnesium, and certain antioxidants are associatedwith greater insulin sensitivity. Lifespan may favorably be affected,and the incidence of many chronic disorders commonly associated bothwith aging and with diabetes can be reduced, by manipulating the dietand its influence upon the glucose/insulin system.

[0019] Diabetes—Pertinent Anatomy and Physiology of Glucose Metabolism

[0020] The pancreas functionally integrates its exocrine and endocrinedomains to modulate the kinetics and dynamics of intermediarymetabolism:

[0021] 1. Exocrine acinar cells produce amylase, which breaks downcomplex carbohydrates to monosaccharides in the intestine forabsorption.

[0022] 2. Endocrine islet α- and β-cells produce insulin, glucagon andsomatostatin which regulate glucose production and utilization.

[0023] Glucose homeostasis requires a modulated endocrine system capableof controlling glucose flux into and out of the extracellular space.Insulin (β-cells) and glucagon (α-cells) must maintain a balance betweenglucose production, intracellular translocation and glucose utilizationin the liver, adipose, muscle and neuronal tissue.

[0024] Failure of this integration between the exocrine and endocrinepancreatic functions is evident in diabetics: there is a loss ofautocorrection—i.e., although exocrine acinar amylase mRNA may decrease,endocrine-produced insulin normally reverses this, causing a correctiveincrease in acinar mRNA and amylase production.

[0025] Insulin

[0026] Insulin is synthesized from a very large physiologically inactivepolypeptide, proinsulin, which is derived from a still largerpolypeptide, preproinsulin. Insulin itself is a large, dual-chainpolypeptide with, respectively, 21 and 30 amino acids in the A and Bchains. The A and B chains of the dimer are linked by disulfide bondsand then complexed with zinc (Zn²⁺) for storage in the pancreaticβ-cells.

[0027] Insulin is released from β-cells in response to elevated glucoselevels. Under conditions of marked hyperglycemia, proinsulin is releasedin addition to insulin. Because of its slower disappearance, proinsulinmay represent as much as 50% of the measured circulating “insulin” inpersons with hyperglycemia. If hyperglycemia is sustained, the continuedoverproduction of inactive proinsulin may exhaust β-cells as theyattempt to respond. This ultimately results in reduced insulinproduction. Moreover, the “numbing” (or progressive reduction in theresponse) of β-cells to the small amount of insulin that is present mayultimately lead to clinically overt type 2 diabetes and its moreserious, often devastating complications. (See below.)

[0028] In addition to maintaining glucose translocation into cells,insulin stimulates cellular uptake of potassium and ascorbate. Thus,when combined with the usual hypomagnesmia of diabetes, insulindeficiency exaggerates or cause hypertension and the “tissue scurvy”commonly associated with type 2 diabetes.

[0029] Caveolar Insulin Transport

[0030] Most hydrophilic cell signaling substances like insulin havedifficulty crossing cell membranes to institute intracellular effects.Instead, signal transduction to the inside of the cell occurs atcaveolae—clusters of receptors located in specialized areas of the cellmembrane. Caveolae, in fact, are membrane systems responsible for signaltransduction and facilitating the integration of nutritional, mechanicaland humoral information at the cell surface. Rich in phospholipids,cholesterol and lipid-anchored membrane proteins, they present ascoherent patches immersed in the lipid bilayer, like floating icebergsin the sea. Resident molecules move through endocytotic/exocytoticcaveolar compartments. Caveolae and other similarly functionalglycolipid rafts are especially abundant in the cellular membranes ofinsulin-sensitive cells.

[0031] Although many different signaling molecules may be available, thecaveolae are the major sites for the integration of cellular signalling.Integration in this context refers to the interplay of two or moresignaling processes that result in reciprocal modulation. In thetreatment of type 2 diabetes, the ability of caveolae to sequestermolecules provides a target for influencing both imported and locallyproduced molecules in the modulation of cellular signaling.

[0032] Within caveolae, glycosylphosphatidylinositol (GPI) proteinstransfer information between different membrane compartments. Inparticular caveolin-1, an insulin receptor, interacts with these GPIproteins permitting insulin translocation. (See GLUT4, below.)

[0033] Three types of receptor proteins are located within the caveolaeof cell membranes:

[0034] Type I receptors have enzyme activity and usually possess anintracellular phosphotyrosine kinase (PTK) domain. Once the domain isactivated by a ligand, e.g., insulin, PTK phosphorylates theintracellular tyrosine present in multiple proteins. These proteins thenbind to phosphorylated tyrosine receptors of caveolin-1 (either to theinsulin receptor itself or complexed with it) and a cascade ofsignalling proceeds to other parts of the cell.

[0035] Type II receptors are ion channels. Here, binding with a ligand,e.g., acetylcholine, causes rapid opening of an ion channel within themembrane protein permitting passage of selected ions: Na⁺, K⁺ or Cl⁻.

[0036] Type III receptors as a class are referred to as G (guaninenucleotide) proteins. These are 7-helix transmembrane proteins thattransfer their signal via a complex intracellular second messengersystem. These receptors only recently have had their structurecompletely defined.

[0037] Once insulin is bound to Type I caveolin-1 receptors andinitiates phosphorylation of the intracellular tyrosine domain, theresulting phosphorylation cascade activates GLUT4 vesicles. These fuseto the plasma membrane and proceed to translocate glucose into the cell.This activation and fusion require interaction between GLUT4 vesicleprotein and cell membrane protein Syntaxin 4 (S4). As long as S4 iscomplexed with the cell membrane protein Synip, GLUT4 vesicles areinactive. Insulin dissociates the Synip:S4 complex, frees S4 to bindwith GLUT4 vesicles and vesicle translocation of glucose into the cellbecomes possible. Synip is the primary insulin regulated proteindirectly involved in glucose transport and GLUT4 vesicle translocation.It should be noted here that the antihyperglycemic effect of the traceelement vanadium may in part be due to direct activation of the insulinreceptor and in part to a prolongation of the action of insulin,possibly by inhibiting the formation of this Synip:S4 complex.

[0038] Complex spatial compartmentalization is involved in thespecificity of insulin action. As examples:

[0039] Once it is complexed, the insulin-activated receptor (caveolin-1)within the caveola is itself translocated endocytotically into thecytoplasm where its passenger insulin is released.

[0040] In addition to dissociating the Synip:S4 complex, insulin alsoactivates “protein targeting for glycogen” (PTG) which forms a distinctinsulin pool of protein phosphatase 1 (PP 1). This is complexed withenzymes regulating a dephosphorylation cascade leading to the productionand storage of glycogen. The insulin receptor is then exocytoticallytranslocated to a position within a caveola of the cell membrane, undercontrol of a feedback mechanism.

[0041] Caveolae are sensitive to lipids, especially cholesterol, andcontain receptors that bind HDL, LDL and oxidized lipoproteins (oxLDL).The presence of elevated levels of oxLDL adversely affect caveolarefficiencies. (See, below.)

[0042] Disruption of these functions can have unexpected consequencesgiven their involvement not only in insulin cell signaling but also incalcium (Ca²⁺) metabolism, blood clotting and cholesterol transport.

[0043] Confounding any understanding of these already intricate,interrelated facets of insulin functionality are the varieties of itsactions according to cell type, dosage, time of dosage and the presenceof other hormones. And to make things even more complicated, insulin mayinitiate either phosphorylation or dephosphorylation cascades within thecell. Although the insulin receptor itself is phosphorylated in itstyrosine domain (as noted above), the subsequent changes in proteinphosphorylation occur predominantly on serine and threonine residuesand, in addition, L-arginine supports ligand binding to phosphotyrosinereceptors, including the insulin receptor.

[0044] Many steps in these phosphorylation cascades involve ATPase,which is dependent on magnesium Mg²⁺ as a cofactor. Mg²⁺ deficiency issufficiently common in diabetics that its oral supplementation isrecommended by the American Diabetes Association for diabetics withnormal renal function.

[0045] OxLDL (which is increased by both hyperinsulinemia andhyperglycemia) displaces cholesterol from the caveolae, drivingendothelial nitric-oxide synthase (eNOS) from caveolae and impairing itsactivation: Vasoconstriction and increased coaguability arise from thisdestabilization of the physiological balance between the vasodilation ofNO, the vasoconstriction of ET-1 and the availability of cGMP. AlthoughHDL helpfully reduces the ability of oxLDL to decrease eNOS activation(and thus preserves subcellular levels of eNOS and indirectly NO), thelevel of HDL is reduced in patients with insulin resistance.

[0046] Mitochondria and Pancreatic β-Cell Apoptosis

[0047] Pancreatic β-cell apoptosis is responsible for irreversibleprogression toward insulin dependence in type 2 diabetes.

[0048] Apoptosis is an enzyme driven catabolic cell-death process.Activation of endonucleases and specific proteases (caspases) occurswhen mitochondria make a “decision to die”. Inhibition of endonucleasesand caspases do not prevent apoptosis, indicating that that the“decision to die” is taken before catabolic enzymes are activated andthat the activation of these enzymes is by-product of the cell-deathprocess and not a regulatory event.

[0049] The sequence leading to apoptosis is: 1) A pre-mitochondrial(induction) phase, in which numerous physiological and some pathologicalstimuli (e.g., prooxidants, increased cytosolic Ca²⁺, induced NO)trigger an increase in mitochondrial membrane permeability. 2) Amitochondrial (effector) phase during which mitochondrial membraneintegrity is lost and the “decision to die” is made. 3) Apost-mitochondrial (degradation) phase during which intermembraneproteins (cytochrome C, apoptosis-inducing factor) are released whichactivate catabolic hydrolases (e.g., endonucleases, caspases)responsible for apoptotic degradation of essential proteins and nuclearDNA. This invention reduces the pathologic stimuli of the inductionphase of apoptosis, including that of the pancreatic β-cell.

[0050] Not unexpectedly, the complexity of the involvedpathophysiologies defines their nonlinearity. This complexity alsoemphasizes the necessity for modulation at the many points of potentialinstability in these processes. The inadequacy or lack of suchmodulation at multiple points may eventually lead to overt type 2diabetes itself. The identification and influence of these modulationpoints represent therapeutic opportunities and underly the rationale ofthis invention.

[0051] Pertinent Pathophysiology of Diabetic Mellitus

[0052] In normal subjects, after an overnight fast, glucose is producedfrom hepatic glycogen (25%) and gluconeogenesis (75%): The kidney, inaddition to the liver, is capable of gluconeogenesis. The maingluconeogenic precursors for the liver are amino acids (predominantlyalanine and glutamine derived from muscle protein) and glycerol fromtriglyceride hydrolysis in adipose tissue. Catecholamines stimulategluconeogenesis, as does glucagon via cAMP, while cortisol has a delayedeffect in causing hyperglycemia. Insulin opposes these gluconeogenic andglycogenolytic actions.

[0053] Hepatic glucose production can be autoregulated according toportal vein glucose levels, assuming there is a normal response toinsulin.

[0054] As previously stated, the initial event in insulin action is itsbinding to an enzymatic caveolar receptor. This causes a conformationalchange in the intracellular tyrosine kinase domain of the receptor, itsautophosphorylation and an intracellular phosphorylation cascade thatmediates some of insulin's effects. After caveolin-1 binding occurs, theresulting insulin-receptor complex is internalized endocytotically andinsulin dissociates intracellularly. Some residual receptors simplydegrade, some pass to the Golgi apparatus to join others, newlysynthesized, and are recycled exocytotically to a caveolar membraneregion to await another insulin ligand.

[0055] In persistent hyperglycemia the turnover of receptor binding andinternalization are increased resulting in a net reduction in the numberof available receptors at the cell membrane (downregulation). As moreand more receptors are occupied, adjacent unoccupied receptors becomeless receptive (negative co-operativity). Downregulation and negativeco-operativity combine to decrease insulin effectiveness duringsustained hyperglycemia. Thus, sustained hyperglycemia results indecreased insulin receptivity and increased insulin resistance.

[0056] Although circulating insulin levels are frequently elevated earlyin type 2 diabetes, a deficiency of intracellular insulin and increasedcellular resistance to many of insulin's actions simultaneously occur:there is resistance to the stimulation of glucose uptake by muscle andliver, there is resistance to the suppression by insulin of hepaticglucose production, there is resistance to the suppression by insulin oflipolysis in adipose tissue, etc. Several possibilities for theseinadequacies have been postulated: 1) that there is some structuralabnormality in the insulin receptor or in the region of the caveolin-1insulin receptor, which results in disruption of the intracellularphosphorylation cascade; or 2) that there is an abnormality in theendocytotically intracellular insulin release effecting glycogenicenzymes; or 3) that there is a Synip related effect. All three probablycontribute to insulin resistance. Again, the process is unclear, complexand nonlinear.

[0057] Recent research suggests that there is a high expression of thecytokine tumor necrosis factor-α (TNF-α) in the adipocytes of obeseindividuals, and that this TNF-α is a principal contributor to insulinresistance and subsequent type 2 diabetes in obese patients. TNF-α is animportant regulator of the processes of apoptosis and thus modulates thevolume of tumor, adipose and muscular tissues. It is produced not onlyby immunocompetent cells but also by adipocytes and muscle cells. Thiscytokine is activated in tumors and obesity, among other conditions.TNF-α promotes insulin resistance and anorexia, by acting on thephosphorylation of IRS-1 and PI-3 kinase, by modifying resistancethrough regulation of the synthesis of the insulin responsive glucosetransporter GLUT4, and through interference with insulin signaling(perhaps via leptin).

[0058] Studies conducted on obese human patients have demonstrated acorrelation between levels of TNF-α, the extent of obesity, as well asthe level of hyperinsulinemia (the results of one recent study areconsistent with the hypothesis that TNF-α could be involved in theregulation of plasma leptin concentrations in obese subjects).

[0059] Irrespective of the cause, insulin resistance is associated withwidespread and adverse effects on health. This is true even when glucosetolerance is only mildly impaired but not yet in the overt diabeticrange. Notable among the adverse effects is the predisposition tovascular disease affecting large blood vessels and an association withhypertension and dyslipidemia (elevated triglycerides and decreasedHDL). In fact, this combination of 1) glucose intolerance, 2) insulinresistance, 3) hypertension and 4) dyslipidemia is common enough to haveacquired the name Syndrome X, the insulin resistance syndrome orReaven's syndrome. Clinically it defines hundreds of millions of peopleworldwide.

[0060] It is clear that the process governing both insulin resistanceand type 2 diabetes is diagrammatically syncytial. It is not a linear,straightforward process that lends itself to a single treatmentmodality. Neither disease is a singularity and the pathophysiologiccontinuum of each is not rationally approachable with a singlepharmaceutical “silver bullet”.

[0061] Aging and Diabetes Mellitus

[0062] With aging there is a gradual decline in glucose tolerance atleast in part because of a progressively increased resistance to insulinat its receptor site and a decreased response by the pancreatic β-cellsto glucose levels. In aging, similar to diabetes, the elevatedcirculating glucose secondary to increasing insulin resistance reactsnonenzymatically with proteins and nucleic acids to form products thatdisturb cell membrane function and diminish tissue elasticity. Also,these disturbances in glucose/insulin metabolism are associated withincreased lipid peroxidation from elevated free radical formationresulting from the autooxidation of glucose. Augmented free radicalformation and lipid peroxidation, common in diabetes mellitus, areassociated with the “premature aging” of diabetic patients. Long term,excessive ingestion of sugars, fats and sodium have been linked todecreased insulin sensitivity, while caloric restriction, exercise,ingestion of chromium, vanadium, Mg²⁺, certain free radical scavengersand nuclear factor kappa B (NFkappaB) inhibitors are associated withgreater insulin sensitivity. Thus, manipulation of the diet byinfluencing the glucose/insulin system may favorably affect lifespan andreduce the incidence of the microvascular and macrovascularcomplications of type 2 diabetes.

[0063] Vascular Pathology

[0064] The earliest microvascular lesion of diabetes is a variablethickness of the basement membrane. A healthy basement membrane providesvascular stability and importantly, a permeability barrier. Cellularimpermeability requires a negative electrical charge provided by heparansulfate, a polyanionic proteoglycan. Sulfate groups provided by lipoicacid, n-acetylcysteine (NAC) and possibly taurine, may contribute to theadequacy of this necessary negativity of the cell membrane. In diabetesboth the basement membrane thickness and heparan sulfate levels aredecreased. As a result, vessel permeability is increased. Increasedvessel permeability is the most notable initial microvascularcomplication in diabetes.

[0065] Early in diabetes there are additional abnormal microvascular(arteriolar and capillary) dysfunctions: e.g., intraluminal pressure andflow are both increased: these changes, plus the increased permeabilityof the basement membrane and the associated vascular endothelialdysfunction, limit normal vascular autoregulatory mechanisms. Thiscombination of failures leads to the familiar diabetic clinicalmanifestations of microvascular and macrovascular insufficiencies of theheart, extremities, kidney, eye and brain.

[0066] Microvascular complications

[0067] 1. Diabetic retinopathy is the leading cause of blindness in theworking population.

[0068] 2. Diabetic nephropathy is common in type 2 diabetes. Risk ofdeath is increased 100 fold.

[0069] 3. Diabetic neuropathy increases each decade to a 60% incidenceafter 25 years.

[0070] Macrovascular complications

[0071] 1. Cardiovascular risk of death is increased three fold.

[0072] 2. Cerebrovascular risk of death is increased.

[0073] 3. Amputation risk is increased five fold.

[0074] Biochemical Mechanisms of Diabetic Complications

[0075] Free Radical Damage

[0076] Release of cytochrome C from dysfunctional mitochondria

[0077] Non-enzymatic glycation

[0078] Lipoprotein modifications

[0079] Disturbances of physiological NO effects

[0080] Sorbitol and myoinositol metabolic abnormalities

[0081] Interference with proteoglycans

[0082] Although diabetes mellitus and insulin resistance areprogressive, complex and frequently unpredictable processes with manypoints of potential instability, the latter are identifiable. To haveany long-term chance of favorably influencing the cellularpathophysiology of insulin resistance and type 2 diabetes, any clinicalapproach must involve not only the coordination of life stylemodification, but also utilize finely calibrated combinations ofpharmaceutical agents acting at multiple biomolecular nodes ofmodulation.

[0083] Therefore it is useful to consider, in turn, the pathologicstates caused by insulin resistance and type 2 diabetes, the underlyingmolecular biologic defects or deficiencies, the existing modalities forfavorably modulating these and the complementary, beneficialinteractions of some of these approaches.

[0084] A. Pathologic States Caused by or Worsened by Insulin Resistanceand/or Type 2 Diabetes

[0085] SPECIFIC: MICROVASCULAR COMPLICATIONS

[0086] 1. NEPHROPATHY

[0087] 2. NEUROPATHY

[0088] 3. RETINOPATHY

[0089] NON-SPECIFIC: MACROVASCULAR COMPLICATIONS

[0090] 1. ATHEROSCLEROSIS

[0091] 2. HYPERTENSION

[0092] 3. CORONARY ARTERY DISEASE

[0093] 4. CEREBROVASCULAR DISEASE

[0094] 5. PERIPHERAL VASCULAR DISEASE

[0095] RELATED MORBIDITY

[0096] 1. OBESITY

[0097] 2. POOR RESISTANCE TO INFECTION

[0098] 3. PREMATURE AGING

[0099] 4. CATARACTS

[0100] 5. ALZHEIMER'S DISEASE (POSSIBLE)

[0101] B. Cellular Physiological and Molecular Biological Disturbancesin Insulin Resistance and/or Type 2 Diabetes

[0102] 1. INSULIN SENSITIVITY IS DECREASED

[0103] 2. INSULIN RESISTANCE IS INCREASED

[0104] 3. DURATION OF INSULIN ACTION IS DECREASED

[0105] 4. HYPERINSULINEMIA

[0106] 5. β-CELL INSULIN SECRETION IS INITIALLY INCREASED, THENDECREASED

[0107] 6. β-CELL DYSFUNCTIONAL APOPTOSIS

[0108] 7. β-CELL SENSITIVITY IS DECREASED

[0109] 8. HYPERGLYCEMIA

[0110] 9. ADVANCED GLYCATION PRODUCTS (AGEs) OCCUR

[0111] 10. GLUCOSE AUTOOXIDATION OCCURS WITH FORMATION OF ROS (OXIDATIVESTRESS)

[0112] 11. FREE RADICALS ARE INCREASED

[0113] 12. GLUTATHIONE (GSH) EFFECTS ARE DECREASED

[0114] 13. ENDOTHELIUM BECOMES DYSFUNCTIONAL

[0115] 14. VASOCONSTRICTION IS INCREASED

[0116] 15. DEFECTIVE ACETYLCHOLINE (ACH) RESPONSE 3 VASOCONSTRICTION

[0117] 16. SYMPATHETIC NERVOUS SYSTEM ENHANCED: NOCTURNAL HEART RATEINCREASED

[0118] 17. CALCIUM SIGNALING IS DISTURBED

[0119] 18. REDUCED eNOS→IMPAIRED VASODILATION

[0120] 19. ET-1 IS INCREASED WITH INTENSE, PROLONGED VASOCONSTRICTION

[0121] 20. VASCULAR SMOOTH MUSCLE (VSMC) HYPERTROPHY RESULTS

[0122] 21. VCAM-1 & ICAM-1 (VASCULAR ADHESION MOLECULES) INCREASE

[0123] 22. DESTABILIZATION OF PLATELETS

[0124] 23. REDUCED SYNTHESIS OF HEPARAN SULFATE WITH PROTEINURIA

[0125] 24. SECONDARY ELEVATION OF HOMOCYSTEINE

[0126] 25. HOMOCYSTEINE AGGRAVATION OF DIABETIC HYPERTENSION &ATHEROGENESIS

[0127] 26. VITAMIN C→DEHYDRO ASCORBIC ACID (DHAA) IMBALANCE OCCURS

[0128] 27. VITAMIN C MAY BECOME A PROOXIDANT

[0129] 28. EXHAUSTION OF VITAMIN E

[0130] 29. CELL MEMBRANE LIPID PEROXIDATION

[0131] 30. DESTABILIZATION OF CELLULAR AND SERUM LIPIDS

[0132] 31. DESTABILIZATION OF MEMBRANE CAVEOLAE

[0133] 32. LDL OXIDATION

[0134] 33. MACROPHAGE ACTIVITY INCREASED (FOAM CELL DEVELOPMENT)

[0135] 34. ALDOSE REDUCTASE IS UNINHIBITED RESULTING IN INCREASEDSORBITOL

[0136] 35. POLYOL OSMOTIC EFFECT IS INCREASED

[0137] 36. MYOINOSITOL AND TAURINE OSMOLAR EFFECTS ARE DISTURBED

[0138] 37. STRUCTURAL AND FUNCTIONAL PERICYTE AND NEURONAL DISRUPTION

[0139] 38. MICROVASCULAR BLOOD FLOW IS REDUCED

[0140] 39. NERVE CONDUCTION VELOCITY IS DECREASED

[0141] 40. HYPOMAGNESEMIA OCCURS, DECREASING INSULIN EFFECT 3 CELLMALFUNCTIONS

[0142] 41. POSSIBLE DIABETIC ADVANCEMENT OF ALZHEIMER'S DISEASE

[0143] Oral Hypoglycemic Agents—Aspects of Biochemistry

[0144] There are various pharmacological approaches to improving glucosehomeostasis, but those currently used in clinical practice, either donot succeed in restoring normoglycemia in most patients, fail after avariable period of time or have side effects that ultimately precludetheir use in many patients. The components of this invention willimprove the performance, duration of effectiveness and safety oftherapies, which depend upon the inclusion of the biguanides (e.g.,metformin), of the sulfonylureas (various) or of sulfonylurea-biguanidecombinations.

[0145] For glycemic regulation, four classes of oral drugs are currentlyavailable: biguanides (e.g., metformin), sulfonylureas (e.g.,tolbutamide, glyburide, glipizide and others),α-glucosidase inhibitors(e.g., acarbose and miglitol) and thiazolidinediones (e.g., troglitazoneand rosiglitazone), each of these has a different mode and site ofaction.

[0146] This invention focuses on formulations containing multiple activeingredients in addition to a biguanide and/or a sulfonylurea forpatients requiring a biguanide, one of the sulfonylureas or theconcurrent use of both (i.e., a combination of sulfonylurea andbiguanide) for treatment of progressive insulin resistance and type 2diabetes.

[0147] The principle of long-term maintenance of glucose control appliesto both progressive insulin resistance and type 2 diabetes. Thetreatment strategies while similar, are somewhat different. Progressiveinsulin resistance has as its central abnormality hyperinsulinemia. Thelatter persists as the disease progresses to type 2 diabetes with itscentral abnormality, hyperglycemia. In each case the process isnonlinear and its pharmacological modulation is complex.

[0148] A. Sulfonylureas

[0149] A.1. Sulfonylurea: Pharmacodynamics and Pharmacokinetics

[0150] The sulfonylurea group has dominated oral antidiabetic treatmentfor years. They primarily increase insulin secretion. Their action isinitiated by binding to and closing a specific sulfonylurea receptor (anATP-sensitive K⁺ channel) on pancreatic β-cells. This closure decreasesK⁺ influx, leading to depolarization of the membrane and activation of avoltage-dependent Ca²⁺ channel. The resulting increased Ca²⁺ flux intothe β-cell, activates a cytoskeletal system that causes translocation ofinsulin to the cell surface and its extrusion by exocytosis.

[0151] The proximal step in this sulfonylurea signal transduction is thebinding to (and closure) of high-affinity protein receptors in theβ-cell membrane. There are both high and low-affinity sulfonylureareceptor populations. Sulfonylurea binding to the high-affinity sitesaffects primarily K(ATP) channel activity, while interaction with thelow-affinity sites inhibits both Na/K-ATPase and K(ATP) channelactivities. The potent second-generation sulfonylureas, glyburide andglipizide, are able to saturate receptors in low nM concentrationranges, whereas older, first-generation drugs bind to and saturatereceptors in microM ranges.

[0152] The association of sulfonylurea receptors (SURs) with K(IR)6.xsubunits to form ATP-sensitive K⁺ channels, presents perhaps the mostunusual function known for members of the transport ATPase family. Theintegration of these two protein subunits extends well beyond conferringsensitivity to sulfonylureas. These SUR-K(IR)6.x interactions arecritical for all of the properties associated with native K(ATP)channels including quality control over surface expression, channelkinetics, inhibition and stimulation by magnesium nucleotides andresponse both to channel blockers like sulfonylureas and to potassiumchannel openers. The K(ATP) channel is a unique example of thephysiologic and medical importance of a transport ATPase and provides aparadigm for how other metallic members of the family may interact withother ion channels. This also speaks to the importance and the mechanismof modulation by Mg²⁺ of many aspects of membrane channel receptors.

[0153] The activity of ATP-sensitive K⁺ channels is also controlled byinsulin secretagogues, by glucose and by certain amino acids such ascationic L-arginine and the non-polar, essential amino acid L-leucine.The amino acid secretagogues must be metabolized to inhibit the K⁺channel activity and appear to do so by increasing the level of ATP, orby increasing the ATP/adenosine diphosphate (ADP) ratio. As a result,the increased availability of ATP reduces channel activity by binding toa specific site on the cytoplasmic surface of the receptor protein. Tofunction as an insulin secretagogue, L-arginine requires adequatethiamine and L-leucine requires thiamine for its catabolic metabolism aswell. This invention will enhance the effectiveness of sulfonylureas bysupplying complementary amino acid secretagogues in a complementarymilieu.

[0154] There is a synergy between the action of glucose and that of thesulfonylureas: sulfonylureas are better effectors of insulin secretionin the presence of glucose. For that reason, the higher the level ofplasma glucose at the time of initiation of sulfonylurea treatment, thegreater the reduction of hyperglycemia.

[0155] Exposure of perfused rat hearts to the second-generationsulfonylurea glyburide leads to a dramatic increase in glycolytic fluxand lactate production. When insulin is included in the buffer, theresponse to glyburide is significantly increased. (Similarly, glyburidepotentiates the metabolic effects of insulin.) Because glyburide doesnot promote glycogenolysis, this increase in glycolytic flux is causedsolely by a rise in glucose utilization. Since the drug does not alteroxygen consumption, the contribution of glucose to overall ATPproduction rises while that of fatty acids falls. These metabolicchanges aid the heart in resisting ischemic insults.

[0156] Insulin, on the other hand, is released by the pancreas into theportal vein, where the resultant hyperinsulinemia suppresses hepaticglucose production and the elevated level of arterial insulin enhancesmuscle glucose uptake, leading to a reduction in postprandial plasmaglucose levels.

[0157] The initial hypoglycemic effect of sulfonylureas results fromincreased circulating insulin levels secondary to the stimulation ofinsulin release from pancreatic β-cells and, perhaps to a lesser extent,from a reduction in its hepatic clearance. Unfortunately, these initialincreases in plasma insulin levels and β-cell responses to oral glucoseare not sustained during chronic sulfonylurea therapy. After a fewmonths, plasma insulin levels decline to those that existed beforetreatment, even though reduced glucose levels are maintained. Because ofdownregulation of β-cell membrane receptors for sulfonylurea, itschronic use results in a reduction in the insulin stimulation usuallyrecorded following acute administration of these drugs. More globally,impairment of even proinsulin biosynthesis and, in some instances,inhibition of nutrient-stimulated insulin secretion may follow chronic(greater than several months) administration of any of thesulfonylureas. (However, the initial view that the proinsulin/insulinratio is reduced by sulfonylurea treatment seems unlikely in light ofrecent research.) If chronic sulfonylurea therapy is discontinued, amore sensitive pancreatic β-cell responsiveness to acute administrationof the drug is restored.

[0158] It is probable that this long-term sulfonylurea failure resultsfrom chronically lowered plasma glucose levels (and a resulting feedbackreduction of sulfonylurea stimulation); it does, however, lead to adiminishment of the vicious hyperglycemia-hyperinsulinemia cycle ofglucose toxicity. As a result, the sulfonylureas reduce nonenzymaticglycation of cellular proteins and the association of the latter with anincreased generation of advanced glycation end products (AGEs), andimprove insulin sensitivity at the target tissues. But, it should bekept in mind that one of these cellular proteins is insulin, which isreadily glycated within pancreatic β-cells and under these conditions,when it is secreted it presumably is now ineffective as a ligand.

[0159] The formulations of this invention reduce protein glycation andwill thereby increase the amount of secreted insulin that is effectiveat the target tissues.

[0160] It has been suggested that sulfonylureas may have a direct effectin reducing insulin resistance on peripheral tissues. However, mostinvestigators believe that whatever small improvement in insulin actionis observed during sulfonylurea treatment is indirect, possiblyexplained (as above) by the lessening of glucose toxicity and/or bydecreasing the amount of ineffective, glycated insulin.

[0161] When sulfonylurea treatment is compared with insulin treatment itis found that: (1) treatment with sulfonylurea or insulin results inequal improvement in glycemia and insulin sensitivity, (2) the levels ofproinsulin and plasminogen activator inhibitor-1 (PAI-1) antigen and itsactivity are higher with sulfonylurea, and (3) there are no differencesin lipid concentrations between therapies.

[0162] Because sulfonylureas (glyburide) are weak acids they are morethan 98% bound to albumin, but this does not appear to be influenced bythe extent of albumin glycation.

[0163] A.2. Sulfonylurea: Effectiveness

[0164] The hypoglycemic potency of sulfonylureas is directly related tothe starting fasting plasma glucose level. The higher the fasting plasmaglucose level, the greater its decrease when treated with sulfonylureas.In the United States, the mean HbAic value in diabetic patients is 10%,which corresponds to a fasting plasma glucose level of more than 200mg/dL. In such patients treated with sulfonylureas, one can expect thefasting plasma glucose level to decrease by 60 to 70 mg/dL and theHbA_(1C) value to decrease by 1.5 to 2.0 percentage points.Approximately 25% of type 2 diabetics treated with a sulfonylurea willachieve a fasting plasma glucose level lower than 140 mg/dL. Howeverthis also means that 75% will not reach this goal, and thus will requiresome type of additional therapy.

[0165] In some type 2 diabetics, autoantibodies to islet-cell cytoplasm(ICA) and glutamic acid decarboxylase (GADA) can occur. The phenotype ofolder adults is similar to type 2 diabetics without antibodies, and theoccurrence of these antibodies predicts an increased likelihood ofinsulin treatment because of progressive β-cell loss. Signs of isletcell autoimmunity occur in 12% of type 2 diabetics over the age of 65.

[0166] In addition, there is an increase in fibrinogen (P=0.005) andC-reactive protein levels (P=0.025) in type 2 diabetic patients withautoantibodies. A pronounced activation of the acute-phase response,found to be associated with islet cell autoimmunity, may in part explainthe associated defects in insulin secretion. This not only has directimplications for adequate classification and treatment of type 2diabetes in the elderly, but also for understanding theautoimmune/inflammatory mechanisms involved in the pathogenesis ofhyperglycemia.

[0167] By reducing dysfunctional β-cell apoptosis, this invention willenhance the effectiveness of sulfonylurea therapy by stopping or slowingthe progression of type 2 diabetes toward this stage of progressiveautoimmune/inflammatory β-cell destruction—sometimes referred to as“type 1.5” diabetes.

[0168] Of those patients who have a good initial response tosulfonylurea therapy, the secondary failure rate is about 5% to 7% peryear. After 10 years this failure has mounted to over 50% and mostsulfonylurea-treated patients require a second oral agent. Less than 20%of type 2 diabetics have satisfactory long-term therapy after 10 yearsof sulfonylurea treatment. First and second generation sulfonylureas areequally subject to secondary failure. Switching from a first to asecond-generation sulfonylurea has been more or less equally“successful”, but ultimately treatment is unsatisfactory. It is theintention of this invention to extend the duration of effect ofsulfonylurea treatment of type 2 diabetes by delaying the onset, andslowing the progression of β-cell dysfunction and inappropriate β-cellapoptosis.

[0169] All sulfonylureas fail at rates that are dependent both on thephenotype at presentation and (perhaps) on the agent used initially.Higher eventual failure rates are found in those with higher initialglucose concentrations, those who are younger, those with lower β-cellreserve and in the United Kingdom Prospective Diabetes Study (UKPDS)those randomized to second generation drugs, compared with firstgeneration drugs . Prospective placebo-controlled trials have shown thatsecond generation sulfonylureas (glipizide, glyburide, and glimepiride)exert equipotent glucose-lowering effects, but it is not known whetherthey also differ in their therapeutic end results.

[0170] Regarding the benefit of intensive therapy with sulfonylureas(chlorpropamide, glibenclamide) or with insulin in type 2 diabetes, theUKPDS interpreted their data to indicate that “. . . intensive bloodglucose control by either of the sulfonylureas or by insulin,substantially decreases the risk of microvascular complications, but notmacrovascular disease . . .”.

[0171] Management of patients with progressive insulin resistance andtype 2 diabetes should focus on decreasing the excess macrovasculardisease with which these are associated, as well as preventing orminimizing microvascular disease. As shown by the UKPDS data,near-normoglycemic control can reduce microvascular disease. However,this requires the concomitant management of the cardiovascular riskfactors of the insulin resistance syndrome associated with type 2diabetes: e.g., a reduction of the macrovascular-disease-promotingsulfonylurea side effect of carnitine depletion and/or a reduction ofmetformin-induced hyperhomocysteinemia.

[0172] The formulations of the invention will enhance the microvascularbenefits associated with the sulfonylureas. In addition, by rectifyingthe adverse side effects of sulfonylurea treatment, and by modifying theadverse components of the insulin resistance syndrome, the inventionwill decrease the risk of macrovascular disease.

[0173] If combined with caloric dietary regulation, rapid- andshort-acting sulfonylureas may help patients reach and maintaineuglycemia without provoking chronic hyperinsulinemia or weightincrease. There is no evidence that sulfonylurea treatment causes β-cellexhaustion; instead, the antihyperglycemic effect helps improve β-cellfunction. Sulfonylurea “failures” are often dietary failures or due tolate introduction of these drugs, i.e., when β-cell function is alreadyattenuated. Desensitization of the insulinotropic effect ofsulfonylureas may occur, but might be avoided by discontinuous (lessthan 24 h/day) sulfonylurea exposure, i.e., once-daily administration ofa short-acting sulfonylurea in a moderate dose. That is, the failurerate seems to dose related. The invention will permit the clinician morelatitude in adjusting downward the dosage of a prescribed sulfonylurea,and it will permit “pulsing” of the latter and avoid desensitization.Furthermore, it will provide the luxury of a safe delay of use of thebecause of a prophylactic prolongation of improved β-cell function: thisdelay in the use of the sulfonylureas will delay the onset of theirfailure. It is not expected that it will eliminate entirely ultimatefailure.

[0174] A.3. Sulfonylurea: Additional Beneficial Effects

[0175] Type 2 diabetes mellitus is part of a complicatedmetabolic-cardiovascular pathophysiologic cluster alternately referredto as the insulin resistance syndrome, Reaven's syndrome, the metabolicsyndrome or syndrome X. Since the macrovascular coronary artery diseaseassociated with insulin resistance and type 2 diabetes is the majorcause of death in the latter, it is desirable that any hypoglycemicagent favorably influences known cardiovascular risk factors. But theresults in this area have been only mildly encouraging. This inventionwill add a cardiovascular risk reduction dimension to syulfonylureatherapy.

[0176] Sulfonylureas have been reported to have a neutral or justslightly beneficial effect on plasma lipid levels: plasma triglyceridelevels decrease modestly in some studies. This hypolipidemic effectprobably results from both a direct effect of sulfonylurea on themetabolism of very-low-density lipoprotein (VLDL) and an indirect effectof sulfonylurea secondary to its reduction of plasma glucose levels.

[0177] It has been shown the sulfonylurea gliclazide (but notnecessarily another oral hypoglycemic) reduces platelet aggregation andhas a beneficial effect on the fibrinolytic system. As a group, thesulfonylureas decrease vessel permeability in a manner that isindependent of their hypoglycemic properties. These additional actionsmay be useful in preventing or attenuating the long-term vascularcomplications of diabetes, e.g., diabetic retinopathy. While thefavorable effect of reducing platelet aggregation seems established, adisturbing recent study shows an increase in PAI-1 in chronicallytreated sulfonylurea patients.

[0178] The formulations of this invention provide appropriatetherapeutic levels of a sulfonylurea and will enhance and/or extend thebeneficial effect of the sulfonylureas upon plasma lipids, coagulopathyand microvascular permeability.

[0179] A.4. Sulfonylurea: Adverse Effects

[0180] The most frequent adverse effect associated with sulfonylureatherapy is weight gain, which is also implicated as a cause of secondarydrug failure.

[0181] Sulfonylureas frequently: (1) stimulate renal renin release; (2)inhibit renal carnitine resorption; (3) increase PAI-1; and (4) increaseinsulin resistance.

[0182] Renal effects from treatment with the sulfonylureas can bedetrimental. Because the sulfonylureas are K(ATP) blockers they arediuretics although, fortunately, they do not produce kaliuresis. Theymay stimulate renin secretion from the kidney, initiating a cascade toangiotensin II in the vascular endothelium that results invasoconstriction and elevated blood pressure.

[0183] They inhibit renal carnitine reuptake. This raises the questionas to what role they play in the homeostasis of other amino acids forwhich deficiencies should be avoided in progressive insulin resistanceand type 2 diabetes, e.g., taurine and L-arginine. Given these renaleffects of the sulfonylureas, it is not surprising that theremacrovascular benefits are not associated with their use. (See above.)Sulfonylureas, while reducing hyperglycemia, tend to intensify theinsulin resistance syndrome: obesity, insulin resistance, hypertension,and coagulopathy. The formulations of this invention reduce thisnegative effect on the insulin resistance syndrome and the secondaryamino acid deficiencies caused by the clinical use of sulfonylureas.

[0184] The kidney plays an important role in the homeostasis ofcarnitine, reabsorbing it almost completely from the glomerularfiltrate. Carnitine is pivotal for the mitochondrial energy system tofunction efficiently. Its deficiency leads to reduced fatty acidoxidation and ATP production, both of which are important in avoidingweight gain and maintaining the effectiveness of nutrient insulinsecretagogues. This invention improves sulfonylurea-induced inhibitionof hepatic fatty acid oxidation and provides support for the productionof ATP (necessary for physiologic pancreatic insulin production),thereby lessening the adverse weight gain secondary to sulfonylureatreatment and reducing the accumulation of fatty acid-derived freeradicals.

[0185] Sulfonylurea treatment induces coronary vasoconstriction from K⁺ATP-channel blockade, and thus reduces coronary blood flow at rest byabout 25%. It does not reduce flow during exercise so long as theL-arginine-cNOS-NO-cGMP pathway is normal. The invention providessupport for the cGMP pathway.

[0186] PAI-1 antigen and activity increase with sulfonylurea treatmentcompared to insulin, perhaps explaining, in part, the failure ofprevention of macrovascular complications in spite of glycemic control.

[0187] Proinsulin levels may increase during sulfonylurea therapy.

[0188] The most discussed, important adverse effect of chronicsulfonylureas use is long lasting, significant hypoglycemia. The lattermay lead to permanent neurological damage or even death, and is mostcommonly seen in elderly subjects who are exposed to some intercurrentevent (e.g., acute energy deprivation) or to drug interactions (e.g.,aspirin, alcohol). Long-lasting hypoglycemia is more common with thelonger-acting sulfonylureas glyburide and chlorpropamide. For thisreason sulfonylurea therapy should be maintained at the lowest possibledose. (Surprisingly, the dose-response relationships of thesulfonylureas have been poorly investigated.) By complementing andefficiently optimizing the therapeutic action of sulfonylurea, theformulations of this invention permit the use of minimal doses ofsulfonylureas, thereby lowering the risks of sulfonylurea therapy,including hypoglycemia.

[0189] There is a greater suppression of hepatic glucose production withglyburide, which may explain the higher incidence of hypoglycemia seenwith its use: mild hypoglycemic reactions occur in about 4% of patients,and severe hypoglycemic reactions requiring hospitalization have beenstated to occur with a frequency of 0.4 cases per 1000 patient treatmentyears. The UKPDS reported a somewhat higher incidence.

[0190] In two surveys (1969 and 1984), all emergency wards inSwitzerland reported on the incidence in their units of severe episodesof hypoglycemia during treatment with sulfonylureas. Each of thesesurveys referred to a ten-year period (period A 1960-1969, period B1975-1984). The number of severe episodes of hypoglycemia reported was78 for period A and 116 for period B. The incidence of fatalities fromsulfonylurea hypoglycemia in these facilities was 6.5% in period A(1960-1969), and 4.3% in period B (1975-1984). Advanced age was a riskfactor in hypoglycemia in these patients: 77% of patients withhypoglycemia were over 69 years of age, whereas only 50% of alldiabetics treated with sulfonylurea preparations were in this age group.Further risk factors were impaired renal function (21%) and possibledrug interactions (27%).

[0191] As our population ages and as the prevalence of ‘couch potatoes’rises, the danger of sulfonylurea hypoglycemia continually increases.The formulations of this invention are of increasing importance, becausethey permit clinical reductions in sulfonylurea dose levels.

[0192] In patients with a reduced glomerular filtration rate, the riskof hypoglycemia is high, and therapy with sulfonylureas, which arerenally excreted, should be avoided.

[0193] The various adverse, dose-related drug interactions that havebeen described (notably, aspirin and alcohol), are especially commonwith first-generation sulfonylureas.

[0194] The controversial results of the University Group DiabetesProgram study (1970) suggested that sulfonylureas might exacerbatecoronary artery disease in patients with type 2 diabetes. Subsequentclinical trials have not demonstrated these increased cardiac mortalityrates in diabetic patients actually treated with sulfonylureas. In fact,the UKPDS found no increased incidence of coronary artery disease inthose patients with type 2 diabetes, who were assigned to intensivetherapy with sulfonylureas, when compared with patients receiving diettherapy. There is no published data to support an advantage of any onesulfonylurea with respect to coronary artery disease. An AmericanDiabetes Association policy statement opposes any formal restrictionsbased on the interpretations of the University Group Diabetes Programfindings.

[0195] A.5. Currently Available Sulfonylureas (USA) Approved UsualDuration Daily Dosage Daily Dosage of Action SULFONYLUREAS mg mg hoursSecond Generation Glimepiride 1-8  1-4 16-24 Glipizide 5-40*  5-20 12-24Glipizide (XL) 5-20   5-20 24 Glyburide 1.5-12    5-20 12-24 Glyburide2.5-20    5-20 16-24 (micronase) First Generation Acetohexamide250-1500  500-750 12-18 Chlorpropamide 100-500  250-375 60 Tolazamide100-1000  250-500 12-24 Tolbutamide 500-2500  1000-2000  6-12

[0196] Sulfonylureas are divided into first-generation andsecond-generation drugs. First-generation sulfonylureas have a lowerbinding affinity to the sulfonylurea receptor and require higher dosesthan second-generation sulfonylureas. Generally, therapy is initiated atthe lowest effective dose and titrated upward every 1 to 4 weeks until afasting plasma glucose level of 110 to 140 mg/dL is achieved. Most (75%)of the hypoglycemic action of the sulfonylurea occurs with a daily dosethat is half of the maximally effective dose. If no hypoglycemic effectis observed with half of the maximally effective dose, it is unlikelythat further dose increases will have a clinically significant effect onblood glucose level.

[0197] In summary, sulfonylureas are effective glucose-lowering drugsthat work by stimulating insulin secretion. They have a beneficialeffect on diabetic microangiopathy, but no appreciable beneficial effecton diabetic macroangiopathy. Weight gain is common with their use.Sulfonylureas may cause hypoglycemia, which can be severe, even fatal.They may reduce platelet aggregation and slightly increase fibrinolysis,perhaps indirectly. However they also may increase PAI-1. They have nodirect effect on plasma lipids. They inhibit renal resorption ofcarnitine and may stimulate renal renin secretion. The sulfonylureas,especially generics, are inexpensive and are the oral antidiabetic drugof choice if cost is the major consideration. Sulfonylurea dosage can beminimized, therapeutic effect maximized, safety improved and the scopeof beneficial effects broadened in progressive insulin resistance,insulin resistance syndrome and type 2 diabetes when delivered in theformulations of this invention.

[0198] A.6. Use of the Invention for the Prevention and Treatment ofInsulin Resistance Syndrome and Type 2 Diabetes (Sulfonylurea+OtherActive Ingredients)

[0199] As illustrated by the foregoing list of cellular physiologicaland molecular biological disturbances, both insulin resistance syndromeand type 2 diabetes are progressive, complex, dynamic metabolic systemfailures with potential instability at many points. Its genesis is inpart related to the aging process and is in part a product ofenvironment and lifestyle. Underlying it all is a genetic dimension,which is not singular in nature. Because there are so many points ofphysiologic instability, neither pathologic process will predictablyrespond in its entirety to a single treatment modality. Rather, it ismore logical to provide a favorable physiologic milieu by identifyingthose multiple points where influence upon biochemical modulation mayreasonably be brought to bear and to design multicomponent therapeuticformulations to target them concurrently. In this fashion the therapywill insure that molecular deficiencies or inadequacies do not triggerthe system to respond nonlinearly to those stresses known to bedetrimental to persons with the potential for developing (or who alreadyhave) insulin resistance or type 2 diabetes. This physiologicalmodulation is achieved by the formulations of this invention and is thebasis for their improvement in the therapeutic efficiency and safety ofsulfonylureas.

[0200] As an individual progresses toward and into type 2 diabetes, anincreasing number of specific complementary biomolecules, biofactors andtrace elements are necessary to compliment sulfonylureas, as shown inthe following illustrations. It should be pointed out that a “shotgun”approach that throws everything in the biochemical bible at insulinresistance or type 2 diabetes not only is illogical, unnecessary andexpensive, but also may be detrimental. Errors of commission in thisregard are as inappropriate as errors of omission.

[0201] The present invention resides in an oral dosage form of apharmaceutical preparation, which contains, as one of its activeingredients, a sulfonylurea for use in the prevention and treatment ofinsulin resistance and/or type 2 diabetes. The preparation containselements of specific, sometimes unique, therapeutic biomolecules,biofactors and trace elements selected because of their particular andcritical, combinational physiological effects. These are formulated inamounts to achieve maximum complementarity of action with sulfonylureas.The formulations are designed to increase the efficiency and prolong theclinical period of use of the sulfonylurea, which is included. Inaddition the formulations will reduce, delay or avoid side effects knownto occur with the clinical use of sulfonylureas.

[0202] In the United States alone, 16 million people have type 2diabetes and a substantial multiple, perhaps 4× to 5×, are insulinresistant—at least one-half of these are undiagnosed. Type 2 diabetes ispreceded by a long period of insulin resistance, impaired glucosetolerance and a reversible metabolic state associated with an increasingprevalence of macrovascular complications. At the time of diagnosis,long-term complications have already developed in almost one fourth ofthese patients, largely because of insulin resistance and its associatedhyperinsulinemia and dyslipidemia.

[0203] Susceptibility to type 2 diabetes requires both genetic (mostlikely polygenic) and acquired factors. Its continuing pathogenesisinvolves an interplay of progressive cellular insulin resistance andpancreatic β-cell failure. Any ideal treatment of type 2 diabetes mustreduce insulin resistance and β-cell dysfunction in a majority oftreated patients and prevent, delay, or reverse the long-termcomplications.

[0204] One strategy of this invention is an attack on multiplepathophysiological processes by innovatively potentiating sulfonylurea.This is accomplished by combinations of biomolecules (some unique),biofactors and trace elements with disparate, although oftencomplementary or synergistic, mechanisms of action in order to providefor better sulfonylurea management of the insulin resistance syndrome,more efficient prevention of type 2 diabetes, better management of type2 diabetes and for prevention of long-term macrovascular andmicrovascular complications.

[0205] This invention enhances sulfonylureas' insulin secretagogueeffect and its effect on reducing glucose toxicity.

[0206] The complexity of type 2 diabetes pathophysiology provides theopportunity to expand sulfonylureas' clinical usefulness by theadministration of complementary, novel combinations of biomolecules,biofactors and trace elements, many of which are deficient orfunctionally inadequate in diabetics, or which may be unfavorablyaltered by sulfonylurea therapy.

[0207] The invention will enhance sulfonylureas' efficiency by:

[0208] Reducing diabetic microvascular complications,

[0209] Modulating Ca²⁺ signaling and β-cell membrane polarization,

[0210] Increasing insulin secretion and reducing hyperglycemia,

[0211] Maintaining synergy in the β-cells between amino acids andsulfonylureas,

[0212] Inhibiting platelet aggregation,

[0213] Reducing norepinephrine (NE) release from cardiac sympatheticnerves.

[0214] The invention will expand sulfonylureas' areas of effect by:

[0215] Reducing diabetic macrovascular complications,

[0216] Inhibiting mitochondrial-derived apoptosis,

[0217] Increasing the number of insulin receptors and the duration ofaction of insulin,

[0218] Increasing hepatic and peripheral insulin sensitivity,

[0219] Optimizing the β-cell cytoplasmic free Ca²⁺ level,

[0220] Improving lipid profiles,

[0221] Reducing non-enzymatic glycation and advanced glycation endproducts,

[0222] Reducing the free radical effect at the caveolae and insulinreceptor,

[0223] Reducing PAI-1 and improving fibrinolysis.

[0224] The invention will reduce sulfonylureas' adverse effects by:

[0225] Reducing sulfonylurea-induced weight gain and inadequate fattyacid oxidation,

[0226] Reducing the sulfonylurea risk of hypoglycemia,

[0227] Reducing sulfonylurea gastrointestinal side effects,

[0228] Lessening the sulfonylurea hypofibrinolytic effect,

[0229] Reducing sulfonylurea-induced vasoconstriction.

[0230] This invention provides therapeutic amounts of a member of thesulfonylurea family of drugs combined with elements to enhance treatmentof progressive insulin resistance and type 2 diabetes. This inventionaddresses sulfonylurea-induced mitochondrial malfunction and the failureof sulfonylurea to prevent diabetic macrovascular disease. It improvesthe useful antihyperglycemic effects of the sulfonylureas and adds anantihyperinsulinemia effect. It improves nocturnal control. It will insome patients provide at least a temporary substitute for insulin. Thecumulative effect of this invention will extend the period of time thatsulfonylureas can provide effective reduction of hyperglycemia.

[0231] By these various means, the invention will increase the number ofpatients who will benefit from sulfonylureas and the sulfonylurea-likeoral antidiabetic drugs.

[0232] B. Biguanides (Metformin)

[0233] B.1. Metformin: Pharmacodynamics and Pharmacokinetics

[0234] The biguanides metformin (GLUCOPHAGEO®) and phenformin wereintroduced in 1957. Phenformin was withdrawn in many countries becauseof an association with lactic acidosis a complication with whichmetformin is only rarely involved. This invention focuses on the diethylbiguanide, metformin

[0235] Metfornin has a unique mechanism of action and controls glycemiain both obese and normal-weight, type 2 diabetes patients withoutinducing hypoglycemia, insulin stimulation or hyperinsulinemia. Itprevents the desensitization of human pancreatic islets usually inducedby hyperglycemia and has no significant effect on the secretion ofglucagon or somatostatin. As a result it lowers both fasting andpostprandial glucose and HbA_(1c) levels. It improves the lipid profile.It does not increase lactate production as much as other biguanides fromskeletal muscle (e.g., phenformin): lactic acidosis associated withmetformin use is rare (reported incidence of 0.03/1,000 patient-yearsexposure) and has occurred mostly in patients for whom the drug wasinappropriate. Metformin can be safely used in the elderly, providingconservative doses are used.

[0236] Glucose levels are reduced during metformin therapy secondary toreduced hepatic glucose output from inhibition of gluconeogenesis andglycogenolysis. To a lesser degree it increases insulin action inperipheral tissues. Metformin also may decrease plasma glucose byreducing the absorption of glucose from the intestine, but this does notappear to be of clinical importance.

[0237] Metformin enhances the sensitivity of both hepatic and peripheraltissues (primarily muscle) to insulin as well as inhibiting hepaticgluconeogenesis and hepatic glycogenolysis. This decline in basalhepatic glucose production is correlated with a reduction in fastingplasma glucose levels. Its enhancement of muscle insulin sensitivity isboth direct and indirect. Improved insulin sensitivity in muscle frommetformin is derived from multiple events, including increased insulinreceptor tyrosine kinase activity, augmented numbers and activity ofGLUT4 transporters, and enhanced glycogen synthesis. However, theprimary receptor through which metformin exerts its effects in muscleand in the liver is as yet unknown. In metformin-treated patients bothfasting and postprandial insulin levels consistently decrease,reflecting a normal response of the pancreas to enhanced insulinsensitivity.

[0238] Metformin has a mean bioavailability of 50-60%. It is eliminatedprimarily by renal filtration and secretion and has a half-life ofapproximately 6 hours in patients with type 2 diabetes; its half-life isprolonged in patients with renal impairment. It has no effect in theabsence of insulin. Metformin is as effective as the sulfonylureas intreating patients with type 2 diabetes, but has a more prominentpostprandial effect than either the sulfonylureas or insulin. It istherefore most useful in managing patients with poorly controlledpostprandial hyperglycemia and in obese or dyslipidemic patients; incontrast, the sulfonylureas or insulin are more effective in managingpatients with poorly controlled fasting hyperglycemia.

[0239] B.2. Metformin: Effectiveness

[0240] Except perhaps for its appearance in aging, insulin resistanceand type 2 diabetes do not usually occur in isolation, but as part ofthe complex metabolic-cardiovascular ‘Syndrome X’, mentioned previously.Hyperinsulinemia and hyperglycemia are risk factors for all of thepathologies involved with the syndrome. Therefore, an initialrecognition of these many intermingled relationships must precede thedesign of effective treatment of these entwined pathologies, and bothhyperinsulinemia and hyperglycemia must be controlled if adversemacrovascular and microvascular complications are to be avoided.Long-term prospective studies have shown that treatment of hypertensionand dyslipidemia reduces cardiac events in patients with type 2diabetes. As an example, the United Kingdom Prospective Diabetes Study(UKPDS) showed that improved control of blood pressure reduced not onlymacrovascular complications (heart attacks, strokes, and death), butalso the risk for microvascular end points by 37% (P=0.009). It isclearly important that pharmacological therapy not aggravate riskfactors but leads to their improvement. Because obesity and physicalinactivity are global risk factors for coronary artery disease as wellas for diabetes, the need for weight loss and exercise must be stressedwhen diabetes initially is diagnosed, and must be reinforced throughoutthe natural history of the disease. However, modification of these maynot be sufficient for clinical management. Metformin has been anattractive therapeutic aid.

[0241] Metformin is absorbed mainly from the small intestine. It isstable, does not bind to plasma proteins, and is excreted unchanged inthe urine. It has a half-life of 1.3 to 4.5 hours. The maximumrecommended daily dose of metformin is 3 g, taken in three doses withmeals.

[0242] When used as monotherapy, metformin clinically decreases plasmatriglyceride and low-density lipoprotein (LDL) cholesterol levels by 10%to 15%, reduces postprandial hyperlipidemia, decreases plasma free fattyacid levels, and free fatty acid oxidation. Metformin reducestriglyceride levels in non-diabetic patients with hypertriglyceridemia.HDL cholesterol levels either do not change or increase slightly aftermetformin therapy. By reducing hyperinsulinemia, metformin improveslevels of plasminogen activator inhibitor (PAI-1) and thus improvesfibrinolysis in insulin resistance patients with or without diabetes.Weight gain does not occur in patients with type 2 diabetes who receivemetformin; in fact, most studies show modest weight loss (2 to 3 kg)during the first 6 months of treatment. In one 1-year randomized, doubleblind trial, 457 non-diabetic patients with android (abdominal) obesity,metformin caused significant weight loss.

[0243] Metformin reduces blood pressure, improves blood flow rheologyand inhibits platelet aggregation. In part this results from themaintenance physiologic levels of constitutive NO; in part byattenuation of the agonist-stimulated (Ca²⁺) response in VSMC inparallel with the effect of calcium channel blockers.

[0244] Treatment of insulin resistance with metformin may also haveimportant applications unique to women, particularly in polycystic ovarysyndrome by reducing ovarian cytochrome P450c17 alpha activity andameliorating hyperandrogenism. It is also possible that improvinginsulin sensitivity after menopause improves the cardiovascularprognosis of aging women.

[0245] These beneficial effects of metformin on various elements of theinsulin resistance syndrome help define its usefulness in the treatmentof insulin resistance and type 2 diabetes. These useful effects areenhanced when metformin is combined with components of this invention.The latter increase its effectiveness and efficiency, improve its safetyand expand the arena of its medical benefit.

[0246] Unquestionably the UKPDS established that type 2 diabetes is aprogressive disorder. Ideally, treatment with metformin (or asulfonylurea, or insulin) would halt the progressive deterioration ofglycemic control; this is not the case. For example: After an initial(and equivalent) decrease in elevated plasma glucose levels (HbA_(1c))of 1.5 to 2.0 percentage points, the long term rate of increase in thisvalue during treatment with metformin (or a sulfonylurea, or insulin)was identical to that for a group treated merely with diet therapy.These results suggest that once overt fasting hyperglycemia hasdeveloped, the decline in glycemic control is relentless. In the UKPDS,this decline was related to deterioration of β-cell function. TheUniversity Group Diabetes Program study similarly confirmed theprogressive nature of type 2 diabetes. These important studies emphasizethe need for constant reassessment of patients with insulin resistanceand/or diabetes, and for appropriate adjustment of the therapeuticregimen in order to avoid hyperinsulinemia, deterioration or apoptosisof β-cells and progressive loss of control over hyperglycemia.

[0247] Metformin reduces measurable levels of plasma triglycerides andLDL cholesterol and is the only oral, monotherapy, antidiabetic agentthat has the potential to reduce macrovascular complications, althoughthis favorable effect is attenuated by its tendency to increasehomocysteine levels. Likewise, it is the only oral hypoglycemic drugwherein most patients treated lose weight or fail to gain weight.

[0248] This invention introduces a strategy to increase the safety andefficiency of metformin in suppressing recognized risk factors, thusslowing the progression of disease by extending both the duration andthe breadth of metformin's therapeutic value. The strategy of thisinvention will increase the number of patients by whom metformin can beused at reduced dose levels, thereby avoiding, delaying and lesseningmetformin's adverse effects.

[0249] B.3. Metformin: Adverse Effects

[0250] Gastrointestinal side effects (diarrhea, nausea, abdominal pain,and metallic taste—in decreasing order) are the most common adverseevents, occurring in 20% to 30% of patients. These side effects usuallyare mild and transient and can be minimized by slow titration. If sideeffects occur during titration, they can be eliminated by return to thedose at which no symptoms were encountered.

[0251] Metformin interferes with vitamin B12 absorption (an effect whichis likely to be exaggerated in the elderly) and reduces serum vitaminB12 levels. This is a probable factor in the elevated levels ofhomocysteine (Hcy) which develop during treatment with metformin: themetabolism of Hcy depends on the vitamins B₆, B₁₂ and folate.

[0252] Lactic acidosis due to interference with the pyruvate oxidativepathway has rarely been reported with metformin use: a reportedfrequency of 3 cases per 100,000 patient-years occurs. However, patientswith renal impairment should not receive metformin; since it is clearedby urinary excretion, severe lactic acidosis can result. Hepaticdisease, a past history of lactic acidosis (of any cause), cardiacfailure, and chronic hypoxic lung disease are additionalcontraindications to its use. These conditions all predispose toincreased lactate production and hence to potentially lethal lacticacidosis.

[0253] This potentially fatal complication of biguanide therapy followsexcessive circulating biguanide levels and is a greater risk in elderlypatients—especially those older than 80—in whom an age-related decreasein glomerular filtration rate is often seen. In such patients, it isrecommended that creatinine clearance be measured before startingmetformin therapy and that the metformin dose be minimized.

[0254] This invention, by specifically countering metformin side effectsand/or by reducing the optimal metformin dose, will in turn, reduce theadverse effects of metformin therapy, while enhancing its beneficialeffects. This is especially true for elderly patients. It may permit aleast a limited number of patients with marginal renal and hepaticfunction to safely use metformin.

[0255] Metformin is included in formulations of this invention in orderto better manage insulin resistance syndrome, avoid hyperinsulinemia andsubsequent hyperglycemia, and help to provide ideal glycemic control.The concurrent delivery by this invention of active ingredients thatcomplement metformin, comprise pharmacological approaches that will helpto improve glycemic control by reducing the risks associated withspecific abnormalities of several conditions and functions frequentlyassociated with insulin resistance and/or type 2 diabetes. Theseinclude, among others, dysfunctional vascular endothelium, inappropriateapoptosis, undesirable platelet agglutination, inadequate maintenance ofcell volume, dyslipedemia, hyperhomocysteinemia, β-cell “exhaustion” ordestruction, and the accumulation of advanced glycation end products.

[0256] B.4. Use of the Invention for the Prevention and Treatment ofInsulin Resistance Syndrome and Type 2 Diabetes (Metformin+Other ActiveIngredients).

[0257] As an individual progresses from often-covert insulin resistancetoward and into type 2 diabetes, and has a corresponding need for drugtherapy, metformin is often the drug of choice. However, because oflimitations upon its chronic use and cumulative adverse effects, is-anincreasing number of specific biomolecules, biofactors and traceelements, as shown in the following illustrations, become necessary tocompensate for these deficiencies and adverse side effects. Other activeingredients of this invention are useful in correcting theseadversities.

[0258] The present invention defines pharmaceutical formulations thatcontain metformin as one ingredient, for use as oral dosage forms whichwill increase the effectiveness, efficiency and safety of the treatmentof insulin resistance and/or type 2 diabetes. In addition to metformin,the invention contains specific, sometimes unique, therapeuticbiomolecules, biofactors and trace elements selected because of theirparticular and critical, combinational physiological effects in reducingadversities commonly associated with insulin resistance, type 2 diabetesand clinical biguanide use.

[0259] One strategy of this invention is to modulate multiplepathophysiological processes to innovatively improve the clinical usemetformin. This is accomplished by combinations of active ingredientswith disparate, although often complementary or synergistic, mechanismsof action in order to provide for better metformin management of theinsulin resistance syndrome, more efficient prevention of type 2diabetes, better management of type 2 diabetes and for prevention oflong-term macrovascular and microvascular complications.

[0260] The invention will enhance metformin's areas of influence in:

[0261] Reducing diabetic microvascular complications.

[0262] Modulating gluconeogenesis.

[0263] Reducing dyslipidemia.

[0264] Reducing hypertension (increase NO).

[0265] Reducing hypertension (modify dysfunctional calcium signaling).

[0266] Improving polycystic ovary syndrome.

[0267] Increasing insulin receptor sensitivity .

[0268] Inhibiting platelet adhesion and aggregation.

[0269] Reducing AGEs.

[0270] Reducing cell membrane damage from free radicals.

[0271] The invention will expand metformin's areas of effect by:

[0272] Reducing diabetic macrovascular complications.

[0273] Inhibiting mitochondrial effected dysfunctional apoptosis.

[0274] Preventing progression from type 2 to “type 1.5” diabetes.

[0275] Improving insulin secretion.

[0276] Modifying post-receptor disturbances of insulin resistance.

[0277] Increasing the number of insulin receptors and the duration ofaction of insulin.

[0278] The invention will prevent or reduce metformin's dose-relatedadverse effects by:

[0279] Reducing gastrointestinal side effects.

[0280] Reducing hyperhomocysteinemia.

[0281] Reducing risk of lactic acidosis

[0282] This invention provides formulations that concurrently delivermetformin and other active ingredients for clinical use directed atenhancing the treatment of progressive insulin resistance and type 2diabetes. By various means the invention will increase the number ofpatients who will benefit from metformin therapy.

[0283] C. Combined Biguanide (Metformin)-Sulfonylurea

[0284] The invention contemplates the concurrent delivery of therapeuticcombinations of metformin and a member of the sulfonylurea family, inconjunction with other active ingredients. Situations may ariseclinically in which a practitioner may wish to prescribe the concurrentuse of metformin and a sulfonylurea, either in a single dosage form oras separate dosage forms, and concurrently prescribe a formulation whichreduces known side effects of these drugs and which improves theefficiency of their use.

[0285] The above recitations describe benefits, side effects anddeficiencies that arise from the individual use of metformin and of thesulfonylureas. Certainly all of the deficiencies and adverse effectsthat are listed may occur together in a single individual—it is morelikely that the incidence of each adverse effect or deficiency should beconsidered a clinical variable with a significantly wide degree ofincidence across patient populations. As a result, predicting thefrequency and intensity of each adverse effect or deficiency for eithermetformin or for one of the sulfonylureas, becomes a statisticalconsideration of greater or lesser accuracy.

[0286] The clinical use of combinations of metformin and a sulfonylureaintroduces more variables into this statistical calculation. Untilsufficient clinical use of these combinations has occurred and has beenevaluated, the existence or development of unique side effects anddeficiencies cannot be known. It may rationally be assumed, however,that the side effects and deficiencies of each will statistically sortinto about the same incidence currently present when each drug is usedindividually. However, whether or not some unknown adverse synergy maydevelop is not now predictable. It therefore cannot be therapeuticallyanticipated.

[0287] The invention contemplates that the formulations describedindividually as containing these two drugs—metformin or thesulfonylureas, along with the other active ingredients of thisinvention—will be equally useful and effective when these therapeuticdrugs are used concurrently.

[0288] The invention gives the practitioner an opportunity to provideconcurrent complementary support for a widened spectrum of patients whoare at risk of insulin resistance and type 2 diabetes, including thosewho require both metformin and sulfonylurea in combination.

[0289] Formulation Groups of this Invention (Active Ingredients OtherThan Metformin or Sulfonylurea)

[0290] The active ingredients (other than metformin or a sulfonylurea)within the invention are organized into four functionally interrelatedand interdependent, formulation groups: 1. Mitochondrial MetabolicGroup, 2. Plasma and Mitochondrial Membrane Integrity Group, 3.Nocturnal Group and 4. Insulin Alternative Group. What follows is asummary. More extensive discussion of each ingredient is present furtherbelow in the document.

[0291] I. Mitochondrial Metabolic Group) Dosages in Milligrams:Preferred Most Preferred L-Carnitine 90-2500 300-1000 Ascorbate 75-2500250-1000 Choline 15-250  50-100 Taurine 75-3125 250-1250 Magnesium30-1000 100-400  Folic Acid 0.3-2.0  0.10-0.80 

[0292] Metformin is involved in a cell-signaling pathway targeted to themitochondrial respiratory chain complex I and has a persistent effecteven after cessation of the signaling process. Mitochondrialabnormalities occur in the hepatocytes of patients withhyperhomocysteinemia via homocysteine-induced expression of themitochondrial electron transport chain gene, cytochrome c oxidaseIII/ATPase 6,8. Homocysteine and H₂O₂ (but not H₂O₂ alone) causes adecrease in mitochondrial RNA levels, providing evidence thathomocysteine and H₂O₂ act synergistically to cause mitochondrial damage.Homocysteine, associated with vasoconstriction, hypertension andthrombogenesis, tends to be elevated by metformin treatment.Metformin-induced hyperhomocysteinemia can be prevented by folic acid, acomponent of this group.

[0293] Sulfonylureas reduce available carnitine by restricting the renalreuptake of carnitine. In turn, this reduces the carnitine-directedtransfer of long chain fatty acids into the mitochondria—the main ATP(energy) source for the latter. Exogenous carnitine and choline (whichlessens carnitine renal loss) tend to normalize the mitochondrial fuelsupply. Taurine, often low in progressive insulin resistance and type 2diabetes, is required to move Ca²⁺ into the mitochondria to signal ATPproduction. Magnesium is also necessary in the modulation ofintracellular Ca²⁺: it works with mitochondrial-generated ATP totransfer excess cytoplasmic Ca²⁺ out of the cell—this transferre-establishes cell membrane repolarization, which is necessary forsulfonylurea-metformin to activate the next shift of insulin into thebloodstream.

[0294] II. Plasma and Mitochondrial Membrane Integrity Group Dosages inMilligrams: Preferred Most Preferred D-α-Lipoic Acid 30-1500 100-600 N-acetyl-Cysteine 78-3900 200-1200 Ubiquinone 4.5-225   15-90  Selenium0.02- 0.05-0.3  0.75  Tocopherol-Tocotrienol 15-1600 50-800 L-Arginine75-3125 250-1250 Tetrahydrobiopterin 24-3000  80-1200

[0295] The plasma membrane consists of a bilayer of amphipathicphospholipids that provides an anionically charged fluid barrier withselective permeability and selective active-transfer mechanisms. Themembrane houses protein molecules in arrangements that support theirfunctionality and provide a surface consistent with the needs ofligands. In the case of the vascular endothelium, this arrangement mustprovide a physiologic surface that is proper both for circulating cellsand favorable luminal flow. If the cell membrane loses its integrity,Ca²⁺ modulation is impossible, endothelin-1(ET-1) increases and NO isinduced into an iNOS Type II inflammatory condition: the lattercontributes to inflammation and cell death, including pancreaticβ-cells. The sum of these events leads to further loss of membraneintegrity. There now exists the proverbial circle in a spiral of,vascular degradation, local hypoxia, thrombogenesis andatrophy/apoptosis causing the macrovascular complications of progressiveinsulin resistance and type 2 diabetes.

[0296] The permeability transition pore, a multiprotein complex formedat the contact site between the mitochondrial inner and outer membranes,is the rate limiter of apoptosis. This mitochondrial permeability porebecomes dysfunctional (it opens) because of: (1) uncoupling of therespiratory chain within the membrane leading to the cessation of ATPsynthesis, (2) hyperproduction of superoxide anions, (3) repletion oroxidation of non-oxidized glutathione, and (4) disruptions of Ca²⁺homeostasis. These perturbations are lethal to the status levels ofmitochondrial energy. Ubiquinone (coenzyme Q 10) is integral to themitochondrial respiratory chain and additionally, workingsynergistically with α-tocopherol, it reduces mitochondrial superoxideanions.

[0297] Some diabetic complications relating to cell membrane integritymay be worsened by sulfonylurea or metformin treatment.

[0298] Glutathione (GSH) is the most important intracellular defenseagainst free radicals generated by mitochondrial metabolism and excessfree radicals secondary to hyperglycemia. It becomes depleted indiabetes. Metformin increases available GSH in both diabetics andnon-diabetics, indicating that it has some antioxidant activity that isindependent of, and in addition to, its reductions of hyperglycemia.

[0299] GSH, a tripeptide, is not adequately absorbed from thegastrointestinal tract and requires a substrate; N-acetyl-cysteine ispresent in this invention as a GSH prodrug. GSH is conserved by thepotent free radical scavenger β-lipoic acid. Selenium is an imperativecofactor for glutathione peroxidase, which is required for optimized GSHactivity. D-α-tocopherol and ascorbic acid act synergistically todirectly reduce peroxidation of membrane phospholipids, complimentingGSH. The combination of these ingredients stabilizes membraneproteoglycans, preserving the anionic charge necessary for normalpermeability characteristics, which are imperative if diabetic micro andmacrovascular complications are to be avoided.

[0300] L-arginine administration maintains the substrate necessary topermit normal, constitutive NO/cGMP. This balances the increased ET-1 ofprogressive insulin resistance, and compliments prostacyclin inmaintaining the smooth, healthy, vascular endothelial surfaces requiredfor normal, laminar blood flow.

[0301] Tetrahydrobiopterin (BH4) is an essential cofactor for nitricoxide synthase. In low concentrations of BH4, as is common in diabetes,nitric oxide synthase produces less constitutive NO and,correspondingly, larger quantities of the superoxide anion and hydrogenperoxide.

[0302] Excessive pancreatic β-cell apoptosis is responsible for theirreversible progression toward insulin dependence found in type 2diabetes. The integrity of the mitochondrial membrane is essential forpreventing β-cell dysfunctional apoptosis. The components of this groupwill inhibit the pre-mitochondrial (induction) phase of apoptosis causedby prooxidants, excessive cytosolic Ca²⁺ and elevations of induced NO.

[0303] III. Nocturnal Group Dosages in Milligrams: Preferred MostPreferred Melatonin 0.15- 0.5-3   7.5  L-Carnitine 90-2500 300-1000Ubiquinone 4.5-225   15-90  Folic Acid 0.03- 0.10-0.80  2.0  Magnesium30-1000 100-400  L-Arginine 75-3125 250-1250 Tetrahydrobiopterin 24-3000 80-1200

[0304] Sulfonylureas can increase the risk of nocturnal hypertension anddecrease myocardial tolerance for ischemia and reperfusion. They doappear to have some antiarrhythmic effect in preventing ventriculararrhythmias induced by transient myocardial hypoxemia.

[0305] Nocturnal occurrences of myocardial ischemia/reperfusion eventsare common in progressive insulin resistance and type 2 diabetes, andthe post-infarction mortality rate in these patients is double that ofnon-diabetics. Bedtime therapy, as defined in this invention, assists inreducing the nighttime risks of blunted nocturnal falls in bloodpressure, myocardial ischemia and cardiac arrythmias; therebycomplementing sulfonylurea and/or metformin treatment, and adding adimension of protection against diabetic macrovascular complications.

[0306] The increased incidence of nocturnal myocardial ischemia andarrhythmias in progressive insulin resistance and type 2 diabetesrelates to: (1) hypertension, (2) a blunted nocturnal fall in bloodpressure, (3) hypoxemia induced by sleep apnea, (4) autonomicneuropathy, and (5) thrombogenesis. These are often interrelated. Forexample: in hypertension, sleep apnea syndrome and diabetes the normalnocturnal fall in blood pressure is absent or reversed. As anotherexample: progressive insulin resistance causes hypertension and isassociated with visceral obesity, which itself is a factor, along withinsulin resistance, in causing sleep apnea. (See Reaven's syndromeabove.) As mentioned earlier, the sulfonylureas increase visceralobesity by interfering with normal fatty acid oxidation in themitochondria.

[0307] The other active ingredients of this invention, used withsulfonylureas and/or metformin, will restore more normal circadianvascular physiology by: (1) reducing the nocturnal vasoconstrictionrelated to hypertension and blunted nocturnal drops in blood pressure,(2) lessening cardiac autonomic neuropathy, (3) reducing thrombogenesis,(4) restoring physiologic fatty acid oxidation, and (5) reducing sleepapnea.

[0308] IV. Insulin Alternative Group Dosages in Milligrams: PreferredMost Preferred Vanadium 7.5-375 25-150 L-Arginine   75-3125 250-1250Chromium 0.01- 0.03-0.25  0.63  Zinc 1.5-125 5-50

[0309] Oral antidiabetic monotherapy, while initially successful inreducing hyperglycemia, seldom succeeds for more than a few years. Evenwith combinations of antidiabetic oral agents many patients eventuallyrequire insulin. The introduction of insulin in patients being treatedwith sulfonylurea or with metformin increases the twin risks ofhypoglycemia and weight gain. It also reintroduces the hyperinsulinemicrisks that are associated both with progressive insulin resistance andwith primary sulfonylurea or metformin treatment. The need forinjectable insulin, however necessary, is a setback for the patient.

[0310] When hyperglycemia control inevitably fails in patients treatedwith metformin and/or a sulfonylurea, (upgrading to) this inventionprovides a temporary oral alternative to insulin. This is achieved by:(1) adding a natural insulin secretagogue, (2) supplying aninsulin-mimetic substance, (3) increasing insulin receptor sensitivity,(4) increasing the number of insulin receptors, (5) improving insulinreceptor binding, and (6) prolonging insulin action. These are discussedmore extensively further below.

[0311] L-arginine is an insulin secretagogue that directly supportsinsulin binding to its receptor, and increases insulin receptorsensitivity via constitutive NO. Glucose uptake is augmented byincreased perfusion of skeletal muscles secondary toL-arginine/NO-induced vasodilation: Insulin's vasodilatation effectdepends on insulin's regulation of NO production by increasing theavailability of cofactor BH4 needed for activation of NO synthase.Supplementation of BH4 is a logical insulin mimic in achievingvasodilation.

[0312] Vanadium mimics insulin intracellularly and prolongs insulinaction. It increases both hepatic and peripheral insulin sensitivity,and activates glycogenesis, decreasing hyperglycemia. Vanadium preservespancreatic β-cells, and decreases diabetic hyperphagia, therebyimproving both the safety and effectiveness of sulfonylurea andmetformin.

[0313] Chromium, often deficient in diabetes, is a cofactor for insulin,increasing its binding to the insulin receptor and reducing insulinresistance. It increases the number of insulin receptors and facilitatesinsulin internalization by endocytosis from caveolae, thereby enhancingmetformin's beneficial effect on peripheral insulin sensitivity.

[0314] Zn²⁺ is involved with the synthesis, storage and secretion ofinsulin (thus aiding the sulfonylureas) as well as preserving itsconformational integrity. At the insulin receptor site, Zn2+ preventshyperglycemia by increasing insulin activity (aiding metformin);diabetics tend to have low plasma Zn²⁺ concentrations and decreasedtotal body Zn²⁺, resulting in reduced insulin efficiency andhyperglycemia. Diabetics have increased urinary loss of Zn²⁺, which inturn contributes to hyperglycemia. This vicious cycle supports the useof supplemental Zn²⁺.

[0315] When added to an ongoing sulfonylurea and/or metformin regimen,this oral dosage form will usually be used in the evening, as is usuallytrue when insulin is added. However, it is specifically designed to beused concomitantly and safely with daytime dosage forms of thisinvention, adding therapeutic complementarity without increasing risk.This provides the physician wide latitude of treatment options accordingpatient need.

[0316] As an upgrade for combined sulfonylurea and/or metformin therapy,this invention will reduce sulfonylurea and/or metformin requirementsand will prevent or delay the need for injectable insulin in type 2diabetes.

[0317] Molecular Complexes Which May be Included in Formulations

[0318] The molecular complexes of this invention address various aspectsof insulin resistance and type 2 diabetes such as 1) mitochondrialmetabolism, 2) mitochondrial membrane integrity, 3) plasma membraneintegrity, 4) adverse cytokine cascades, 5) dysfunctional β-cellapoptosis, 6) inappropriate Ca²⁺ signaling, 7) insulin secretion, 8)insulin receptor sensitivity and 9) adverse effects of combinations ofsulfonylurea-metformin.

[0319] 1. α-lipoic acid complexes

[0320] 2. L-arginine or L-arginine ascorbate complexes

[0321] 3. L-carnitine or L-carnitine ascorbate complexes

[0322] 4. L-taurine or L-taurine ascorbate complexes

[0323] 5. Tocotrienol nicotinate, tocotrienol picolinate

[0324] 6. D,α-tocopherol nicotinate, D,α-tocopherol picolinate

[0325] 7. Peroxovanadate-nicotinic acid (POV)

[0326] 8. Propionylcarnitine taurine bi-amide

[0327] 1. α-Lipoic Acid Complexes

[0328] α-Lipoic acid complexes included in the invention are used toincrease the effectiveness, efficiency and safety of metformin and/orsulfonylureas in the prevention and treatment of progressive insulinresistance and diabetes mellitus. They have the following formulae:

[A]M X

[0329] wherein

[0330] a. A is α-lipoic acid or thioctic acid,

[0331] b. M is a metal ion taken from Mg²⁺ or Zn²⁺,

[0332] c. X is an anion taken from the group including hydroxides,halides, acetates or ascorbates acid salts.

[0333] or

M[A]

[0334] wherein,

[0335] a. A is α-lipoic acid or thioctic acid,

[0336] b. M is a metal ion taken from Mg²⁺ or Zn²⁺.

[0337] The invention is a method for the oral administration of lipoicacid ascorbate or metallolipoate complexes, alone or in combination, asan active ingredient for humans. The cation of the metallolipoatecomplexes may be Mg²⁺ or Zn²⁺.

[0338] The compound is preferably administered in an oral daily dosagewith Preferred and Most Preferred amounts of individual components asshown in the example below.

[0339] Example: Magnesium α-Lipoate (including excipients) Ranges inMilligrams Per Day Entire Compound Magnesium α-Lipoate Preferred: 87-1735 3.6-72  60-1200 Most Preferred: 173-867   7-36 120-600

[0340]2. L-Arginine Complexes

[0341] L-arginine complexes included in the invention are used toincrease the effectiveness, efficiency and safety of metformin and/orsulfonylureas in the prevention and treatment of progressive insulinresistance and diabetes mellitus. They have the following formulae:

[Arg]C

[0342] wherein

[0343] a. A is L-arginine or bis-L-arginine,

[0344] b. C is ascorbic acid or ascorbate,

[0345] or

[Arg]M X

[0346] a. Arg is the amino acid L-arginine or bis-L,arginine,

[0347] b. M is a metal ion taken from Mg²⁺ or Zn²⁺,

[0348] c. X is an anion taken from the group including hydroxides,halides, sulfates, phosphates, acetates, ascorbates or bis-ascorbic acidsalts,

[0349] or

M[Arg]

[0350] wherein

[0351] a. M is a metal ion taken from Mg²⁺ or Zn²⁺,

[0352] b. Arg is L-arginine or bis-L,arginine.

[0353] The invention is a method for the oral administration of arginineascorbate or metalloarginate complexes, alone or in combination, as anactive ingredient for humans. The cation of the metalloarginatecomplexes may be Mg²⁺ or Zn²⁺.

[0354] The compound is preferably administered in an oral daily dosagewith preferred and most preferred amounts of individual components asshown in the example below.

[0355] Example: L-Arginine Ascorbate (including excipients) Ranges inMilligrams Per Day Entire Compound L-Arginine Ascorbate Preferred:213-7113  83-2761  75-2500 Most Preferred: 711-2845 276-1104 250-1000

[0356] 3. L-Carnitine Complexes

[0357] Metal L-carnitine complexes included in the invention are used toincrease the effectiveness, efficiency and safety of metformin and/orsulfonylureas in the prevention and treatment of progressive insulinresistance and diabetes mellitus. They have the following formulae:

[Car]C

[0358] wherein

[0359] a. Car is L-carnitine or bis-L-carnitine,

[0360] b. C is ascorbic acid or ascorbate,

[0361] or

[CAR]M X

[0362] wherein

[0363] a. Car is L-carnitine or bis-L,carnitine,

[0364] b. M is a metal ion taken from Mg²⁺ or Zn²⁺,

[0365] c. X is an anion taken from the group including hydroxides,halides, sulfates, phosphates, acetates, ascorbates or bis-ascorbic acidsalts,

[0366] or

M[Car]

[0367] wherein

[0368] a. M is a metal ion taken from Mg²⁺ or Zn²⁺,

[0369] b. Car is the amino acid L-carnitine or bis-L-carnitine.

[0370] The invention is a method for the oral administration ofcarnitine ascorbate or metallocarnitate complexes, alone or incombination, as an active ingredient for humans. The cation of themetallocarnitate complexes may be Mg²⁺ or Zn²⁺.

[0371] The compound is preferably administered in an oral daily dosagewith Preferred and Most Preferred amounts of individual components asshown in the example below. (Including Excipients) Ranges in MilligramsPer Day Entire Compound Magnesium Carnitine Preferred: 44-1754 2.3-9130-1200 Most Preferred: 88-877    5-46 60-600 

[0372] Example: Magnesium L-Carnitate

[0373] 4. L-Taurine Complexes

[0374] L-Taurine complexes included in the invention are used toincrease the effectiveness, efficiency and safety of metformin and/orsulfonylureas in the prevention and treatment of progressive insulinresistance and diabetes mellitus. They have the following formulae:

[Tau]C

[0375] wherein

[0376] a. Tau is L-taurine or bis-L-taurine,

[0377] b. C is ascorbic acid or ascorbate,

[0378] or

[Tau]M X

[0379] wherein

[0380] a. Tau is L-taurine or bis-L,taurine,

[0381] b. M is a metal ion taken from Mg²⁺ or Zn²⁺,

[0382] c. X is an anion taken from the group including hydroxides,halides, sulfates, phosphates, acetates, ascorbates or bis-ascorbic acidsalts,

[0383] or

M[Tau]

[0384] wherein

[0385] a. M is a metal ion taken from Mg²⁺ or Zn²⁺,

[0386] b. Tau is the amino acid L-taurine or bis-L,taurine.

[0387] The invention is a method for the oral administration of taurineascorbate or metallotarurate complexes, alone or in combination, as anactive ingredient for humans. The cation of the metallotaurate complexesmay be Mg²⁺ or Zn²⁺.

[0388] The compound is preferably administered in an oral daily dosagewith preferred and most preferred amounts of individual components asshown in the example below. (Including Excipients) Ranges in MilligramsPer Day Entire Compound Zinc Taurate Preferred:  51-2044 7.9-317 30-1200Most Preferred: 102-1022  16-158 60-600 

[0389] Example: Zinc Taurate

[0390]5. Tocotrienol Nicotinate and Tocotrienol Picolinate

[0391] Tocotrienol complexes included in the invention are used toincrease the effectiveness, efficiency and safety of metformin and/orsulfonylureas in the prevention and treatment of progressive insulinresistance and diabetes mellitus.

[0392] Example: Tocotrienol Nicotinate (Including Excipients) Ranges inMilligrams Per Day Entire Compound Tocotrienol Nicotinate Preferred: 61-1844  34-1024 10-293 Most Preferred: 307-1229 171-683 49-195

[0393] 6. D,α-Tocopherol Nicotinate and D,α-Tocopherol Picolinate

[0394] D,α-Tocopherol complexes included in the invention are used toincrease the effectiveness, efficiency and safety of metformin and/orsulfonylureas in the prevention and treatment of progressive insulinresistance and diabetes mellitus.

[0395] Example: D,α-Tocopherol Nicotinate Including Excipients Ranges inMilligrams Per Day Entire Compound Tocopherol Nicotinate Preferred: 61-1844  34-1024 10-293 Most Preferred: 307-1229 171-683  49-195

[0396] 7. Propionylcarnitine Taurine Bi-amide

[0397] This invention is a method for the oral administration of thebi-amide of propionylcarnitine and taurine, for the facilitation ofmitochondrial fatty acid oxidation and ATP production. It is included inthe invention and used to increase the effectiveness, efficiency andsafety of metformin and/or sulfonylureas in the prevention and treatmentof progressive insulin resistance and diabetes mellitus.

[0398] The compound is preferably administered in an oral daily dosagewith Preferred and Most Preferred amounts of individual components asshown in the example below.

[0399] Example Propionylcarnitine-Taurine Amide Including ExcipientsRanges in Milligrams Per Day Entire Compound Propionylcarnitine TaurinePreferred:  97-3867 46.2-1849 25-1000 Most Preferred: 193-1933  92-92450-500 

[0400] 8. Peroxovanadate-Nicotinic Acid

[0401] This invention is a method for the oral administration of thebi-amide of peroxovanadate and nicotinic acid, for the facilitation offatty acid oxidation and ATP production. It is included in the inventionand used to increase the effectiveness, efficiency and safety ofmetformin and/or sulfonylureas in the prevention and treatment ofprogressive insulin resistance and diabetes mellitus.

[0402] The biofactors and the physiological activities listed above arereviewed in more specificity below.

PRESENT INVENTION

[0403] The present invention resides in pharmaceutical preparationscontaining sulfonylurea, metformin or metformin-sulfonylureacombinations with active, complementary ingredients in the treatment ofprogressive insulin resistance and type 2 diabetes. The inventiondescribes combinations of specific, sometimes unique, therapeuticbiomolecules, biofactors and trace elements selected because of theirparticular and critical, combinational physiological effects inimproving the safety and effectiveness of sulfonylurea, metformin andsulfonylurea-metformin. These are formulated in amounts to achievemaximum complementarity of action.

[0404] Type 2 diabetes is preceded by a long period of impaired glucosetolerance and a reversible metabolic state associated with an increasingprevalence of macrovascular complications. Unfortunately, at the time ofdiagnosis, long-term complications have already developed in almost onefourth of these patients. Susceptibility to type 2 diabetes requiresboth genetic (most likely polygenic) and acquired factors. Itscontinuing pathogenesis involves interplay between progressive cellularinsulin resistance and pancreatic β-cell failure. Any ideal treatment oftype 2 diabetes must reduce insulin resistance and β-cell dysfunction ina majority of treated patients and, in addition, prevent, delay, orreverse long-term complications.

[0405] Sulfonylurea and/or metformin treatment reduces hyperglycemia andmicrovascular complications of the diseases, but fails to preventmacrovascular complications—indeed, such therapy may worsenmacrovascular complications: sulfonylurea by promoting hyperinsulinemia;metformin by inducing hyperhomocysteinemia.

[0406] The therapeutic strategy of the invention is founded upon themodification of multiple pathophysiological processes by innovativecombinations of biomolecules, biofactors and trace elements withdistinct, but complementary or synergistic, mechanisms of action inorder to provide a safe and effective improvement to sulfonylurea and/ormetformin therapy. The invention clinically expands the effect of thistherapy by preventing both diabetic microvascular complications(nephropathy, neuropathy, retinopathy) and diabetic macrovascularcomplications (heart attack, stroke, peripheral vascular disease).

[0407] This invention physiologically complements the clinical use ofsulfonylurea and/or metformin by improving the disturbed mitochondrialfunction that occurs as a result of this treatment, and by preventingthe disturbance of plasma and mitochondrial membrane integrity thatleads to vascular diabetic complications.

[0408] The complexity of progressive insulin resistance and type 2diabetes pathophysiology, and the nature of the effect of either or bothsulfonylurea and of metformin on the disease process, provides anopportunity to improve the clinical value of these drugs and reducedevastating long-term diabetic complications. By the concurrentadministration of complementary combination of biomolecules, biofactorsand trace elements, many of which are deficient or functionallyinadequate in progressive insulin resistance and type 2 diabetes, andsome of which are inadequately moderated or worsened by sulfonylureaand/or metformin treatment, the clinical usefulness of the latter willbe expanded.

[0409] The invention will: (1) improve disturbed mitochondrial function,(2) increase insulin receptor sensitivity, amplifying thesulfonylurea-metformin ability to reduce hyperglycemia, (3) modifydiabetic post-receptor disturbances, including deleterious types of Ca²⁺signaling, (4) reduce plasma and mitochondrial membrane damage from freeradicals, (5) optimize repolarization of the β-cell as required for acontinued sulfonylurea effect, (6) protect pancreatic β-cells frompremature apoptosis, (7) reduce the deleterious metformin inducedelevated homocysteine, (8) lessen non-enzymatic glycation and, (9)prolong the timeframe over which sulfonylurea and/or metformin treatmentis useful.

[0410] Components of the Invention

[0411] The components within the invention are those that havesubstantial and varied complementarity. For a variety of reasons, manyof the components are deficient in persons with insulin resistance andin diabetic patients. Mg²⁺, ascorbate, chromium and certain amino acids(viz., carnitine, taurine, arginine) are important examples of suchdiabetic deficiencies, either because of inadequate intake or pathologicdepletion.

[0412] L-arginine

[0413] L-arginine is usually limited in insulin resistance syndrome andtype 2 diabetes; an insufficiency that can be overcome by dietarysupplementation.

[0414] L-arginine is the substrate required for NO synthesis via theconstitutive endothelial enzyme eNOS, leading to the formation of cyclicGMP, the messenger of NO's physiological effects. NO is a chemicallyunstable radical formed by enzymatic conversion of L-arginine in thepresence of molecular oxygen. It elicits relaxation of vascular smoothmuscle cells (VSMC) by activating cytosolic guanylate cyclase, theenzyme involved in cGMP production. In addition to its pivotal role invasodilation, NO inhibits platelet and leukocyte adhesion to endothelialcells, inhibits platelet aggregation and facilitates the dissolution ofsmall platelet aggregates. NO also affects fibrinolytic activity byregulating the release of tissue-type plasminogen activator from thevascular endothelial cells and plasminogen activator inhibitor-1. Thesebiological actions make NO a key substance in the endogenous defenseagainst vascular occlusion and thrombosis, and in improving the dynamicand theological vascular responses in patients with insulin resistancesyndrome and/or type 2 diabetes.

[0415] Metformin and L-arginine are complementary in modulatingendothelial function by normalizing constitutive NO production. Thisenhances the antihypertensive effects evident in some individuals, andreduces the hypertensive and thrombogenic effects in those individualsin whom metformin induces hyperhomocysteinemia. Furthermore, metforminand L-arginine are complementary in decreasing both platelet aggregationand blood viscosity.

[0416] Activation of ATP sensitive K⁺ channels (K(ATP)) and the NO-cGMPpathway both reduce norepinephrine (NE) release from cardiac sympatheticnerves during stimulation. In this regard NO and sulfonylurea-sensitivechannels act in a complementary fashion, but appear to be independent ofeach other in the regulation of heart rate during cardiac sympatheticnerve activation.

[0417] As noted above, sulfonylurea treatment can induce coronaryvasoconstriction and reduce coronary blood flow at rest by about 25%,but does not reduce flow during exercise, providing theL-arginine-cNOS-NO-cGMP pathway is normal. Increased perfusionpulsatility, as accompanies exercise, offsets vasoconstriction fromsulfonylurea-induced K+ATP-channel blockade. And the channel blockade isreduced by nitric oxide synthase (eNOS) and constitutive NO release fromthe vascular endothelium. This effect is mediated by A(2A) receptors,activation of which elicit the vasodilation by endothelial release of NOand by the smooth muscle opening of K(ATP) channels.

[0418] In addition, L-arginine stimulates insulin secretion via NO andimproves insulin sensitivity at the receptor via eNOS. Each of theseL-arginine actions augments sulfonylurea therapy: The former as aninsulin secretogue, an effect that complements sulfonylurea; the latterby increasing peripheral insulin sensitivity, which both complements andextends the effects of combined sulfonylurea-metformin on glycemiccontrol.

[0419] Treatment with L-arginine inhibits lipid peroxidation,additionally protecting the endothelium and reducing long-termmicroangiopathic complications in insulin resistance syndrome and type 2diabetes.

[0420] Finally, it is reasonable to expect that L-arginine like Viagra®will have a favorable effect on the digestive disorders of diabetics,including perhaps, a reduction in the gastrointestinal side effects ofsulfonylurea-metformin.

[0421] When L-arginine is administered it increases the effectiveness,efficiency, and safety of combined sulfonylurea-metformin in theprevention and treatment of insulin resistance and diabetes mellitus.

[0422] Ascorbic Acid

[0423] Diabetics have at least 30% lower circulating ascorbic acidconcentrations than people without diabetes mellitus. The cellularuptake and cellular level of vitamin C (ascorbic acid, AA) is promotedby insulin and reduced in insulin resistance and hyperglycemia.Additionally, AA is excessively lost via the diabetic kidney.

[0424] Ascorbic acid is a cofactor of two-enzyme hydroxylation in thepathway of carnitine biosynthesis . . . epsilon-N-trimethyllysinehydroxylase and gamma-butyrobetaine hydroxylase. Carnitine levels arereduced in individuals with subnormal (although still non-scorbutic) AAstatus, providing evidence that metabolic changes occur prior to theclassic manifestation of scurvy. In addition to the evident diabeticangiopathies and dyslipidemia derived directly from inadequatecarnitine, the symptoms of weakness and fatigue often seen inprogressive insulin resistance and type 2 diabetes may relate tocarnitine deficient mitochondrial dysfunction, indirectly due toinadequate cytosolic AA.

[0425] The hydrophilic scavengers, ascorbate and GSH, are found inmitochondrial compartments. They scavenge oxidizing free radicals inthese mitochondrial water compartments by means of one-electron orhydrogen atom transfer.

[0426] Mitochondria are cellular organelles in which the generation ofreactive oxygen species (ROS) is high and in which ROS productiongreatly multiplies during pathological processes such as diabetes.Normally ROS are effectively protected against by the high capacity ofinherent antioxidative systems: enzymes and water- or lipid-soluble lowmolecular weight antioxidants. The latter defense systems can beregenerated after or during oxidative stress, as long as themitochondria are in an energized state. The energizing of mitochondriamainly depends on the availability of suitable respiratory substratesthat provide hydrogen for the reduction of either the GSH orα-tocopherol system. GSH is regenerated by glutathione reductase withthe substrate NADPH; the α-tocopheroxyl-radical by reduced coenzyme Q orascorbate. Mitochondria do not undergo damage as long as they can keep ahigh-energy state. The delicate balance betweenprooxidative/antioxidative activities can be shifted rapidly towardsoxidation if prooxidants exist—such as excessive levels ofascorbate—especially in the presence of iron. After exhaustion of theirantioxidative defense systems, damage of mitochondrial membranes finallyoccurs leading to total degradation of the mitochondria. Theformulations of this invention provide supplements in amounts andschedules to provide ascorbate sufficient to avoid its deficiency, butnot at excessive, potentially prooxidant levels.

[0427] ROS have been implicated in a variety of pathological processes.The generation of highly reactive oxygen metabolites is an integralfeature of normal cellular metabolism (mitochondrial respiratory chain,phagocytosis, arachidonic acid metabolism, ovulation and fertilization),however their production can multiply during pathological circumstances.Free oxygen radicals act either on the extracellular matrix or directlyupon cellular membranes themselves. The fundamental defenses of theorganism against ROS include scavenger enzymes (superoxide dismutase,catalase, glutathione peroxidase) and lipid- and water solubleantioxidant compounds (ascorbic acid, glutathione, albumin, transferrin,etc.). Their role in ischemia-reperfusion models have now beencomprehensively investigated and it has become clear that ROS are to beblamed for the bulk of post-ischemic injuries, hence the basis for newlyestablished antioxidant therapy in such cases. Also, more and morestudies have concluded a pivotal role of ROS in degenerative andinflammatory conditions, post-radiation processes and aging.

[0428] While the free radical scavenging abilities of AA are wellestablished, its complementary actions for free radical defense withother components of the this invention may be less well known: withtaurine for HOCI-defense; with GSH for hydrogen peroxide defense; andwith Zn²⁺ for superoxide defense.

[0429] Insulin is readily glycated and secreted from insulin secretingβ-cells under hyperglycemic conditions; the extent of insulin glycationincreasing in relation to the level of hyperglycemia, attaining levelsup to 27%. Such glycation interferes with its function at the insulinreceptor. Cellular insulin glycation is decreased by 66-80% byascorbate. The reduction of hyperglycemia secondary to the use oflong-term treatment with combinations of sulfonylurea-metformin is alsoassociated with a decrease in the extent of insulin glycation. Thisevidences one of the important complementary actions ofsulfonylurea-metformin and ascorbate that is lost in AA deficientpatients.

[0430] Ascorbic acid is not only a powerful antioxidant in the cytosol,but is also a cofactor in collagen biosynthesis and an inhibitor ofplatelet activation, prostaglandin synthesis and the polyol (sorbitol)pathway. The latter is of particular importance in reducingmicrovascular permeability and nonenzymatic protein glycation.

[0431] Because free radicals are released from the autooxidation ofglucose, hyperglycemia induces oxidative free radical stress. AA hasbeen shown to be highly consumed in diabetes, presumably through freeradical scavenging. If a continuous supply of AA is available, itindirectly maintains appropriate levels of other free radicalscavengers, particularly intracellular GSH, thus complementingsulfonylurea-metformin GSH preserving action.

[0432] AA exhibits an important synergism with α-tocopherol (which isshared by two other components of this invention: lipoic acid, andubiquinone) and is complementary to L-arginine in lessening endothelialdysfunction by normalizing constitutive NO production in patients withinsulin resistance syndrome and/or type 2 diabetes. This action of AAimproves impaired acetylcholine-induced vasodilation by a mechanismlinked to NO formation. AA selectively restores impairedendothelium-dependent vasodilation even in patients withinsulin-dependent diabetes mellitus

[0433] In addition to causing oxidative stress, hyperglycemia—viaglycation of proteins—generates Maillard products that cross-link. Theseadvanced glycation products occur in vivo in diabetes mellitus as wellas in aging. Activation of the polyol (sorbitol) pathway leads to suchnonenzymatic protein glycation that causes thickening of basementmembrane and proliferation of endothelium cells. AA lessens nonenzymaticglycation principally because of its aldose reductase activity andconsequent inhibition of the polyol pathway.

[0434] Besides preventing endothelial dysfunction by scavenging freeradicals, AA increases levels of the eNOS cofactor BH4 and thus thebioavailability of NO. The latter effect appears to be independent ofthe ability of AA to scavenge directly superoxide anions and other freeradicals. BH4 is itself an antioxidant, which like tocopherol may beregenerated by AA. Likewise, GSH may affect constitutive NOS kinetics byrecycling or preventing the autooxidation of BH4. Thus, eNOS activitydepends on BH4, the reduced state of essential protein thiols and theready availability of AA. This further illustrates the interrelatedpathophysiological nodes that this invention identifies and influences,the better to enhance and expand the effectiveness of metformin and/orsulfonylurea.

[0435] Tetrahydrobiopterin (and its biosynthetic precursors in thisinvention: 7,8-dihydroneopterin;1′-hydroxy-2′-oxopropyltetrahydropterin; L-sepiapterin,7,8-dihydrobiopterin; pyruvoyltetrahydropterin;lactoyltetrahydropterin.)

[0436] Tetrahydrobiopterin (BH4) is one of the most potent naturallyoccurring reducing agents and is an essential cofactor for the enzymaticactivity of eNOS. Suboptimal concentration of BH4, as occurs indiabetes, reduces formation of NO and “uncouples” eNOS leading to aneNOS-mediated reduction of oxygen, the formation of superoxide anionsand of hydrogen peroxide.

[0437] Put differently, eNOS catalysis results in either the formationof NO or of superoxide depending on the presence or absence of BH4.Although eNOS releases NO, which regulates vascular tone under normalconditions, eNOS produces the superoxide anion and hydrogen peroxidewhen either its required cofactor BH4 or when L-arginine, is decreased.Thus, eNOS may become a direct source of reactive oxygen species underpathological conditions such as diabetes, when either or both may belacking. Because NO reacts with the superoxide anion and hydrogenperoxide to form peroxynitrite, singlet oxygen and the hydroxyl radical,any simultaneous release of NO and reactive oxygen species in thepresence of inadequate concentrations of BH4 (and/or L-arginine) istoxic. An increase in BH4 in cells reduces this eNOS dysfunction andprotects the cells against related cell injury. The concomitant additionof L-arginine and BH4 has been shown to abolish superoxide generation byeNOS.

[0438] Recent findings suggest that accelerated catabolism of BH4 inarteries exposed to oxidative stress contributes to the pathogenesis ofthe endothelial dysfunction known to exist in the arteries of diabetics;unfortunately, elevated glucose prevents an increase in cellular levelsof BH4. Fortunately, in animals and humans, experimental supplementationof BH4 has demonstrated beneficial effects on endothelial function. Thisbenefit may exist because it appears that the beneficial effects of someantioxidants (e.g., vitamin C) on vascular function are mediated viaincreased intracellular concentration of BH4.

[0439] Insulin resistance decreases vascular relaxation secondary toimpaired eNOS activity and increased oxidative breakdown of NO from theenhanced formation of superoxides (the latter resulting from adeficiency of BH4 in vascular endothelial cells). The consequenthypertension of insulin resistance is associated with an attenuatedendothelium-dependent vasodilatation to acetylcholine. This is improvedby concomitant oral treatment with BH4: Further evidence thatendothelial function in insulin resistance and type 2 diabetes ismodulated by the availability of BH4.

[0440] Carnitine ( L-carnitine and congeners in this invention:acetyl-L-carnitine; propionyl-L-carnitine; propionylcarnitine taurineamide; butyrylcarnitine taurine amide)

[0441] Carnitine levels are reduced in diabetes, and are furtherdecreased by sulfonylurea treatment.

[0442] Carnitine (beta-hydroxy-gamma-N-trimethylaminobutyric acid) isrequired for transport of long-chain fatty acids into the innermitochondrial compartment for beta-oxidation. Carnitine is thereforenecessary for the mitochondrial energy system to function efficiently.Its deficiency leads to reduced fatty acid oxidation and limitedmitochondrial ATP (energy) production. This is of particular importancefor the heart since it depends on fatty acids as its primary fuel. Ifthe heart is denied adequate fatty acids transport into the mitochondriaby carnitine to supply its energy need, glucose is used as the backupfuel; however, glucose may not provide sufficient energy for normalcardiac function, especially in progressive insulin resistance and type2 diabetes. This can lead to severe cardiac arrhythmias, cardiac arrestand death. In addition, the excessive exposure of tissues to fattyacids, which occurs in carnitine deficiency, is one of the causes ofprogressive insulin resistance, and this problem is compounded when theexisting carnitine deficiency reduces ATP propelled pancreaticproduction of insulin.

[0443] Widely distributed in foods from animals but not plants,carnitine is also synthesized endogenously in the liver and kidney fromtwo essential amino acids, lysine and methionine. Human skeletal andcardiac muscles contain relatively high carnitine concentrations, whichthey receive from the plasma, since they are incapable of carnitinebiosynthesis themselves.

[0444] As stated, carnitine is deficient in type 2 diabetes, and furtherdepleted by sulfonylurea treatment. It is surprising that this importantadverse effect—sulfonylurea-induced carnitine deficiency—is seldomreferred to. This is especially true when one considers that a majordisappointment of sulfonylurea therapy is that it fails to prevent themacrovascular complications of type 2 diabetes, presumably, in partbecause of its adverse effect on carnitine homoeostasis.

[0445] Sulfonylurea treatment inhibits physiological renal resorption ofcarnitine, and also adversely affects carnitine metabolism by inhibitingacetyltransferase activity in liver microsomes, thereby inducing themacrovascular complications associated with carnitine deficiency, whichare the same as the macrovascular complications of type 2 diabetes:heart attacks, stroke and peripheral vascular disease. Additionally, thereperfusion injury that occurs after a macrovascular ischemic event isworse in carnitine deficient patients and is less severe in patients whohave normal tissue levels at the time of the ischemic event. Theclinical recovery after an ischemic event, like a heart attack, isimproved if the patient is not carnitine deficient at the time of themyocardial infarction.

[0446] This results in a vicious cycle in which patients with coronaryartery disease, either with prolonged periods of myocardial ischemia orwith short-term mild myocardial ischemia, have a significant loss ofcardiac carnitine with an overall net decrease in myocardial carnitinecontent, which further increases the heart's vulnerability to ischemiaand further reduces its capacity to recover from infarction.

[0447] Serious results from heart attacks, the leading cause of death intype 2 diabetes, can be divided into cardiomyopathy, if the area ofdamage is sufficiently large that the heart can no longer function as apump, and/or potentially fatal cardiac arrhythmias, if the pacemakercells are damaged. Carnitine is beneficial in prevention andamelioration of both of these heart attack-induced pathologies; indeed,carnitine deficiency alone can actually cause cardiomyopathy in theabsence of myocardial infarction.

[0448] Myocardial and peripheral ischemia in man are associated with theactivation of circulating neutrophils and platelets. Carnitine inhibitsthe synthesis of platelet activating factor (PAF) from human neutrophilsand platelets, thus exerting a protective effect in tissue ischemia andin other diseases associated with neutrophil and platelet activation,such as atherosclerosis.

[0449] Enhancement of hepatic fatty acid oxidation by carnitine hasconsiderable clinical potential in patients with both insulin resistanceand type 2 diabetes although this same activity also tends to enhancehepatic gluconeogenesis, limiting its usefulness to some extent.However, there is also a reciprocal complementarity with metformin:carnitine's stimulation of gluconeogenesis is negated by the biguanide,and metformin's ability to improve insulin sensitivity is enhanced bycarnitine. That they each lead to reduced body weight in at-risk, obesepatients is an added complement, making a combination of metformin andcarnitine especially valuable.

[0450] Oral treatment with carnitine improves not only the function ofcardiac muscle but also of retina and peripheral nerves. It improvesdiabetic nerve conduction velocity (NCV) peripherally and in the retina.Carnitine improves diabetic neuropathy and retinopathy withoutinfluencing the polyol pathway, perhaps by modulating myoinositol andreducing the serum triglyceride level.

[0451] Implementation of mitochondrial fatty acid oxidation with ATPproduction by carnitine is of enormous physiologic importance, and itsdeficiency in pathologic states such as progressive insulin resistanceand type 2 diabetes worsens the outlook. Carnitine is safe and, exceptfor a tendency to increase hepatic gluconeogenesis, it has no sideeffects of note in these disease states.

[0452] Carnitine is absorbed by both active transport and passivediffusion in the duodenum and jejunum. Variable amounts are absorbedfrom the intestine, ranging from 15 to 87% of ingested carnitine, inpart depending on the ongoing level of cellular (liver, kidney)synthesis of carnitine. Carnitine is not synthesized in either skeletalor cardiac muscle, which contain more than 90% of the total bodycarnitine; each being dependent entirely on carnitine uptake from theblood. This uptake occurs via an active transport system, which allowstissue concentrations to be 20- to 50-fold higher than in the plasma.

[0453] Carnitine reaches its plasma levels slowly, still rising twohours after oral administration. Absorption via the portal vein isfollowed by hepatic extraction and appearance in bile with resorption ofa fraction, thus establishing an enterohepatic circulation.

[0454] Carnitine enters the cell from the plasma slowly; thus oraltherapy does not cause rapid repletion of body stores of carnitine. Oraladministration of carnitine requires continuous use to achieve andmaintain its important physiological effects.

[0455] When L-carnitine is administered, it increasessulfonylurea-metformin effectiveness, efficiency, and safety in theprevention and treatment of progressive insulin resistance and type 2diabetes, reduces the cardiovascular risks associated with thesediseases and reduces adverse side effects which arise from the combineduse of these therapeutic agents.

[0456] Choline (2-Hydroxy-N,N,N-trimethylethanaminium)

[0457] Choline provides an essential structural component of manybiological membranes. It affects the mobilization of fat from the liverand is essential for the formation of the neurotransmitteracetylcholine. Of particular importance, as a component of thisinvention, choline maintains serum carnitine concentrations byconserving urinary carnitine, thus counteracting a significant adverseeffect of sulfonylurea. It also reduces the homocysteine risk ofmetformin by transferring one of its methyl groups to homocysteine toform methionine, thereby lessening the threat of homocysteine-inducedthrombosis in diabetes.

[0458] Choline is important in the diet to stimulate removal of excessfat from the liver (lipotropic), thereby reducing the indirect “obesityadverse effect” of sulfonylureas and complimenting the weight controladvantage of metformin. Although choline can be made in the body, itssynthesis is limited.

[0459] Oral administration of choline is effective reaching the bloodcirculation without losing its activity. The needs of the tissues forcholine are met from both exogenous (dietary) and endogenous (metabolic)sources. Biosynthesis of choline occurs by transmethylation ofethanolamine with the methyl group of methionine, or by a series ofreactions requiring vitamin B₁₂ and folate as cofactors.

[0460] Chromium

[0461] There is a dietary deficiency of Chromium (Cr) in more thanone-half of the USA population.

[0462] Cr is a cofactor for insulin: it increases insulin binding to itsreceptor, thereby reducing cellular insulin resistance. Cr not onlyimproves insulin binding, it also: increases the number of insulinreceptors, improves insulin internalization by endocytosis fromcaveolae, increases β-cell sensitivity and increases insulin receptorenzymes resulting in an overall increase in insulin sensitivity.

[0463] Cr is known to be an essential nutrient for normal sugar and fatmetabolism. Insufficient dietary Cr has been associated with thedevelopment of the insulin resistance syndrome and of type 2 diabetes,and with their associated cardiovascular diseases. This dietaryshortfall has been exacerbated by the worldwide increase intake ofrefined foods that not only contain little Cr, but also simultaneouslyincrease Cr excretion.

[0464] Cr supplementation improves the diabetic control afforded byexercise. Supplements of chromium nicotinate or picolinate complexeslower blood sugar, LDL cholesterol and increase lean body mass. Crsupplementation can reduce metformin requirements by more than one-half.

[0465] N-acetyl-L-Cysteine

[0466] N-acetylcysteine (NAC) is a GSH prodrug, an independentantioxidant, and promotes the synthesis of the glycosaminoglycan heparansulfate.

[0467] As stated above, the tripeptide GSH is insufficiently absorbedfrom oral dosage forms, and therefore any supplementation must be fromprodrugs like N-acetyl-cysteine or α-lipoic acid, both of which aresatisfactorily absorbed from the gastrointestinal tract.

[0468] NAC is a very good antioxidant itself with a notable effect inpreventing endothelial dysfunction, and it reduces the paradoxicalvasoconstriction effect of acetylcholine on VSMC that occurs whenadjacent endothelial cell are damaged. Perhaps more important in thiscontext is its role as an orally available source for GSH synthesis.

[0469] Cysteine is the essential sulfur-containing amino acid in GSH.NAC increases systemic GSH by supplying the necessary cysteineintracellularly. GSH and glutathione peroxidase levels are notablyreduced in progressive insulin resistance and type 2 diabetes. Thedeficiencies and the associated peroxide-mediated damage to cellmembranes may appear early in the progressive insulin resistance andtype 2 diabetes, before the development of secondary complications.Additionally, GSH counterbalances the effects of ICAM-1, one of the mostimportant intercellular adhesion molecules involved with theatherogenesis associated with insulin resistance syndrome and type 2diabetes. GSH similarly reduces thrombin activation, which results fromhyperglycemia.

[0470] GSH acts in concert with ascorbate to inhibit the reactionbetween superoxide and excessive NO, which produces the cell membranedamaging peroxynitrite. In addition, GSH stimulates superoxide dismutase(SOD) an activity that further reduces the toxic effects of thesuperoxide radical. And furthermore, GSH supplies the substrate forglutathione peroxidase, which quenches hydrogen peroxide and reduces itsconversion to OFF (a highly toxic radical). It also lessens RBCmicroviscosity, thus augmenting blood flow in the microvasculature. It'seasy to see why it is reasonable to concede the title of the mostimportant intracellular free radical defense to GSH.

[0471] Separate from its importance as a GSH prodrug, NAC, as asulfur-containing amino acid, promotes the synthesis of heparan sulfate.The importance of synthesizing heparan sulfate to maintain thestructural and anionic charge of the vascular endothelial basementmembrane cannot be overemphasized; failure in this area, induced byhyperglycemia, is the root cause of the blindness of diabeticretinopathy and the mortality of diabetic nephropathy.

[0472] The antioxidant abilities of NAC and other elements of thisinvention, have the potential to delay the onset and delay theprogression of “type 1.5 diabetes”. In the latter, ROS destroypancreatic β-cells. This β-cells destruction results in the addition ofinsulin-dependent (type 1) diabetes mellitus clinical findings to thosealready existing from type 2 diabetes. Activation of NFkappaB byROS-induced release of mitochondrial cytochrome C seems to be the keycellular signal in initiating a cascade of events leading to β-celldeath in this scenario. Thus, enhancement of pancreatic GSH (via oraladministration of the prodrug NAC or α-lipoic acid)—a key intracellularregulator of NF-kappaB—affords protection against the insidious onset of“type 1.5 diabetes”. In this context, supplementation with 500 mg/kg ofNAC as a GSH precursor, has been shown to inhibit alloxan-inducedNFkappaB activation, and subsequently reduce hyperglycemia. Byinference, NFkappaB activation by ROS (via the mitochondria) mayinitiate a sequence of events eventually leading to type 1 diabetes, byway of “type 1.5 diabetes”: In one study, inhibition of NF-kappaBactivation by NAC has been shown to attenuate the severity of type 1diabetes.

[0473] Folic Acid

[0474] Homocysteine (Hcy) is a notable contributor to hypertension andthromboangiogenesis. Folic acid administration reduces the circulatingHcy levels that are adversely elevated by metformin treatment.

[0475] Mitochondrial abnormalities have been identified in hepatocytesof patients with hyperhomocysteinemia, however, the mechanism by whichhomocysteine affects mitochondria is not entirely established.Homocysteine and H₂O₂, but not H₂O₂ alone, cause decreases inmitochondrial RNA levels and catalase. This provides evidence thathomocysteine and H₂O₂ act synergistically to cause mitochondrial damage.There is some evidence that intracellular GSH plays a role in protectingmitochondria against the adverse effects elicited by this combination ofhomocysteine and H₂O₂. The importance of avoiding folic acid deficiencyand secondary hyperhomocysteinemia and mitochondrial damage is evident.

[0476] Less well known is that homocysteine inhibits the expression ofheparan sulfate, which may contribute to its thrombogenic property,which also potentially exacerbates the diminished heparan sulfatesynthesis commonly observed in diabetes (See above.). A circular problemis therefore initiated in diabetes: homocysteine reduces heparan sulfatein the glomerulus, which leads to renal malfunction, which in turn leadsto hyperhomocysteinemia, which aggravates the hypertension andthromboangiogenesis of diabetes, etc.

[0477] Hyperhomocysteinemia is associated with macrovascular disease ina significant proportion of patients with type 2 diabetes. Furthermore,this hyperhomocysteinemia is related to 5-year mortality ratesindependent of other major risk factors, and is a stronger (1.9-fold)risk factor for mortality in type 2 diabetic patients than innondiabetic subjects.

[0478] Inadequate heparan sulfate in the microvascular basement membranereduces the basement membrane's negative charge that is essential forits structural integrity; the latter results in the vascular leakageassociated with the devastating microangiopathies of diabetes.

[0479] Folic acid is well absorbed and rapidly converted totetrahydrofolic acid, the active coenzyme for intracellular metabolism.Tetrahydrofolate is required as a methyl donor for the conversion ofhomocysteine to methionine. Plasma levels of homocysteine are thuslowered by folic acid, directly reducing the potent vasoconstrictive,endothelial cytotoxicity, vascular basement membrane failure andthrombotic effects of homocysteine.

[0480] Diabetes significantly lowers folate in kidney, heart, brain, andmuscle. The addition of metformin worsens this situation. For thesereasons folate inclusion in a formula with sulfonylurea and/or metforminin progressive insulin resistance and type 2 diabetes is logical.

[0481] α-Lipoic Acid

[0482] α-Lipoic acid is an important inclusion in sulfonylurea and/ormetformin treatment for insulin resistance syndrome and type 2 diabetes.It increases insulin sensitivity, prevents depletion of GSH, limitsprotein glycation and attenuates NFkappaB transcription.

[0483] α-Lipoic acid improves insulin-responsive glucose utilization,demonstrating a positive effect on insulin-stimulated glucose uptake,and it is a potent antioxidant in both fat- and water-soluble media.Furthermore, its antioxidant activity extends to both the oxidized andthe reduced form. α-lipoic acid regenerates AA from dehydroascorbic acidand indirectly regenerates α-tocopherol. It increases intracellular GSHand limits protein glycation. It has the potential favorably to modifydiabetes and reduce diabetes-induced complications, particularlydiabetic neuropathy.

[0484] Hyperglycemia induces neuronal dysfunction via at least threesecondary biochemical disturbances—the sorbitol (polyol) pathway, thenon-enzymatic glycation of proteins and oxidative stress—and there areclear interactions between all three. Because of these interactions,interference with one of these biochemical transducers worsens orattenuates the effects of the others. Pharmacological interventionshould consist of a combined attack on all these sources of disturbance.α-lipoic acid has the potential to correct effects arising from multiplepathways of disorder in experimental diabetic neuropathy.

[0485] Depletion of cellular antioxidant defense mechanisms in the faceof increased generation of oxygen free radicals by advanced glycationend products (AGES) play a major role in the pathogenesis of diabeticvascular complications. The endothelial migration of monocytes is one ofthe first steps in atherogenesis and monocyte-endothelial interactionitself is linked to the expression of adhesion molecules like vascularcell adhesion molecule-1 (VCAM-1). Stimulation of VCAM-1 by AGEs hasbeen demonstrated. Supplementation of the cellular antioxidative defensewith the natural occurring antioxidant α-lipoic acid before AGE albumininduction, prevents the AGE albumin-dependent depletion of reduced GSHand AA. α-lipoic acid seems to reduce AGE albumin-induced NF-kappaBmediated transcription and the expression of relevant endothelial genesin diabetes. Among others these include, tissue factors for VCAM-1 andfor endothelin-1. Thus, in vitro supplementation of cellularantioxidative defense mechanisms by extracellularly administeredα-lipoic acid reduces AGE albumin-induced endothelial dysfunction.

[0486] α-Lipoic acid attenuates NFkappaB, a key cellular signal thatinitiates a cascade of events leading to β-cell death. This, plusα-lipoate's enhancement of pancreatic GSH, affords protection againstprogression from type 2 diabetes to “type 1.5 diabetes”.

[0487] When α-lipoic acid is administered it increases theeffectiveness, efficiency, and safety of sulfonylurea and/or metformincombinations in the prevention and treatment of insulin resistance anddiabetes mellitus and expands the scope of sulfonylurea and/or metformintreatment to include macrovascular diabetic complications. Sulfonylureaand/or metformin pharmacokinetics do not appear to be altered by lipoicacid in any clinically meaningful extent. Plasma insulin and glucoseconcentrations did not indicate any interaction between α-lipoic acidand sulfonylurea, or of α-lipoic acid and acarbose. Co-administration ofsingle doses of α-lipoic acid and sulfonylurea and/or metformin appearto be safe and not cause drug-drug interactions.

[0488] Magnesium

[0489] Magnesium (Mg²⁺) inclusion with sulfonylurea and/or metforminshould improve hepatic and peripheral insulin sensitivity (wheresulfonylurea has no apparent beneficial effect and metformin has only amodest effect), avoid defective tyrosine-kinase activities at theinsulin receptor, optimize cytoplasmic free Ca²⁺ levels, reestablishcell membrane polarization after sulfonylurea action, and enhance thesulfonylurea insulin secretagogue effect: each of these adds to thetherapeutic effectiveness of sulfonylurea and/or metformin.

[0490] Sulfonylurea receptors have a unique function in many areas ofmembrane physiology. They are responsive to modulation by inhibition andby stimulation by magnesium-nucleotides. This underlines the importanceof Mg²⁺ in determining the reactiveness of sulfonylurea on ion channels.There is laboratory evidence that the effect of sulfonylurea isoptimized when adequate levels of intracellular Mg²⁺ are present.

[0491] Oral magnesium hydroxide enhances the absorption of sulfonylurea.The possibility that Mg²⁺, delivered in an oral dosage form, coulddecrease the required dose of sulfonylurea is encouraging, in that itcould reduce the gastrointestinal intolerance experienced by somepatients.

[0492] The American Diabetes Association recommends that all patientswith normal renal function who have hypomagnesemia and diabetes mellitusreceive Mg²⁺ supplementation. This represents a majority of patientswith progressive insulin resistance or type 2 diabetes. Mg²⁺deficiencies are widespread in the progressive insulin resistance andtype 2 diabetes. Patients receiving sulfonylurea exhibit little changein urinary excretion of Mg²⁺ yet they show a significant rise in serumMg²⁺. Metformin has been described as one of the mechanisms involved inthe induction of hypomagnesemia although not all studies support thisview. As an example: Poorly controlled type 2 diabetic patients withhypomagnesemia, hypermagnesuria, and hypercalciuria were treated withmetformin. Glycemic control was improved, as assessed by glucose andhemoglobin A1. A reduction in Mg²⁺ renal excretion resulted from themetformin treatment, but patients remained hypomagnesemic andhypercalciuric.

[0493] While the combined effect of sulfonylurea and metformin onmagnesium levels is unclear, their pharmacodynamic complementarity forpatients with progressive insulin resistance or type 2 diabetes isfortunate, since both hyperinsulinemia and hyperglycemia can result inhypomagnesemia, which in turn increases insulin resistance—anothervicious cycle.

[0494] Hypomagnesemia occurs in 25-38% of patients with type 2 diabetes.Current dietary amounts of Mg²⁺ are marginal. The average dietary intakeof 450 to 485 mg per day of Mg²⁺ in the USA at the turn of the centuryhas now decreased to about one-half of this. There now exists a generalpopulation dietary Mg²⁺ shortfall of 90 to 180 mg per day. Unfortunatelyfor patients with insulin resistance and type 2 diabetes, circulatinginsulin (and perhaps proinsulin) induce an increase in the renalexcretion of Mg²⁺. This might partly explain the Mg²⁺ depletion observedin various hyperinsulinemic states.

[0495] A Mg²⁺ deficient state (and a rise in cellular free Ca²⁺) appearsto cause insulin resistance, with the plasma Mg²⁺ level inverselyrelated to insulin sensitivity. Insulin-resistant states generally arecharacterized by the accumulation of cytosolic free Ca²⁺ and thedepletion of free Mg²⁺. Mg²⁺ supplementation should improve both insulinsensitivity and insulin secretion in patients with type 2 diabetes.

[0496] Decreased cellular Mg²⁺ concentrations represent a risk factor inthe pathogenesis of both microvascular and macrovascular complicationsof diabetes. Low serum and dietary Mg²⁺ may be related to the etiologiesof CVHD, hypertension, and atherosclerosis as well as progressiveinsulin resistance and type 2 diabetes. One of the most seriouscomplications of diabetes, cardiac irregularity, including ventricularectopic beats, is associated with decreased intracellular Mg²⁺.

[0497] Elevated levels of serum glycosaminoglycans (GAG), associatedwith hypomagnesemia were observed in patients with coronary arterydisease and thrombotic stroke. Serum lipid profiles are normal in themajority of these patients, indicating that elevated serum GAG may be aneven more reliable indicator of atherosclerosis than elevated serumtotal cholesterol or LDL cholesterol. The implication of thisobservation is that GAG escape from the basement membrane inhypomagnesemia, thereby lessening its normal anionic charge andantithrombotic character, and that Mg²⁺ deficiency may be one of thefactors involved in the increased serum level of GAG.

[0498] Intracellular Mg²⁺ levels may mediate the effects of reduced GSHand α-tocopherol on glucose metabolism. α-tocopherol has beendemonstrated to improve insulin action. Recent evidence also suggeststhat α-tocopherol enhances GSH levels and may play a protective role inMg²⁺ deficiency-induced cardiac lesions. This clinical link betweenα-tocopherol, cellular Mg²⁺, GSH, and tissue glucose metabolismcertainly illustrates the importance of Mg⁺, but it more importantlyillustrates the synergistic and synergetic relationships that can (andmust) be addressed by approaching insulin resistance and type 2 diabetesas nonlinear complexities, as is done by this invention.

[0499] In addition to complementary effects of Mg²⁺ with α-tocopheroland GSH in diabetes, similar synergisms for Mg⁺ have been defined withtaurine, carnitine and vanadium, and with sulfonylurea and/or metformin.

[0500] Intracellular Mg²⁺ concentration modulates insulin actions thatoffset Ca²⁺-related, excitation-contraction coupling. Mg²⁺ functionsboth intracellularly and extracellularly to optimize the cytoplasmicfree Ca²⁺ level. Excess cytoplasmic free Ca²⁺ has the deleterious effectof leading to an increase in ET-1 with its associated decrease in bloodflow and increase in apoptosis.

[0501] The inadequate intracellular Mg²⁺ concentration often found inprogressive insulin resistance and type 2 diabetes results in defectivetyrosine-kinase activities at the insulin receptor level and exaggeratedintracellular Ca²⁺ concentration. Daily Mg²⁺ administration to type 2diabetes patients restores intracellular Mg²⁺ concentration and cancontribute to improved insulin-mediated glucose uptake.

[0502] In some studies, the correction of Mg²⁺ deficiency exertsadditional antihypertensive, anti-atherosclerotic, anti-arrhythmic andantithrombotic effects, addressing the failure of sulfonylurea and/ormetformin in preventing macrovascular diabetic complications, whilecomplementing them in reducing microvascular diabetic complications.

[0503] Mg²⁺ is an important component in formulations containingsulfonylurea and/or metformin.

[0504] Melatonin

[0505] Melatonin is an indole produced in the pineal gland and theretina. Its importance in orchestrating diurnal rhythms is well known.Less known is its potent antioxidant action similar to SOD. Some studieshave shown that melatonin protects against oxidative stress and theseverity of diabetes induced by STZ. Two activities are becomingapparent: 1) the powerful antioxidant action of this indole and, 2) theimportance of oxidative stress in the maintenance of hyperglycemia andprotein glycation. (See above.) Melatonin reduces hyperglycemia, proteinglycation and lipid peroxidation—all diabetic complications in whichoxidative stress, either in a high or in a low degree, is present.

[0506] TNF-α has an important role in the development of insulinresistance, and type 2 diabetes and its progressive vascularcomplications. It can be favorably modified by melatonin. Cytokineproduction, including TNF-α, in human whole blood exhibits diurnalrhythmicity. Peak production of the pro-inflammatory cytokinesIFN-gamma, TNF-alpha, IL-1 and IL-12 occurs during the night and earlymorning at a time when plasma cortisol is lowest. Melatonin levels arehighest during these hours and tend to inhibit this cytokine surge. Thealtered nightly quantity (reduced) or pattern of melatonin secretion inthe elderly could fail to reduce the cytokine surge adequately and bedetrimental in patients with progressive insulin resistance or type 2diabetes. This may foster well-known, diabetic microvascular andmacrovascular complications.

[0507] Melatonin also reduces the visceral fat that is associated withprogressive insulin resistance and type 2 diabetes. Thus it is importantin enhancing the weight loss potential of metformin.

[0508] Visceral fat and plasma insulin levels increase with aging, andare associated with progressive insulin resistance and type 2 diabetes.Since melatonin favorably modulates visceral fat and the nighttimecytokine surge, its inclusion with metformin and/or sulfonurea ispotentially important, especially in light of the propensity ofsulfonylurea to increase weight gain.

[0509] The role of melatonin as an immunomodulator is now established;it exerts protective effects in inflammation, extending beyond itsantioxidant action. Melatonin reduces the inducible isoform of nitricoxide synthase (iNOS), an important contributor to the pathophysiologyof inflammation, including the macrovascular complications of diabetesand pancreatic β-cell destruction. Melatonin reduces iNOS steady-statemRNA levels and iNOS protein. This inhibition of iNOS expression isassociated with inhibition of activation of the transcription factornuclear factor kappa B (NFkappaB), which has been associated withpancreatic β-cell apoptosis in type 1 diabetes.(See above.)Additionally, melatonin decreases the production of nitrite/nitrate (thebreakdown products of NO) in macrophages stimulated with bacteriallipopolysaccharide, reducing inflammation. These effects may beimportant in inhibiting the progression from type 2 diabetes to “type1.5 diabetes”, wherein there is an added immunologically driven β-celldestruction superimposed on type 2 diabetes.

[0510] A preponderance of evidence indicates that melatonin productiondeclines after age 45 in parallel with a statistically increasingoccurrence of type 2 diabetes. It is reasonable to believe that theage-related loss of availability of melatonin and a subsequent reductionin capacity to reduce lipid peroxidation and AGEs, could be detrimentalin type 2 diabetes. Melatonin is a useful component in metformin and/orsulfonylrea formulations used as treatment for progressive insulinresistance and type 2 diabetes is physiologically appropriate, andpossibly should be made not only at night, but also during the day.

[0511] Nicotinate/Nicotinamide

[0512] Nicotinic acid (and its derivatives) and metformin are bothuseful for reducing hypertriglyceridemia, thus having complementarypotential in treating the dyslipidemia of progressive insulin resistanceand type 2 diabetes.

[0513] In addition, nicotinic acid reduces the fibrinogen concentrationin plasma and stimulates fibrinolysis.

[0514] Nicotinamide has value in preventing β-cells destruction in type1 diabetes. That there are beneficial effects in type 2 diabetes is notyet established, but prevention of progression from type 2 diabetes to“type 1.5 diabetes” seems likely, thus complementing sulfonylurea.Interleukin-1 beta (IL-1 beta) is known to inhibit glucose-inducedinsulin release by pancreatic islets. When islets are simultaneouslyexposed to IL-1 beta and increasing concentrations of nicotinamide, adose-dependent recovery of glucose-induced insulin secretion can beobserved, with the maximum effect at 25 mmol/L nicotinamide.

[0515] Type 1diabetes is caused by an immune-mediated destruction of theinsulin-producing β-cells. β-cells are destroyed by induction ofoxygen-derived free radicals and induced nitric oxide. This results inperturbation of the mitochondrial respiratory system and frequent DNAstrand breaks. As a result of β-cells destruction, islet cell antibodiescan be demonstrated in the circulation. These antibodies can be detectedup to eight years prior to overt type 1 diabetes and are also seen insome progressing type 2 diabetics (thus the name “type 1.5 diabetes”).Nicotinamide, a vitamin B₃ derivative, interferes with theimmune-mediated β-cell destruction by reducing the content of freeradicals and NO, thereby reducing their deleterious effects.

[0516] Nicotinamide increases the intracellular nicotinamide adeninedinucleotide (NAD) pool, thus increasing the energy supply of the cellas well as activating cNOS and the myriad beneficial vascular effects ofconstitutive NO/cGMP, which have been discussed above.

[0517] Nicotinamide protects β-cell from desensitization to glucose thatoccurs after prolonged exposure to hyperglycemia.

[0518] Unfavorable Theological properties of blood, and abnormal redcell deformability, in diabetes are factors in its frequentmicrovascular complications. The improvements in blood rheology and inred cell deformability by α-tocopherol nicotinate, can be mainlyattributed to reducing lipid peroxidation stress on the membrane of redblood cells. Treatment with α-tocopherol nicotinate may havecomplementary effects in slowing the microangiopathy of type 2 diabetes.

[0519] Pyridoxine

[0520] Nonenzymatic protein glycation (Amadori→Maillard reactions) leadsto heterogeneous, toxic and antigenic AGEs and to reactive precursorsthat are implicated in the pathogenesis of diabetes. Pyridoxamine andthiamine pyrophosphate potently inhibit AGE formation, suggesting thatthese two compounds may have clinical potential in preventing vascularcomplications in type 2 diabetes and in insulin resistance.

[0521] Increased dietary intakes of pyridoxine (and of folate andvitamin B₁₂) have been associated with reduced serum homocysteineconcentrations in persons at high risk of cardiovascular andcerebrovascular disease, and to those diabetic macrovascularcomplications not reduced even by intensive sulfonylurea or metformintreatment. iNOS within activated macrophages contributes to theinflammation that characterizes early atherogenesis and may, in part,account for the adverse vascular effects of hyperhomocysteinemia. Theincorporation of pyridoxine (and folic acid) lessens the conversion ofL-arginine to toxic levels of homocysteine-induced NO (from iNOS withinactivated macrophages) and in such a fashion, fueling the ubiquitous‘methionine cycle-homocysteine cycle’. This adds an element of safety tothe invention by addressing a problem that the nonspecific, “shotgun”supplementation of “multivitamins” usually overlooks.

[0522] Selenium

[0523] Selenium (Se) has insulin-mimetic actions relating to itsinvolvement with the activity of MAPK and S6 kinases.

[0524] Se is also the cofactor for glutathione peroxidase, enabling thescavenging of hydrogen peroxide and avoiding its progression to thehydroxyl radical. It has also been shown to favorably influence thecoagulopathy associated with endothelial dysfunction and to improve RBCmicroviscosity. Reduced Se concentrations in RBCs contribute to impairedhemorheology in diabetic patients.

[0525] Se, and more efficiently Se plus Vitamin E, supplementation indiabetes may play a role in controlling oxidative status and unfavorablelipid metabolism in the liver, thereby maintaining favorable fatty aciddistribution in the major tissues affected by diabetic complications.

[0526] Taurine (2-aminoethanesulfonic acid)

[0527] Sulfonylurea-metformin's combined clinical efficacy is reflectiveof reduced hepatic glucose output and increased insulin secretion; theseactions are complemented by peripheral insulin sensitizers like taurine,the small, sulfur containing, amino acid which is the predominant freeintracellular amino acid in most mammals.

[0528] Cysteine (a taurine precursor) is formed from methionine in areaction catalyzed by cystathionase, which is very low in man. For thisreason taurine is classified as a conditionally essential amino acid.

[0529] The first established physiologic function of taurine is bileacid conjugation in the liver resulting in water-soluble bile salts,which are essential for fat absorption from the small intestine.However, while the exact mechanism is not clear, taurine also inhibitslipid peroxidation and decreases blood triglycerides and LDL-cholesterollevels in diabetes.

[0530] A deficient dietary level of taurine is associated with a varietyof pathologies, including type 2 diabetes. Since 1981 taurine has beenadded to infant formulas and parental nutrition solutions in countriesaround the world and was approved by the FDA for this purpose in 1984.

[0531] The insulin secretion action of sulfonylurea is optimized by theaction of taurine in maintaining intracellular Ca²⁺ homeostasis and inmaintaining the integrity of the pancreatic β-cells within which it ispresent in large amounts.

[0532] Taurine extends the effectiveness of sulfonylurea-metformintherapy by increasing peripheral insulin sensitivity, reducinghypercholesterolemia, inhibiting peroxidation of cell membranecomponents and modulating pericyte and other cell volume instabilitiesof type 2 diabetes. Its ACE inhibitor-like action adds an importantdimension in modulating the characteristic hypertension of progressiveinsulin resistance and type 2 diabetes. The cardiac failure seen inlater stages of these diseases may benefit from the mild cardiacglycoside-like effect of taurine, in addition to blocking the productionof angiotensin II. Finally, it protects against glutamateexcitotoxicity, inhibiting diabetic neuropathy.

[0533] Taurine can prolong the effectiveness of treatment withsulfonylurea-metformin combinations by protecting the pancreatic β-cellsfrom lipid peroxidation, thereby reducing the resulting β-celldysfunctional apoptosis that can lead to “type 1.5 diabetes”.

[0534] Taurine stabilizes cellular functions when challenged withexternal or internal stressors such as perturbations in Ca²⁺, freeradicals or osmolality fluctuations.

[0535] Intracellular taurine declines with advancing age and in type 2diabetes. This compounded decrease during both senescence and type 2diabetes exacerbates age-related declines in antioxidant defensesystems, Ca²⁺ regulation and membrane integrity. The actions ofsulfonylurea in K⁺ channel blockade, membrane depolarization and Ca²⁺influx, depend upon the subsequent recovery of Ca²⁺ homeostasis andmembrane repolarization. Taurine contributes to this recovery withoutwhich sulfonylurea loses its effect on insulin secretion. Theintracellular Ca²⁺ membrane stabilization scenario is complex; taurine,carnitine and Mg²⁺ are all major players. In summary: Taurine movescytosolic Ca²⁺ into the mitochondria where it is involved in themitochondrial production of ATP, providing carnitine has movedsufficient long chain fatty acid into the mitochondria to fuel themanufacturing of ATP. ATP then moves out of the mitochondria to supplyenergy to pump cytosolic Ca²⁺ out of the cell—the ion transfer beingcatalyzed by Mg²⁺ co-factored ATPase. At this point the membrane hasbeen repolarized and is again receptive to sulfonylurea stimulation.However, taurine, carnitine and Mg²⁺ are all characteristicallydeficient in type 2 diabetes. This emphasizes the importance of the useof components described in this invention in formulations containingmetformin and/or sulfonylurea.

[0536] Taurine is an important intracellular osmolyte, maintainingoptimum cell volume and adjusting the water content of intracellularspaces. In some highly specialized tissues such as brain, kidney,muscle, pericytes and photoreceptors, uncontrolled changes inintracellular water can lead to rapid disruption of the cellulararchitecture and loss of cell function. In hyperglycemia, especiallywith the polyol pathway activated, osmotic imbalance leads to membranedisorganization and cellular dysfunction or death, all of which areaggravated by taurine deficiency. A number of the complications ofdiabetes are associated with or attributed to osmotic disruption of thecytoarchitecture. These may be lessened if there is adequateintracellular taurine and are worsened if there is a deficiency oftaurine, as there often is in diabetes.

[0537] Taurine appears to reduce cellular insulin resistance and mayreduce the accumulation of AGEs within the kidney.

[0538] Taurine, as an osmoregulator, should ameliorate diabeticneuropathy and nephropathy, clinically reducing total proteinuria andalbuminuria. It inhibits activation of protein kinase C(PKC) -signaledincreases in the major cytokine, transforming growth factor beta (TGF-β)that occurs in response to high glucose levels. An increase in TGF-β isimplicated in the pathogenesis of glomerulosclerosis in diabetes.

[0539] Taurine modulates cell membrane stabilization and levels ofcellular Ca²⁺. This modulation of Ca²⁺ signaling further complements thesimilar action of Mg²⁺. Also, similar to Mg²⁺, taurine stabilizesplatelet membranes and reduces platelet aggregation.

[0540] Taurine is an important intracellular hydroxyl radical scavengerand participates in systems that include the antioxidant enzymes(superoxide dismutase, catalase, and glutathione peroxidase) and thenutrient-derived antioxidant small molecules (vitamin E, AA, carotenes,flavonoids, GSH and uric acid).

[0541] Thiamine

[0542] Biguanide-induced lactic acidosis is due to an interference withthe pyruvate dehydrogenase complex, thereby altering the normal pyruvateoxidative pathway such that an excessive amount of pyruvate is divertedto lactic acid. Thiamine pyrophosphate is a cofactor in the pyruvatedehydrogenase complex and promotes the aerobic metabolism of pyruvate.Treatment with thiamine can be effective in reducing biguanide-inducedlactic acidosis.

[0543] Thiamine is also very important in the synthesis of insulin, suchthat its deficiency reduces insulin secretion. Sulfonylurea cannotincrease the biosynthesis of insulin in the face of thiamine deficiency.As a result, blood glucose is elevated and insulin is reduced inthiamine deficiency and when this deficiency is corrected, blood glucoselevels are lowered.

[0544] The glycation of membrane bound proteins associated with theproduction of AGEs, may be reduced in diabetics given thiamine. Thiseffect is increased further when pyridoxamine is used concurrently withthiamine.

[0545] Tocotrienol (Tocopherol Analog) and α-tocopherol

[0546] Approximately 80% of all patients with diabetes die ofcardiovascular disease. Treatment with sulfonylurea-metformin has beenineffective in altering this dismal prognosis. Progressive insulinresistance, the fundamental defect of type 2 diabetes leads tohyperinsulinemia, which is associated with hypertension, atherogenicdyslipidemia, left ventricular hypertrophy, impaired fibrinolysis,visceral obesity, and a sedentary lifestyle. Although all theseconditions are associated with atherosclerosis and adversecardiovascular events, the therapeutic effect of sulfonylurea and/ormetformin treatment in patients with diabetes focuses solely onnormalizing glucose levels and may even increase hyperinsulinemia,increasing the risk of cardiovascular events. Metformin and/orsulfonylurea formulations should include components such as tocotrienolor tocopherol, and other limited but clearly defined components toinhibit diabetic macrovascular disease.

[0547] Tocotrienol is a natural famesylated analogue of tocopherol,which alters the way in which it is anchored to protein, providingadditional functional effectiveness to its influence upon lipidmetabolism. In addition to actions shared with tocopherol, tocotrienoldecreases hepatic cholesterol production and reduces plasma cholesterollevels in animals.

[0548] Tocotrienol influences the mevalonate pathway in mammalian cellsby post-transcriptional suppression of HMG-CoA reductase, and modulatesthe intracellular mechanisms that control the degradation of thisreductase protein—an activity that mirrors the actions of the putativenon-sterol, isoprenoid regulators derived from mevalonate. Thus,tocotrienol has effects on various lipid parameters different from thoseof α-tocopherol, while having similar effects otherwise.

[0549] D,α-Tocopherol inhibits the hyperglycemia-induced activation andfree fatty acid-induced activation of the diacylglycerol-phosphokinase C(DAG-PKC) pathway. This pathway is one of the most destructivemechanisms involved with vascular endothelial damage and is at the rootof many long-term complications of insulin resistance and diabetes,particularly nephropathy and retinopathy.

[0550] Hyperglycemia is the major causal factor in the development ofdiabetic microvascular complications and can mediate the adverse effectsof those complications through multiple pathways. One, is the activationof protein kinase C (PKC) by hyperglycemia-induced increases indiacylglycerol (DAG) level, partly due to de novo synthesis. Theactivation of PKC regulates various vascular functions by modulatingenzymatic activities such as cytosolic phospholipase A2 and Na⁺,K⁺-ATPase, and gene expressions including extracellular matrixcomponents and contractile proteins. Some of the resulting vascularabnormalities include changes in retinal and renal blood flow,contractility, permeability, proliferation, and basement membranedisturbances. Administration of vitamin E, which decreases DAG levelthrough the activation of DAG kinase, prevents hemodynamic changes inretina and renal glomeruli of diabetic rats. In addition, the inhibitionof PKC can normalize the changes in gene expression of cytokines,caldesmon, and hemodynamics.

[0551] Tocopherol also has an antiplatelet effect. It significantlyinhibits fibrinogen-induced platelet aggregation, perhaps throughinterference with fibrinogen binding at its receptor.

[0552] Supplementation with α-tocopherol reduces lipids and lipidperoxides in diabetics and may be beneficial reducing LDL oxidizability.It also can have an effect on reducing AGEs.

[0553] Tocopherol is the main defense against the peroxidation cascadewithin the lipid layer of cell membranes. The latter is the principalcause of the loss of cell membrane integrity in many pathologic statesof vascular and neuronal cells, including diabetes. Tocopherol preservesSOD, involved in free radical hydrogen peroxide defense.

[0554] In animals supplemental α-tocopherol inhibits calcium-inducedcytosolic enzyme efflux.

[0555] Increased oxidative stress, hypofibrinolysis and insulinresistance are present in obese type 2 diabetes patients. High doses ofvitamin E (600 mg/day) used alone, may further worsen insulin efficiencyand increase fibrinolysis in these patients. This finding supports thecomplementary, multicomponent design of this invention, as opposed tothe widespread practice of using high doses of single components withoutregard either to their useful or to their deleterious interaction withother biofactors. The other components of this invention, whichcomplement tocopherol in reducing oxidative stress are lipoic acid,N-acetyl-cysteine, ascorbate, taurine, Se, Mg²⁺, and taurine (Seeabove.).

[0556] When tocotrienol or D,α-tocopherol are administered they increasethe effectiveness, efficiency, and safety of combinations ofsulfonylurea-metformin in the prevention and treatment of insulinresistance and diabetes mellitus and addresses their shortcomings indiabetic macrovascular disease.

[0557] Ubiguinone (Coenzyme Q10)

[0558] Ubiquinone acts as an electron carrier within the mitochondrialrespiratory chain that leads to ATP (energy) generation. It also is aneffective scavenger of free radicals.

[0559] Since the oxidative process within the mitochondria is only 95%efficient, mitochondrial metabolism is a significant contributor ofunmodified reactive oxygen species within the mitochondria. Ubiquinonenot only is of pivotal importance in mitochondrial energy production,but it cleans up the free radicals generated by the process. In thisfashion it prevents mitochondrial GSH depletion and reducesoxidant-induced losses of mitochondrial functions. This lowers oxidativestresses within the mitochondria, which otherwise could promoteextra-mitochondrial activation of the NFkappaB apoptotic cascade.

[0560] Outside the mitochondria, ubiquinone prevents lipid peroxidationof the plasma and liposomal membranes, sparing GSH and tocopherol inthese domains. Unlike tocopherol it is not recycled by ascorbate.

[0561] Ubiquinone is significantly lower in diabetics. Diabetic patientscontrolled by diet may have a deficiency of ubiquinone, andadditionally, ubiquinone may be inhibited by sulfonylureas and/ormetformin. A deficiency of ubiquinone in the pancreas could impairbioenergetics—the generation of ATP—and the biosynthesis of insulin,perhaps accounting in part to the loss of effect insulin secretoryeffect that occurs with long-term sulfonylurea use.

[0562] In one randomized, double blind trial 30 patients (with essentialhypertension and coronary artery disease receiving antihypertensivemedication) the effects of oral coenzyme Q10 (60 mg twice daily for 8weeks) were evaluated. The systolic and diastolic blood pressure,fasting and 2-h plasma insulin, glucose, triglycerides, lipid peroxides,malondialdehyde and diene conjugates were all reduced, andHDL-cholesterol was increased. These findings suggest that oraltreatment with coenzyme Q10 can be effective in decreasing bloodpressure and improving insulin response.

[0563] Vanadium

[0564] Most patients with type 2 diabetes mellitus requirepharmacotherapy, initially as monotherapy, subsequently in combination.Exogenous insulin is ultimately required in a substantial proportion,reflecting the progressive natural history of the disease. As notedearlier, both the sulfonylureas and the biguanides have been employedfor over 4 decades as oral antidiabetic agents, but they have a limitedcapacity to provide long-term glycemic control.

[0565] Vanadium increases both hepatic and peripheral insulinsensitivity, thus expanding the activity of combinations ofsulfonylurea-metformin. It also activates glycogenesis and therebydecreases hyperglycemia by complementing metformin's inhibition ofglycogenolysis. Furthermore, it has been reported to activateATP-sensitive potassium (K(ATP)) channels in the absence of nucleotides.K(ATP) channels comprise Kir6.2 and sulfonylurea receptor subunits (SUR1in pancreatic β-cells, SUR2A in cardiac and skeletal muscle, and SUR2Bin smooth muscle).

[0566] Vanadium has therapeutic potential in both type 1 and type 2diabetes in doses ranging from 0.083 mmol/d to 0.42 mmol/d. Althoughvanadium has significant biological potential, it has a poor (narrow)therapeutic index. Organic forms of vanadium, as opposed to theinorganic sulfate salt, may be safer, more absorbable, and may be ableto deliver a therapeutic effect up to 50% greater than the inorganicforms. Vanadium has been administered to pregnant women diagnosed withpregnancy-induced diabetes without adverse effects upon either themother or fetus.

[0567] Vanadium is present in a variety of foods that we commonly eat.The daily dietary intake in humans varies from 10 micrograms to 2 mg ofelemental vanadium, depending on the sources available in variousregions. The 100 mg/day often used in treating type 2 diabetes isclearly greater than physiological, probably accounting for what isdescribed as a narrow therapeutic index. Utilizing vanadium as oneelement in multicomponent formulations, as defined in this invention,will permit the dosage to be minimized and safety increased.

[0568] Vanadate and pervanadate (pV) are protein tyrosine phosphatase(PTP) inhibitors that mimic insulin to stimulate glucose transport.Vanadate and pV are able to stimulate glucose transport and GLUT4translocation by mechanisms independent of PI3-kinase and PKC. Similarto insulin, stimulation of glucose transport by vanadate requires thepresence of an intact actin network.

[0569] Vanadate (V⁵⁺), an oxidized form of vanadium, or vanadyl (V⁴⁺)promote both hepatic and peripheral insulin action by threemechanisms: 1) direct insulin-mimesis; 2) enhancement of insulinsensitivity and 3) prolongation of the insulin biological response. Theinsulin-mimetic action of these forms of vanadium persists afterwithdrawal of treatment. Vanadium treatment of non-diabetic animalslowers plasma insulin levels by reducing insulin demand, and theseanimals remain normoglycemic. Chronic treatment with vanadium has alsobeen shown to result in sustained antidiabetic effects in STZ-diabeticanimals long after treatment has ceased. Thus, 13 weeks after withdrawalfrom vanadium administration, treated animals have normalized glucoselevels and normal weight gain, and improved basal insulin levels. Inaddition, near-normal glucose tolerance is found despite aninsignificant insulin response. Since vanadium accumulates in severaltissue sites when pharmacological doses are administered (e.g., bone,kidney), it is possible that stored vanadium may be important inmaintaining near-normal glucose tolerance, at least in the short-termfollowing withdrawal from treatment.

[0570] In humans, after 3 weeks of vanadyl sulfate (100 mg/day), bothhepatic and peripheral insulin sensitivity appear to improve ininsulin-resistant type 2 diabetes patients. These effects are sustainedfor up to 2 weeks after discontinuation of vanadyl sulfate.

[0571] There are some distinct signal-transduction pathways for vanadateand for insulin in the activation of glycogen synthase and glycogenesis.Although both vanadate and insulin increase glycogenesis and glycogensynthase, there are differences as well as similarities. In severalaspects, vanadate and insulin resemble each other: 1) in theiractivation of glycogen synthase; 2) each requires nonarrested proteinphosphatase 1 activity; 3) each is equally suppressed by conditions thatelevate cAMP-levels' and 4) each depends on the activation ofphosphatidylinositol-3 kinase. The differences between them are equallyspecific: 1) vanadate promotes glycogenesis through the activation of acytosolic protein tyrosine kinase, in an insulin-receptor-independentmanner; 2) vanadate elevates glucose-6-phosphate (G-6-P) to a higherlevel than insulin; 3) vanadate-activated glycogenesis is accompanied byan increase in the cellular content of immunoreactive glycogen synthase,an effect less noticeable with insulin; 4) adipose glucose-6-phosphataseis inhibited by vanadate but not by insulin. Thus, insulin and vanadateboth activate glycogenesis through a phosphatidylinositol-3 kinase anddephosphorylation-dependent mechanism. Vanadate, however, uses areceptor-independent pathway and is superior to insulin in elevating thelevel of G-6-P, a key metabolite for activating glycogen synthase. Thisis attributed to the combined effect of vanadate in enhancing glucoseentry and in inhibiting dephosphorylation of endogenously formed G-6-P.The latter effect is not exerted by insulin.

[0572] Vanadium has several mechanisms of action in progressive insulinresistance and type 2 diabetes:

[0573] 1. Increased insulin sensitivity.

[0574] 2. Activates glycogenesis.

[0575] 3. Enzyme effects:

[0576] PTPase inhibition

[0577] PTK activation

[0578] P13K activation

[0579] Glycogen synthase activation

[0580] Improves activation of S6 kinase by insulin

[0581] 4. Preserves pancreatic β-cells

[0582] 5. Mimics insulin effect on calmodulin in liver and adiposetissue

[0583] 6. Accelerates the metabolic reaction from sorbitol pathway toglycolysis

[0584] 7. Decreases diabetic hyperphagia

[0585] 8. Down-regulates small intestine glucose carriers

[0586] 9. Inhibits NO production by macrophages

[0587] Tolerance does not appear to develop with long term oraladministration of vanadium, but the safety of chronic vanadium treatmentbeyond five months is not yet established. This may have an impact onthe therapeutic use of vanadium. To reduce this possibility of chronicuse toxicity, the invention describes a pulsing of vanadiumadministration and/or once a day bedtime use to take advantage of theprolonged vanadium insulin-mimetic effect following withdrawal oftreatment.

[0588] Zinc

[0589] Zn²⁺ plays a clear role in the synthesis, storage and secretionof insulin as well as preserving the conformational integrity of insulinin the hexameric form.

[0590] The relationship between diabetes, insulin and Zn²⁺ is complex.Functioning as an insulin cofactor, Zn²⁺ prevents hyperglycemia byincreasing insulin activity at its receptor site. Diabetics tend to havelow plasma Zn²⁺ concentrations and decreased total body Zn²⁺.Hyperglycemia, rather than any primary lesion related to diabetes, isresponsible for increased urinary loss and a decrease in total bodyZn²⁺, which in turn is in part responsible for hyperglycemia. DietaryZn²⁺ is potentially inadequate in any given geographic region; a lowgroundwater content of Zn²⁺ may contribute to population deficiencies.

[0591] In comparison to healthy control subjects, a significantly lowerCu, Zn-superoxide dismutase activity is found in both lymphocytes andpolymorphonuclear cells of type 1 diabetes and type 2 diabetes patients.A Zn²⁺ deficiency can, therefore, reduce immunoefficiency or aggravatean existing immune deficiency, and contribute to the slow wound healingseen in diabetics.

[0592] Adequate Zn²⁺ is necessary for angiotensin converting enzymeinhibitors (ACE). All ACE inhibitors bind to Zn²⁺ ions. ACE inhibitorshave clinically beneficial effects; not only for patients withhypertension or congestive heart failure, but also for the prevention ofthe progression of renal dysfunction induced by diabetes mellitus.

DEFINITIONS AND PREFERRED EMBODIMENTS

[0593] Definitions

[0594] All terms appearing in this specification and the appended claimsare used in the same manner as commonly recognized among those skilledin the technology and terminology of pharmacology. These terms aretherefore used in accordance with their conventional definitions, exceptas otherwise noted. Further clarifications of some of these terms asthey apply specifically to this invention are offered below.

[0595] “Unit dosage form” refers to a composition intended for a singleadministration to treat a subject suffering from a disease or medicalcondition. Each unit dosage form typically comprises each of the activeingredients of this invention plus pharmaceutically acceptableexcipients. Examples of unit dosage forms are individual tablets,individual capsules, bulk powders, and liquid solutions, emulsions orsuspensions. Treatment of the disease or condition may require periodicadministration of unit dosage forms, for example: one or two unit dosageforms two or more times a day, one or two with each meal, one or twoevery four hours or other interval, or only one per day. The expression“oral unit dosage form” indicates a unit dosage form designed to betaken orally.

[0596] An “active agent” or “active ingredient” is a component of adosage form that performs a biological function when administered orinduces or affects (enhances or inhibits) a physiological process insome manner. “Activity” is the ability to perform the function, or toinduce or affect the process. Active agents and ingredients aredistinguishable from excipients such as carriers, vehicles, diluents,lubricants, binders, and other formulating aids, and encapsulating orotherwise protective components.

[0597] “Delivery vehicle” is a composition, which comprises one or moreactive agents, and is designed to release the active agent in aparticular fashion, either by immediately dispersing the agents in thedigestive system, or by releasing the agents in a slow sustainedfashion. The term encompasses porous microspheres, microcapsules,cross-linked porous beads, and liposomes that contain one or more activeingredients sequestered within internal cavities or porous spaces. Theterm also includes osmotic delivery systems, coated tablets or capsulesthat include nonporous microspheres, microcapsules, and liposomes, andactive agents dispersed within polymeric matrices. A dosage form caninclude one or more delivery vehicles.

[0598] “Controlled” or “sustained” or “time release” delivery areequivalent terms that describe the type of active agent delivery thatoccurs when the active agent is released from a delivery vehicle at anascertainable and manipulatable rate over a period of time, which isgenerally on the order of minutes, hours or days, typically ranging fromabout thirty minutes to about 3 days, rather than being dispersedimmediately upon entry into the digestive tract or upon contact withgastric fluid. A controlled release rate can vary as a function of amultiplicity of factors. Factors influencing the rate of delivery incontrolled release include the particle size, composition, porosity,charge structure, and degree of hydration of the delivery vehicle andthe active ingredient(s), the acidity of the environment (eitherinternal or external to the delivery vehicle), and the solubility of theactive agent in the physiological environment, i.e., the particularlocation along the digestive tract.

[0599] “Targeted” or “site-specific” delivery means that thepharmaceutical preparation is formulated to limit the release of itscontents in an amount appropriate to the site where release occurs. Theterm refers in particular to the active agent, whose site-specificdelivery implements the performance of the therapeutic function at aspecific site within the body of the subject to whom the preparation isadministered.

[0600] The phrase “therapeutically effective amount” means an amountsufficient to produce a therapeutic result. Generally the therapeuticresult is an objective or subjective improvement of a disease orcondition, achieved by inducing or enhancing a physiological process,blocking or inhibiting a physiological process, or in general termsperforming a biological function that helps in or contributes to theelimination or abatement of the disease or condition.

[0601] “Vasoconstriction” is the reduction of the cross section of ablood vessel lumen, inhibiting the free flow of blood through thevessel. Vasoconstriction can arise from vasospasm, deposits on or in thelumen wall or from the thickening of the wall material due to excessivegrowth or proliferation of one or more of the wall layers.

[0602] The phrase “substantially homogeneous,” when used to describe aformulation (or portion of a formulation) that contains a combination ofcomponents, means that the components, although each may be in particleor powder form, are fully mixed so that the individual components arenot divided into discrete layers or form concentration gradients withinthe formulation.

[0603] Compositions, Formulations and Dosages

[0604] The amounts of the twenty-one primary components of thepharmaceutical preparation of this invention can vary, although inpreferred preparations the components are present in amounts lyingwithin certain ranges as follows: TABLE 1 Dosages in Milligrams per DayPreferred Most Preferred Biguanides Metformin 125 to 2000   125 to 1000Sulfonylureas (first generation) Acetohexamide 250 to 1500  500 to 750Chlorpropamide 100 to 500  250 to 375 Tolazamide 100 to 1000  250 to 500Tolbutamide 500 to 2500  1000 to 2000 Sulfonylureas (second generation)Glimepiride 0.5 to 8    1 to 4 Glipizide 2.5 to 40    5 to 20 Glipizide(XL) 2.5 to 40    5 to 20 Glyburide 1.25 to 30     5 to 20 Glyburide(micro) 1.25 to 30     5 to 20 Active Ingredients in Addition toMetformin and/or Sulfonylurea L-Arginine 75 to 6250  250 to 2500Ascorbate 75 to 3125  250 to 1250 Tetrhydrobiopterin 24 to 3000  80 to1200 L-Carnitine 90 to 2500  300 to 1000 Choline 15 to 250   50 to 100Chromium 0.01 to 0.63  0.03 to 0.25 Folate 0.03 to 2.0   0.10 to 0.80Lipoate 30 to 1500 100 to 600 Magnesium 30 to 1000 100 to 400 Melatonin0.15 to 7.5   0.5 to 4   L-Acetyl-L-cysteine 78 to 3900  200 to 1200Nicotinate 3 to 375  10 to 150 Pyridoxine 0.3 to 15   1.0 to 6.0Selenium 0.02 to 0.75  0.05 to 0.3  Taurine 75 to 3125  250 to 1250Thiamine 0.45 to 37.5  1.5 to 15  Tocopherol D,α 15 to 1600  50 to 800Tocotrienol 15 to 2000  50 to 800 Ubiquinone 4.5 to 225   15 to 90Vanadium 7.5 to 375    25 to 150 Vitamin B12 0.001 0.002 to 0.004 to 0.010 Zinc 1.5 to 80    5 to 32

[0605] A slower, more sustained release of the active agents can beachieved by placing the active agents in one or more delivery vehiclesthat inherently retard the release rate. Examples of such deliveryvehicles are polymeric matrices that maintain their structural integrityfor a period of time prior to dissolving, or that resist dissolving inthe stomach but are readily made available in the post-gastricenvironment by the alkalinity of the intestine, or by the action ofmetabolites and enzymes that are present only in the intestine. Thepreparation and use of polymeric matrices designed for sustained drugrelease is well known. Examples are disclosed in U.S. Pat. No. 5,238,714(Aug. 24, 1993) to Wallace et al.; Bechtel, W., Radiology 161: 601-604(1986); and Tice et al., EPO 0302582, Feb. 8, 1989. The disclosures ofeach of these documents are incorporated herein by reference in theirentirety. Selection of the most appropriate polymeric matrix for aparticular formulation can be governed by the intended use of theformulation. Preferred polymeric matrices are hydrophilic,water-swellable polymers such as hydroxymethylcellulose,hydroxypropylcellulose, hydroxyethylcellulose,hydroxymethylpropylcellulose, polyethylene oxide, and porous bioerodibleparticles prepared from alginate and chitosan that have been ionicallycrosslinked.

[0606] A delayed, post-gastric, prolonged release of the activeingredients in the small intestine (duodenum, ileum, jejunum) can alsobe achieved by encasing the active agents, or by encasing hydrophilic,water-swellable polymers containing the active agents, in an enteric(acid-resistant) film. One class of acid-resistant agents suitable forthis purpose is that disclosed in Eury et al., U.S. Pat. No. 5,316,774(“Blocked Polymeric Particles Having Internal Pore Networks forDelivering Active Substances to Selected Environments”), incorporatedherein by reference in its entirety. The formulations disclosed in thispatent consist of porous particles whose pores contain an activeingredient and a polymer acting as a blocking agent that degrades andreleases the active ingredient upon exposure to either low or high pH orto changes in ionic strength. The most effective enteric materialsinclude polyacids having a pK_(a) of from about 3 to 5. Examples of suchmaterials are fatty acid mixtures, methacrylic acid polymers andcopolymers, ethyl cellulose, and cellulose acetate phthalates. Specificexamples are methacrylic acid copolymers sold under the name EUDRAGIT®,available from Rohm Tech, Inc., Maiden, Mass., USA; and the celluloseacetate phthalate latex AQUATERIC®, available from FMC Corporation, NewYork, N.Y., USA, and similar products available from Eastman-Kodak Co.,Rochester, New York, USA.

[0607] Acid-resistant films of these types are particularly useful inconfining the release of magnesium lactate and magnesium citrate to thepost-gastric environment. Acid-resistant films can be applied ascoatings over individual particles of the components of the formulation,with the coated particles then optionally compressed into tablets. Anacid-resistant film can also be applied as a layer encasing an entiretablet or a portion of a tablet where each tablet is a single unitdosage form.

[0608] The dosage forms of the invention optionally include one or moresuitable and pharmaceutically acceptable excipients, such as ethylcellulose, cellulose acetate phthalates, mannitol, lactose, starch,magnesium stearate, sodium saccharin, talcum, glucose, sucrose,carbonate, and the like. These excipients serve a variety of functions,as indicated above, as carriers, vehicles, diluents, binders, and otherformulating aids. In general, the dosage forms of this invention includepowders, liquid forms, tablets or capsules.

[0609] In certain embodiments of the invention, the dosage form is asubstantially homogeneous single layer tablet that releases all of itscomponents into the stomach upon ingestion. Examples of tabletscontaining metformin, a sulfonylurea (or sulfonylurea-like) or abiguanide-sulfonylurea combination, and additional active ingredientsare shown in Examples I, II and III.

EXAMPLE I Metformin+Other Ingredients

[0610] A single layer tablet, substantially homogenous in composition,which will disintegrate upon ingestion to provide simultaneousaccessibility to all components, is prepared with the followingcomposition: SINGLE LAYER UNIT DOSAGE FORM FOR:

TABLET WEIGHT 786 FOR IMMEDIATE RELEASE IN THE STOMACH 100% % of formulamilligrams active ingredients Mg(C6H7O6)2 Magnesium L-Ascorbate 8.51%267.35 (C2H7N03S)2Mg Magnesium Taurate 13.97% 439.16 C5H9NO3SN-Acetyl-L-Cysteine 12.73% 400.00 C9H15N5O3 Tetrahydrobiopterin 7.95%250.00 C4H11N5 METFORMIN 15.91% 500.00 C62H51O4 Ubiquinone 4.77% 150.00C29H50O2 D,a-Tocopherol 9.93% 312.00 C19H19N7O6 Folic acid 0.006% 0.20excipients Mg(C18H3502)2 Magnesium Stearate 0.76% 23.98 . . . Starch25.46% 800.00

EXAMPLE II Sulfonylurea (Glyburide)+Other Ingredients

[0611] A single layer tablet, substantially homogenous in composition,which will disintegrate upon ingestion to provide simultaneousaccessibility to all components, is prepared with the followingcomposition: SINGLE LAYER UNIT DOSAGE FORM FOR:

TABLET WEIGHT 826 FOR IMMEDIATE RELEASE IN THE STOMACH 100% % of formulamilligrams active ingredients (C7H15NO3)2Mg Magnesium L-Carnitine 24.40%806.54 Mg(C6H7O6)2 Magnesium L-Ascorbate 8.09% 267.35 Mg(C6H13N4O2)2Magnesium L-Arginate 24.28% 802.62 Zn(C8H12O2S2)2 Zinc Lipoate 7.02%232.00 C23H28C1N3O5S GLYBURIDE 0.08% 2.50 C29H50O2 D,a-Tocopherol 9.44%312.00 excipients Mg(C18H3502)2 Magnesium Stearate 0.76% 25.03 . . .Starch 25.93% 857.00

EXAMPLE III Metformin/Sulfonylurea (Glyburide)+Other Ingredients

[0612] A single layer tablet, substantially homogenous in composition,which will disintegrate upon ingestion to provide simultaneousaccessibility to all components, is prepared with the followingcomposition: SINGLE LAYER UNIT DOSAGE FORM FOR:

TABLET WEIGHT 838 FOR IMMEDIATE RELEASE IN THE STOMACH 100% % of formulaMilligrams active ingredients (C7H15NO3)2Mg Magnesium L-Carnitine 12.84%430.16 Mg(C6H7O6)2 Magnesium L-Ascorbate 7.98% 267.35 (C2H7N03S)2MgMagnesium Taurate 13.11% 439.16 Zn(C8H12O2S2)2 Zinc Lipoate 5.19% 174.00C9H15N5O3 Tetrahydrobiopterin 5.97% 200.00 C4H11N5 METFORMIN 14.92%500.00 C23H28C1N3O5S GLYBURIDE 0.07% 2.50 C62H51O4 Ubiquinone 4.48%150.00 C29H50O2 D,a-Tocopherol 9.31% 312.00 C19H19N7O6 Folic acid 0.006%0.20 excipients Mg(C18H3502)2 Magnesium Stearate 0.75% 25.03 . . .Starch 25.37% 850.00

[0613] In certain other embodiments of the invention, the dosage form isprotected by an acid-resistant coating for release only in theintestine, and optionally in a sustained-release manner over a period oftime.

[0614] In another embodiment of the invention, the dosage form is acombination tablet in which the components are divided into twoportions: one that is fully released into the stomach upon ingestion,and the other protected by an acid-resistant coating for release only inthe intestine, and optionally in a sustained-release manner over aperiod of time.

[0615] The controlled release layer comprises about 50% by weight of thetablet and has an acid-resistant coating separating it from theimmediate release layer. The immediate release layer comprises about 50%by weight of the tablet and has a coating that dissolves in an aqueousenvironment.

[0616] Ingredients for each layer are fed into appropriate hoppers of atwo-layer, rotary tablet press, and compressed into two-layer tablets.The magnesium stearate present in both layers provides lubrication ofthe tablet press and serves as a minimal source of magnesium in theformulation. Se and folic acid are each added as a spray.

[0617] Upon oral ingestion of the tablet, agents of the immediaterelease layer dissolve rapidly in the stomach and are available forimmediate absorption in the gastrointestinal tract. The polymer matrixof the controlled release layer, having been given an enteric coating inthe granulation process with EUDRAGIT, does not dissolve in the acid pHof the stomach, but remains intact until it passes to the upper part ofthe small intestine, where the enteric coating dissolves in the morealkaline environment of the intestine. The polymeric matrix thenimmediately begins to imbibe water from the intestinal fluid, forming awater-swollen gel. The agents incorporated into this layer are thenavailable for intestinal absorption as they osmotically diffuse from thegel. Since the agents have been selected with a view toward their watersolubilities, the rate of diffusion of each agent is reasonably constantfor the useful life of the matrix (approximately four hours), by whichtime the incorporated agents are finally depleted and the matrixdisintegrates.

[0618] The dosage forms of this invention can be formulated foradministration at rates of two or more unit dosage forms per dose. Unitdosage forms to be taken two units, three to four times per day arepreferred.

Methods of Administration and Types of Utility

[0619] The compositions and dosage forms of the invention are useful forincreasing the effectiveness, efficiency and safety in the delivery ofsulfonylurea or metformin pharmaceuticals, and of combinedsulfonylurea/metformin pharmaceutical agents, in the prevention andtreatment of insulin resistance and diabetes mellitus, as an activeingredient for humans. The carefully chosen active ingredients of theinvention provide therapeutic levels of a metformin, of a sulfonylureaor of a biguanide/sulfonylurea combination, concurrently with otherelements that act in a well-defined and complementary biochemicalpartnership with these drugs to avoid the development of, or ameliorate,progressive insulin resistance, to retard its progression to diabetesmellitus and to ensure an improvement in glucose tolerance, hypertensionand obesity associated with type 2 diabetes, and a reduction in themorbidity rate. The invention anticipates that diabetic microvascularcomplications (nephropathy, retinopathy, neuropathy, etc.) as well asdiabetic macrovascular complications (atherosclerosis, heart attack,stroke, peripheral vascular disease, etc.) will be lessened.

[0620] The invention will achieve these therapeutic objectives by:

[0621] Enhancing sulfonylurea, metformin and biguanide-sulfonylureaeffectiveness by:

[0622] 1. prolonging the duration of sulfonylurea-metformin's clinicalusefulness;

[0623] 2. reducing sulfonylurea-metformin dosage required by increasingits efficiency;

[0624] 3. reducing diabetic microvascular complications;

[0625] 4. increasing insulin secretion;

[0626] 5. decreasing insulin resistance at its receptor;

[0627] 6. reducing hyperglycemia;

[0628] 7. decreasing lipid peroxidation secondary to free radicalformation of hyperglycemia;

[0629] 8. preventing formation of advanced glycation end products;

[0630] 9. modulating calcium signaling and β-cell membrane polarizationand repolarization;

[0631] 10. preventing endothelial cell dysfunction;

[0632] 11. improving lipid profiles;

[0633] 12. inhibiting platelet aggregation;

[0634] 13. reducing norepinephrine release from cardiac sympatheticnerves.

[0635] Expanding sulfonylurea, metformin and biguanide-sulfonylureaareas of effect by:

[0636] 1. reducing diabetic macrovascular complications;

[0637] 2. reducing premature apoptosis of pancreatic b-cell;

[0638] 3. reducing dysfunctional vasoconstriction;

[0639] 4. increasing hepatic and peripheral insulin sensitivity;

[0640] 5. decreasing insulin post-receptor disturbances;

[0641] 6. increasing the number of insulin receptors and the duration ofaction of insulin;

[0642] 7. maintaining pancreatic islet B-cell sensitivity to glucose;

[0643] 8. optimizing the b-cell cytoplasmic free Ca2+ level;

[0644] 9. inhibiting the polyol pathway and consequent sorbitol effects;

[0645] 10. reducing LDL oxidation;

[0646] 11. reducing the free radical effect at the caveolae andmitochondrial permeability transition pore complex;

[0647] 12. decreasing vascular adhesion factors and maintaining membraneproteoglycans;

[0648] 13. reducing PAI-1 inhibitor and improving fibrinolysis.

[0649] Reducing metformin, sulfonylurea and biguanide-sulfonylureaadverse effects by:

[0650] 1. reducing sulfonylurea-metformin gastrointestinal intolerance;

[0651] 2. reducing sulfonylurea induced weight gain and inadequate fattyacid oxidation;

[0652] 3. reducing sulfonylurea risk of hypoglycemia;

[0653] 4. reducing the sulfonylurea hypofibrinolytic effect;

[0654]15. reducing coronary vasoconstriction secondary to sulfonylureareduced ATP-sensitive, K+ channel blockade;

[0655] 6. avoiding biguanide induced hyperhomocysteinemia;

[0656] 7. avoiding biguanide lactic acidosis.

[0657] Formulations designed for different aspects of progressiveinsulin resistance and type 2 diabetes processes are illustrated in thespecifications and defined in the section on claims. Formulations willbe used in appropriate sequencing, or pulsing to maximize effectivenesswhile avoiding toxicity. This is defined in the claims section.

[0658] The foregoing is offered primarily for purposes of illustration.It will be readily apparent to those skilled in the art that theproportions, materials, formulation procedures, administration protocolsand other parameters of this invention may be further modified orsubstituted in various ways without departing from the spirit and scopeof the invention.

References

[0659] Aarsand A K, Carlsen S M. Folate administration reducescirculating homocysteine levels in NIDDM patients on long-term metformintreatment. J Intern Med 1998; 244( 2):169-174.

[0660] Abdel-Wahab Y H, O'Harte F P, Ratcliff H, McClenaghan N H,Barnett C R, Flatt P R. Glycation of insulin in the islets of Langerhansof normal and diabetic animals. Diabetes 1996; 45(11):1489-96.

[0661] Berger W, Caduff F, Pasquel M, Rump A. [The relatively frequentincidence of severe sulfonylurea-induced hypoglycemia in the last 25years in Switzerland. Results of 2 surveys in Switzerland in 1969 and1984]. Schweiz Med Wochenschr 1986; 116(5):145-151.

[0662] Bierhaus A, Chevion S, Chevion M, Hofmrann M, Quehenberger P,Illmer T et al. Advanced glycation end product-induced activation ofNF-kappaB is suppressed by alpha-lipoic acid in cultured endothelialcells. Diabetes 1997; 46(9):1481-90.

[0663] Bollineni J S, Alluru I, Reddi A S. Heparan sulfate proteoglycansynthesis and its expression are decreased in the retina of diabeticrats. Curr Eye Res 1997; 16(2):127-30.

[0664] Boyd A E, III. The role of ion channels in insulin secretion. JCell Biochem 1992; 48(3):235-241.

[0665] Campbell I W. Metformin and the sulphonylureas: the comparativerisk. Horm Metab Res Suppl 1985; 15:105-111.

[0666] Carlsen S M, Folling I, Grill V, Bjerve K S, Schneede J, RefsumH. Metformin increases total serum homocysteine levels in non-diabeticmale patients with coronary heart disease. Scand J Clin Lab Invest 1997;57(6):521-527.

[0667] Charles M A, Eschwege E. Prevention of type 2 diabetes: role ofmetformin. Drugs 1999; 58 Suppl 1:71-73.

[0668] Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetesand modes of action of therapeutic interventions. Arch Intern Med 1997;157(16):1802-1817.

[0669] DeFronzo R A, Goodman A M. Efficacy of metformin in patients withnon-insulin-dependent diabetes mellitus. The Multicenter Metformin StudyGroup. N Engl J Med 1995; 333(9):541-549.

[0670] DeFronzo R A. Pharmacologic therapy for type 2 diabetes mellitus.Ann Intern Med 1999; 131(4):281-303.

[0671] D'hahan N, Jacquet H, Moreau C, Catty P , Vivaudou M. Atransmembrane domain of the sulfonylurea receptor mediates activation ofATβ-sensitive K(+) channels by K(+) channel openers. Mol Pharmacol 1999;56(2):308-315.

[0672] Ferrannini E, Haffner S M, Mitchell B D, Stern M P.Hyperinsulinaemia: the key feature of a cardiovascular and metabolicsyndrome [see comments]. Diabetologia 1991; 34(6):416-22.

[0673] Fujimoto W Y. The importance of insulin resistance in thepathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108 Suppl6a:9S-14S.

[0674] Gorren A C, Schrammel A, Riethmuller C, Schmidt K, Koesling D,Werner E R et al. Nitric oxide-induced autoinhibition of neuronal nitricoxide synthase in the presence of the autoxidation-resistant pteridine5-methyltetrahydrobiopterin. Biochem J 2000; 347(Pt 2):475-484.

[0675] Gregorio F, Ambrosi F, Manfrini S, Velussi M, Carle F, Testa R etal. Poorly controlled elderly Type 2 diabetic patients: the effects ofincreasing sulphonylurea dosages or adding metformin. Diabet Med 1999;16(12):1016-1024.

[0676] Haupt E, Laube F, Loy H, Schoffling K. [Secondary failures inmodern therapy of diabetes mellitus with blood glucose loweringsulfonamides (author's transl)]. Med Klin 1977; 72(38):1529-1536.

[0677] Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterinimproves endothelium-dependent vasodilation by increasing nitric oxideactivity in patients with Type II diabetes mellitus. Diabetologia 2000;43(11): 1435-1438.

[0678] Kilo C. Metformin: a safe and effective treatment in themanagement of NIDDM. Mo Med 1997; 94(3):114-123.

[0679] Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrialdeath/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998;60:619-642. Ref ID: 28214

[0680] Lebovitz HE. Effects of oral antihyperglycemic agents inmodifying macrovascular risk factors in type 2 diabetes. Diabetes Care1999; 22 Suppl 3:C41-C44.

[0681] Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patientswith cardiovascular disease: a mixed blessing? Diabetologia 1996;39(5):503-514.

[0682] Li D, Devaraj S, Fuller C, Bucala R, Jialal I. Effect ofalpha-tocopherol on LDL oxidation and glycation: in vitro and in vivostudies. J Lipid Res 1996; 37(9 ):1978-86.

[0683] Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A,Lorenzetti M et al. The biguanide compound metformin preventsdesensitization of humnan pancreatic islets induced by high glucose. EurJ Pharmacol 1999; 364(2-3):205-209.

[0684] Marfella R, Acampora R, Verrazzo G, Ziccardi P, De Rosa N, GiuntaR et al. Metformin improves hemodynamic and rheological responses toL-arginine in NIDDM patients. Diabetes Care 1996; 19(9):934-9.

[0685] Mastick C C, Brady M J, Saltiel A R. Insulin stimulates thetyrosine phosphorylation of caveolin. J Cell Biol 1995; 129(6):1523-31.

[0686] Matthews D R, Cull C A, Stratton I M, Holman R R, Turner R C.UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabeticpatients over six years. UK Prospective Diabetes Study (UKPDS) Group.Diabet Med 1998; 15(4):297-303.

[0687] Melchior W R, Jaber L A. Metformin: an antihyperglycemic agentfor treatment of type II diabetes. Ann Pharmacother 1996; 30(2):158-64.

[0688] Olgemoller B, Schleicher E. Alterations of glomerular matrixproteins in the pathogenesis of diabetic nephropathy. Clin Investig1993; 71(5):13-9.

[0689] Pagliaro P, Paolocci N, Isoda T, Saavedra W F, Sunagawa G, Kass DA. Reversal of glibenclamide-induced coronary vasoconstriction byenhanced perfusion pulsatility: possible role for nitric oxide.Cardiovasc Res 2000; 45(4):1001-1009.

[0690] Pieper GM. Acute amelioration of diabetic endothelial dysfunctionwith a derivative of the nitric oxide synthase cofactor,tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29(1):8-15.

[0691] Preuss H G. Effects of glucose/insulin perturbations on aging andchronic disorders of aging: the evidence. J Am Coll Nutr 1997;16(5):397-403.

[0692] Reaven G M. Pathophysiology of insulin resistance in humandisease. Physiol Rev 1995; 75(3):473-86.

[0693] Saltiel A R. Diverse signaling pathways in the cellular actionsof insulin. Am J Physiol 1996; 270(3 Pt 1):375-85.

[0694] Shimizu S, Ishii M, Momose K, Yamamoto T . Role oftetrahydrobiopterin in the function of nitric oxide synthase, and itscytoprotective effect (Review). Int J Mol Med 1998; 2(5):533-540.

[0695] Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima Het al. Oral administration of tetrahydrobiopterin prevents endothelialdysfunction and vascular oxidative stress in the aortas ofinsulin-resistant rats. Circ Res 2000; 87(7):566-573.

[0696] Uittenbogaard A, Shaul P W, Yuhanna I S, Blair A, Smart E J. Highdensity lipoprotein prevents oxidized low density lipoprotein-inducedinhibition of endothelial nitric-oxide synthase localization andactivation in caveolae. J Biol Chem 2000; 275(15):11278-11283.

[0697] UKPDS. Effect of intensive blood-glucose control with metforminon complications in overweight patients with type 2 diabetes (UKPDS 34).UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-865.

[0698] Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters B S,Karoui H et al. Superoxide generation by endothelial nitric oxidesynthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998;95(16):9220-9225.

[0699] White J, Jr., Campbell R K. Magnesium and diabetes: a review. AnnPharmacother 1993; 27(6):775-80. (the Amer Diab Ass statement)

[0700] Wiernsperger N F. Membrane physiology as a basis for the cellulareffects of metformin in insulin resistance and diabetes. Diabetes Metab1999; 25(2):110-27.

[0701] Wollen N, Bailey C J. Inhibition of hepatic gluconeogenesis bymetformin. Synergism with insulin. Biochem Pharmacol 1988;37(22):4353-8.

[0702] Xia Y, Tsai A L, Berka V, Zweier J L. Superoxide generation fromendothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent andtetrahydrobiopterin regulatory process. J Biol Chem 1998;273(40):25804-25808.

What is claimed is:
 1. A unit dosage form containing metformin forsupporting mitochondrial metabolism as a method for the prevention,management and clinical amelioration of insulin resistance and type 2diabetes and conditions giving rise thereto, said unit dosage formcomprising as active ingredients: (a) choline, (b) ascorbate (c)L-carnitine, (d) magnesium, (e) taurine, (f) folic acid, and (g)metformin.
 2. A unit dosage form in accordance with claim 1 in whichsaid active ingredients are formulated as a substantially homogeneoustablet or capsule that releases all of said active ingredients into thestomach upon ingestion for contact with gastric fluid.
 3. A unit dosageform in accordance with claim 2 in which: (a) said choline is in anamount ranging from about 15 mg to about 250 mg, and (b) said ascorbateis in an amount ranging from about 75 mg to about 2500 mg, (c) saidL-carnitine is in an amount ranging from about 90 mg to about 2500 mg,(d) said magnesium is in an amount ranging from about 30 mg to about1000 mg, (e) said taurine is in an amount ranging from about 75 mg toabout 3000 mg, said folic acid is in an amount ranging from about 0.03mg to about 2 mg, and (f) said metformin is in an amount ranging fromabout 150 mg to about 3000 mg.
 4. A unit dosage form containingmetformin for the preservation of plasma and mitochondrial membraneintegrity for use as a method for the prevention, management andclinical amelioration of insulin resistance and type 2 diabetes andconditions giving rise thereto, said unit dosage form comprising asactive ingredients: (a) D,α-lipoic acid, (b) ubiquinone, (c) L-arginine,(d) N-acetyl-cysteine, (e) selenium, (f) a member selected from thegroup consisting of D,α-tocopherol and tocotrienol, (g)tetrahydrobiopterin, and (h) metformin.
 5. A unit dosage form inaccordance with claim 4 in which said active ingredients are formulatedas a substantially homogeneous tablet or capsule that releases all ofsaid active ingredients into the stomach upon ingestion for contact withgastric fluid.
 6. A unit dosage form in accordance with claim 5 inwhich: (a) said D,α-lipoic acid is in an amount ranging from about 30 mgto about 1500 mg, (b) said ubiquinone is in an amount ranging from about4 mg to about 225 mg, (c) said L-arginine is in an amount ranging fromabout 75 mg to about 3100 mg, (d) said N-acetyl-cysteine is in an amountranging from about 80 mg to about 3000 mg, (e) said selenium is in anamount ranging from about 0.02 mg to about 0.75 mg, (f) saidD,α-tocopherol or tocotrienol is in an amount ranging from about 15 mgto about 1600 mg, (g) said tetrahydrobiopterin is in an amount rangingfrom about 24 mg to about 3000 mg, and (h) said metformin is in anamount ranging from about 150 mg to about 3000 mg.
 7. A unit dosage formcontaining metformin for the preservation and functional maintenance ofinsulin receptors and pancreatic β-cells for use as a method for theprevention, management and clinical amelioration of insulin resistanceand type 2 diabetes and conditions giving rise thereto, said unit dosageform comprising as active ingredients: (a) chromium, (b) L-arginine, (c)vanadium, (d) zinc, and, (e) metformin.
 8. A unit dosage form inaccordance with claim 7 in which said active ingredients are formulatedas a substantially homogeneous tablet or capsule that releases all ofsaid active ingredients into the stomach upon ingestion for contact withgastric fluid.
 9. A unit dosage form in accordance with claim 8 inwhich: (a) said chromium is in an amount ranging from about 0.01 mg toabout 0.63 mg, (b) said L-arginine is in an amount ranging from about 75mg to about 3100 mg, (c) said vanadium is in an amount ranging fromabout 7.5 mg to about 375 mg, (d) said zinc is in an amount ranging fromabout 1.5 mg to about 125 mg, and (e) said metformin is in an amountranging from about 150 mg to about 3000 mg.
 10. A unit dosage formcontaining metformin specifically for nocturnal use as a method for theprevention, management and clinical amelioration of insulin resistanceand type 2 diabetes and conditions giving rise thereto, said unit dosageform comprising as active ingredients: (a) melatonin, (b) L-carnitine,(c) ubiquinone, (d) L-arginine, (e) magnesium, (f) folic acid, and (g)metformin.
 11. A unit dosage form in accordance with claim 10 in whichsaid active ingredients are formulated as a substantially homogeneoustablet or capsule that releases all of said active ingredients into thestomach upon ingestion for contact with gastric fluid.
 12. A unit dosageform in accordance with claim 11 in which: (a) said melatonin is in anamount ranging from about 0.15 mg to about 7.5 mg, (b) said L-carnitineis in an amount ranging from about 90 mg to about 2500 mg, (c) saidubiquinone is in an amount ranging from about 4.5 mg to about 225 mg,(d) said folic acid is in an amount ranging from about 0.03 mg to about2 mg, (e) said magnesium is in an amount ranging from about 30 mg toabout 1000 mg, (f) said L-arginine is in an amount ranging from about 75mg to about 3100 (g) said metformin is in an amount ranging from about150 mg to about 3000 mg.
 13. A unit dosage form in accordance with claim1 in which said unit dosage form is a bilayer tablet comprising animmediate-release layer and a sustained-release layer, said activeingredients are distributed between said immediate-release layer andsaid sustained-release layer in the following approximate proportionsexpressed as relative weight percents: Immediate-Release LayerSustained-Release Layer choline 100% ascorbate 100% L-carnitine 40-60%balance magnesium 40-60% balance taurine 40-60% balance folic acid 100%metformin 40-60% balance


14. A unit dosage form in accordance with claim 4 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer D,α-lipoicacid 40-60% balance ubiquinone 100% L-arginine 40-60% balanceN-acetyl-cysteine 40-60% balance selenium 40-60% balance D,α-tocopherol100% tetrahydrobiopterin 40-60% balance metformin 40-60% balance


15. A unit dosage form in accordance with claim 7 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer chromium40-60% balance L-arginine 40-60% balance vanadium 40-60% balance zinc40%-60%   balance metformin 40%-60%   balance


16. A unit dosage form containing sulfonylurea or a sulfonylurea-likecompound for supporting mitochondrial metabolism as a method for theprevention, management and clinical amelioration of insulin resistanceand type 2 diabetes and conditions giving rise thereto, said unit dosageform comprising as active ingredients: (a) choline, (b) ascorbate, (c)L-carnitine, (d) magnesium, (e) taurine, (f) folic acid, and (g)sulfonylurea or sulfonylurea-like compound.
 17. A unit dosage form inaccordance with claim 16 in which said active ingredients are formulatedas a substantially homogeneous tablet or capsule that releases all ofsaid active ingredients into the stomach upon ingestion for contact withgastric fluid.
 18. A unit dosage form in accordance with claim 17 inwhich: (a) said choline is in an amount ranging from about 15 mg toabout 250 mg, and (b) said ascorbate is in an amount ranging from about75 mg to about 2500 mg, (c) said L-carnitine is in an amount rangingfrom about 90 mg to about 2500 mg, (d) said magnesium is in an amountranging from about 30 mg to about 1000 mg, (e) said taurine is in anamount ranging from about 75 mg to about 3000 mg, (f) said folic acid isin an amount ranging from about 0.03 mg to about 2 mg, and (g) saidsulfonylurea or sulfonylurea-like compound is in an amount ranging fromabout 1 mg to about 20 mg.
 19. A unit dosage form containingsulfonylurea or a sulfonylurea-like compound for the preservation ofplasma and mitochondrial membrane integrity for use as a method for theprevention, management and clinical amelioration of insulin resistanceand type 2 diabetes and conditions giving rise thereto, said unit dosageform comprising as active ingredients: (a) D,α-lipoic acid, (b)ubiquinone, (c) L-arginine, (d) N-acetyl-cysteine, (e) selenium, (f) amember selected from the group consisting of D,α-tocopherol andtocotrienol, (g) tetrahydrobiopterin, and (h) a sulfonylurea orsulfonylurea-like compound.
 20. A unit dosage form in accordance withclaim 19 in which said active ingredients are formulated as asubstantially homogeneous tablet or capsule that releases all of saidactive ingredients into the stomach upon ingestion for contact withgastric fluid.
 21. A unit dosage form in accordance with claim 20 inwhich: (a) said D,α-lipoic acid is in an amount ranging from about 30 mgto about 1500 mg, (b) said ubiquinone is in an amount ranging from about4 mg to about 225 mg, (c) said L-arginine is in an amount ranging fromabout 75 mg to about 3100 mg, (d) said N-acetyl-cysteine is in an amountranging from about 30 mg to about 1000 mg, (e) said selenium is in anamount ranging from about 80 mg to about 3900 mg, (f) saidD,α-tocopherol or tocotrienol is in an amount ranging from about 0.02 mgto about 0.75 mg, (g) said tetrahydrobiopterin is in an amount rangingfrom about 24 mg to about 3000 mg, and (f) said sulfonylurea orsulfonylurea-like compound is in an amount ranging from about 1 mg toabout 20 mg.
 22. A unit dosage form containing sulfonylurea or asulfonylurea-like compound for the preservation and functionalmaintenance of insulin receptors and pancreatic β-cells for use as amethod for the prevention, management and clinical amelioration ofinsulin resistance and type 2 diabetes and conditions giving risethereto, said unit dosage form comprising as active ingredients: (a)chromium, (b) L-arginine, (c) vanadium, (d) zinc, and (e) a sulfonylureaor a sulfonylurea-like compound.
 23. A unit dosage form in accordancewith claim 22 in which said active ingredients are formulated as asubstantially homogeneous tablet or capsule that releases all of saidactive ingredients into the stomach upon ingestion for contact withgastric fluid.
 24. A unit dosage form in accordance with claim 23 inwhich: (a) said chromium is in an amount ranging from about 0.01 mg toabout 0.63 mg, (b) said L-arginine is in an amount ranging from about 75mg to about 3100 mg, (c) said vanadium is in an amount ranging fromabout 7.5 mg to about 375 mg, (d) said zinc is in an amount ranging fromabout 1.5 mg to about 125 mg, and (e) said sulfonylurea is in an amountranging from about 1 mg to about 20 mg.
 25. A unit dosage formcontaining sulfonylurea specifically for nocturnal use as a method forthe prevention, management and clinical amelioration of insulinresistance and type 2 diabetes and conditions giving rise thereto, saidunit dosage form comprising as active ingredients: (a) melatonin, (b)L-carnitine, (c) ubiquinone, (d) folic acid, (e) magnesium, (f)L-arginine, and (g) a sulfonylurea or sulfonylurea-like compound.
 26. Aunit dosage form in accordance with claim 25 in which said activeingredients are formulated as a substantially homogeneous tablet orcapsule that releases all of said active ingredients into the stomachupon ingestion for contact with gastric fluid.
 27. A unit dosage form inaccordance with claim 26 in which: (a) said melatonin is in an amountranging from about 0.15 mg to about 7.5 mg, (b) said L-carnitine is inan amount ranging from about 90 mg to about 2500 mg, (c) said ubiquinoneis in an amount ranging from about 4.5 mg to about 225 mg, (d) saidfolic acid is in an amount ranging from about 0.03 mg to about 2 mg, (e)said magnesium is in an amount ranging from about 30 mg to about 1000mg, (f) said L-arginine is in an amount ranging from about 75 mg toabout 3100 mg, and (g) said sulfonylurea or sulfonylurea-like compoundis in an amount ranging from about 1 mg to about 20 mg.
 28. A unitdosage form in accordance with claim 16 in which said unit dosage formis a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate-Release Layer Sustained-Release Layer choline 100% ascorbate100% L-carnitine 40-60% balance magnesium 40-60% balance taurine 40-60%balance folic acid 100% sulfonylurea or 40-60% balance sulfonylurea-like compound


29. A unit dosage form in accordance with claim 19 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer D, α-lipoicacid 40-60% balance ubiquinone  100% L-arginine 40-60% balanceN-acetyl-cysteine 40-60% balance selenium 40-60% balance D, α-tocopherol 100% tetrahydrobiopterin 40-60% balance sulfonylurea or 40-60% balancesulfonylurea-like compound


30. A unit dosage form in accordance with claim 22 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer chromium40-60% balance L-arginine 40-60% balance vanadium 40-60% balance zinc40%-60% balance sulfonylurea or 40%-60% balance sulfonylurea-likecompound


31. A unit dosage form containing a sulfonylurea (or asulfonylurea-like)-biguanide complex for supporting mitochondrialmetabolism as a method for the prevention, management and clinicalamelioration of insulin resistance and type 2 diabetes and conditionsgiving rise thereto, said unit dosage form comprising as activeingredients: (a) choline, (b) ascorbate, (c) L-carnitine, (d) magnesium,(e) taurine, (f) thiamine, (g) folic acid, and (h) a sulfonylurea orsulfonylurea-like biguanide complex.
 32. A unit dosage form inaccordance with claim 31 in which said active ingredients are formulatedas a substantially homogeneous tablet or capsule that releases all ofsaid active ingredients into the stomach upon ingestion for contact withgastric fluid.
 33. A unit dosage form in accordance with claim 32 inwhich: (a) said choline is in an amount ranging from about 15 mg toabout 250 mg, (b) said ascorbate is in an amount ranging from about 75mg to about 2500 mg, (c) said L-carnitine is in an amount ranging fromabout 90 mg to about 2500 mg, (d) said magnesium is in an amount rangingfrom about 30 mg to about 1000 mg, (e) said taurine is in an amountranging from about 75 mg to about 3000 mg, (f) said folic acid is in anamount ranging from about 0.03 mg to about 2 mg, (g) said sulfonylurea(or a sulfonylurea-like)-biguanide complex with a sulfonylurea componentselected from the following group in an amount ranging in milligrams:(for first generation sulfonylureas) Acetohexamide from 150 to about1875, Chlorpropamide from 75 to about 938, Tolazamide from 75 to about1250, Tolbutamide from 300 to about 5000,

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanide component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


34. A unit dosage form containing sulfonylurea (or asulfonylurea-like)-biguanide complex for the preservation of plasma andmitochondrial membrane integrity for use as a method for the prevention,management and clinical amelioration of insulin resistance and type 2diabetes and conditions giving rise thereto, said unit dosage formcomprising as active ingredients: (a) D,α-lipoic acid, (b) ubiquinone,(c) L-arginine, (d) N-acetyl-cysteine, (e) selenium, (f) a memberselected from the group consisting of D,α-tocopherol and tocotrienol,(g) tetrahydrobiopterin, and (h) a sulfonylurea (or asulfonylurea-like)-biguanide complex.
 35. A unit dosage form inaccordance with claim 34 in which said active ingredients are formulatedas a substantially homogeneous tablet or capsule that releases all ofsaid active ingredients into the stomach upon ingestion for contact withgastric fluid.
 36. A unit dosage form in accordance with claim 35 inwhich: (a) said D,α-lipoic acid is in an amount ranging from about 75 mgto about 2500 mg, (b) said ubiquinone is in an amount ranging from about0.03 mg to about 2 mg, (c) said L-arginine is in an amount ranging fromabout 75 mg to about 3100 mg, (d) said N-acetyl-cysteine is in an amountranging from about 30 mg to about 1000 mg, (e) said selenium is in anamount ranging from about 80 mg to about 3900 mg, (f) said a memberselected from the group consisting of D,α-tocopherol and tocotrienol isin an amount ranging from about 0.02 mg to about 0.75 mg, (g) saidtetrahydrobiopterin is in an amount ranging from about 15 mg to about1600 mg, and (h) said sulfonylurea (or a sulfonylurea-like)-biguanidecomplex with a sulfonylurea component selected from the following groupin an amount ranging in milligrams: (for first generation sulfonylureas)Acetohexamide from 150 to about 1875, Chlorpropamide from 75 to about938, Tolazamide from 75 to about 1250, Tolbutamide from 300 to about5000,

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanide component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


37. A unit dosage form containing a sulfonylurea (or asulfonylurea-like)-biguanide complex for the preservation and functionalmaintenance of insulin receptors and pancreatic β-cells for use as amethod for the prevention, management and clinical amelioration ofinsulin resistance and type 2 diabetes and conditions giving risethereto, said unit dosage form comprising as active ingredients: (a)chromium, (b) L-arginine, (c) vanadium, (d) zinc, and, (e) asulfonylurea (or a sulfonylurea-like)-biguanide complex.
 38. A unitdosage form in accordance with claim 37 in which said active ingredientsare formulated as a substantially homogeneous tablet or capsule thatreleases all of said active ingredients into the stomach upon ingestionfor contact with gastric fluid.
 39. A unit dosage form in accordancewith claim 38 in which: (a) said chromium is in an amount ranging fromabout 0.01 mg to about 0.63 mg, (b) said L-arginine is in an amountranging from about 75 mg to about 3100 mg, (c) said vanadium is in anamount ranging from about 7.5 mg to about 375 mg, (d) said zinc is in anamount ranging from about 1.5 mg to about 125 mg, (e) said sulfonylurea(or a sulfonylurea-like)-biguanide complex with a sulfonylurea componentselected from the following group in an amount ranging in milligrams:(for first generation sulfonylureas) Acetohexamide from 150 to about1875, Chlorpropamide from 75 to about 938, Tolazamide from 75 to about1250, Tolbutamide from 300 to about 5000,

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanide component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


40. A unit dosage form containing a sulfonylurea (or asulfonylurea-like)-biguanide complex specifically for nocturnal use as amethod for the prevention, management and clinical amelioration ofinsulin resistance and type 2 diabetes and conditions giving risethereto, said unit dosage form comprising as active ingredients: (a)melatonin, (b) L-carnitine, (c) ubiquinone, (d) folic acid, (e)magnesium, (f) L-arginine, and (g) a sulfonylurea (or asulfonylurea-like)-biguanide complex.
 41. A unit dosage form inaccordance with claim 40 in which said active ingredients are formulatedas a substantially homogeneous tablet or capsule that releases all ofsaid active ingredients into the stomach upon ingestion for contact withgastric fluid.
 42. A unit dosage form in accordance with claim 41 inwhich: (a) said melatonin is in an amount ranging from about 0.15 mg toabout 7.5 mg, b) said L-carnitine is in an amount ranging from about 90mg to about 2500 mg, (c) said ubiquinone is in an amount ranging fromabout 4.5 mg to about 225 mg, (d) said folic acid is in an amountranging from about 0.03 mg to about 2 mg, (e) said magnesium is in anamount ranging from about 30 mg to about 1000 mg, (f) said L-arginine isin an amount ranging from about 75 mg to about 3100 mg, (g) saidsulfonylurea (or a sulfonylurea-like)-biguanide complex with asulfonylurea component selected from the following group in an amountranging in milligrams: (for first generation sulfonylureas)Acetohexamide from 150 to about 1875, Chlorpropamide from 75 to about938, Tolazamide from 75 to about 1250, Tolbutamide from 300 to about5000,

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanide component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


43. A unit dosage form in accordance with claim 31 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer choline 100%ascorbate 100% L-carnitine 40-60% balance magnesium 40-60% balancetaurine 40-60% balance folic acid 100% sulfonylurea-biguanide 40-60%balance


44. A unit dosage form in accordance with claim 34 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer D, α-lipoicacid 40-60% balance ubiquinone 100% L-arginine 40-60% balanceN-acetyl-cysteine 40-60% balance selenium 40-60% balance D, α-tocopherol100% tetrahydrobiopterin 40-60% balance sulfonylurea-biguanide 40-60%balance


45. A unit dosage form in accordance with claim 37 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer chromium40-60% balance L-arginine 40-60% balance vanadium 40-60% balance zinc40%-60%  balance sulfonylurea-biguanide 40%-60%  balance


46. A unit dosage form in accordance with claims 4 or 19 in which saidα-lipoic acid is in the form of a member selected from the groupconsisting of an α-lipoic acid salt of a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, and a complex of α-lipoic acid, ametal ion selected from the group consisting of Mg²⁺ and Zn²⁺, and ananion selected from the group consisting of hydroxide, halide, acetate,and ascorbate.
 47. A unit dosage form in accordance with claims 4, 7,10, 19, 22, 25, 34, 37 or 40 in which said L-arginine is in the form ofa member selected from the group consisting of L-arginine ascorbate,bis-L-arginine ascorbate, L-arginine salt of a metal ion selected fromthe group consisting of Mg²⁺ and Zn²⁺, bis-L-arginine salt of a metalion selected from the group consisting of Mg²⁺ and Zn²⁺, and a complexof L-arginine or bis-L-arginine, a metal ion selected from the groupconsisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 48. A unitdosage form in accordance with claims 1, 10, 16, 25, 31 or 40 in whichsaid L-carnitine is in the form of a member selected from the groupconsisting of L-carnitine ascorbate, bis-L-carnitine ascorbate,L-carnitine salt of a metal ion selected from the group consisting ofMg²⁺ and Zn²⁺, bis-L-carnitine salt of a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, and a complex of L-carnitine orbis-L-carnitine, a metal ion selected from the group consisting of Mg²⁺and Zn²⁺, and an anion selected from the group consisting of hydroxide,halide, acetate, and ascorbate.
 49. A unit dosage form in accordancewith claims 1, 16 or 31 in which said L-taurine is in the form of amember selected from the group consisting of L-taurine ascorbate,bis-L-taurine ascorbate, L-taurine salt of a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, bis-L-taurine salt of a metal ionselected from the group consisting of Mg²⁺ and Zn²⁺, and a complex ofL-taurine or bis-L-taurine, a metal ion selected from the groupconsisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 50. A unitdosage form in accordance with claims 1, 10, 16, 25, 31 or 40 in whichsaid magnesium is in the form of a member selected from the groupconsisting of magnesium, magnesium L-arginate, magnesium L-arginineascorbate and bis-ascorbate, magnesium α-lipoate, magnesium α-lipoateascorbate and bis-ascorbate, magnesium taurate, magnesium taurineascorbate and bis-ascorbate, magnesium L-acetylcysteine, magnesiumL-carnitate, magnesium L-carnitine ascorbate and bis-ascorbate,magnesium ascorbate and magnesium bis-ascorbate.
 51. A unit dosage formin accordance with claims 7, 22 or 37 in which said zinc is in the formof a member selected from the group consisting of zinc halide, zincsulfate, zinc L-carnitate, zinc L-carnitate ascorbate and bis-ascorbate,zinc taurate, zinc taurine ascorbate and bis-ascorbate, zinc L-arginate,zinc L-arginine ascorbate and bis-ascorbate, zinc L-carnitate, zincL-carnitine ascorbate and bis-ascorbate, zinc phosphate, zinc acetate,zinc ascorbate, and zinc bis-ascorbate.
 52. A unit dosage form inaccordance with claims 7, 22 or 37 in which said vanadium is in the formof a member selected from the group consisting of vanadate,peroxovanadate, vanadyl sulfate salts, andbis(maltolato)oxovanadium(IV).
 53. A unit dosage form in accordance withclaims 7, 22 or 37 in which said chromium is in the form of a memberselected from the group consisting of chromium dinicotinate, andchromium tripicolinate.
 54. A unit dosage form in accordance with claims4, 19 or 34 in which said D,α-tocopherol is present in the form of amember selected from the group consisting of D,α-tocopherol succinate,D,α-tocopherol nicotinate, D,α-tocopherol picolinate, D,α-tocopherolacetate, and tocotrienol.
 55. A unit dosage form in accordance withclaims 4, 19 or 34 in which said tocotrienol is present in the form of amember selected from the group consisting of tocotrienol succinate,tocotrienol nicotinate, tocotrienol picolinate, and tocotrienol acetate.56. A method for treating a patient who requires biguanide therapy forthe prevention, management, and clinical amelioration of insulinresistance and type 2 diabetes and conditions giving rise thereto, toreduce undesirable physiological side effects, and enhance thetherapeutic effectiveness of said biguanide therapy by supportingmitochondrial metabolism, said method comprising administering to saidpatient a unit dosage form comprising as active ingredients: (a)choline, (b) ascorbate (c) L-carnitine, (d) magnesium, (e) taurine, (f)folic acid, and (g) metformin.
 57. A method in accordance with claim 56in which said active ingredients are formulated as a substantiallyhomogeneous tablet or capsule that releases all of said activeingredients into the stomach upon ingestion for contact with gastricfluid.
 58. A method in accordance with claim 57 in which: (a) saidcholine is in an amount ranging from about 15 mg to about 250 mg, and(b) said ascorbate is in an amount ranging from about 75 mg to about2500 mg, (c) said L-carnitine is in an amount ranging from about 90 mgto about 2500 mg, (d) said magnesium is in an amount ranging from about30 mg to about 1000 mg, (e) said taurine is in an amount ranging fromabout 75 mg to about 3000 mg, (f) said folic acid is in an amountranging from about 0.03 mg to about 2 mg, and (g) said metformin is inan amount ranging from about 150 mg to about 3000 mg.
 59. A method fortreating a patient who requires biguanide therapy for the for theprevention, management, and clinical amelioration of insulin resistanceand type 2 diabetes and conditions giving rise thereto, to reduceundesirable physiological side effects, and enhance the therapeuticeffectiveness of said biguanide therapy by the preservation of plasmaand mitochondrial membrane integrity, said method comprisingadministering to said patient a unit dosage form comprising as activeingredients: (a) D,α-lipoic acid, (b) ubiquinone, (c) L-arginine, (d)N-acetyl-cysteine, (e) selenium, (f) a member selected from the groupconsisting of D,α-tocopherol and tocotrienol, (g) tetrahydrobiopterin,and (h) metformin.
 60. A method in accordance with claim 59 in whichsaid active ingredients are formulated as a substantially homogeneoustablet or capsule that releases all of said active ingredients into thestomach upon ingestion for contact with gastric fluid.
 61. A method inaccordance with claim 60 in which: (a) said D,α-lipoic acid is in anamount ranging from about 30 mg to about 1500mg, (b) said ubiquinone isin an amount ranging from about 4 mg to about 225 mg, (c) saidL-arginine is in an amount ranging from about 75 mg to about 3100 mg,(d) said N-acetyl-cysteine is in an amount ranging from about 80 mg toabout 3000 mg, (e) said selenium is in an amount ranging from about 0.02mg to about 0.75 mg, (f) said D,α-tocopherol or tocotrienol is in anamount ranging from about 15 mg to about 1600 mg, (g) saidtetrahydrobiopterin is in an amount ranging from about 24 mg to about3000 mg, and (h) said metformin is in an amount ranging from about 150mg to about 3000 mg.
 62. A method for treating a patient who requiresbiguanide therapy for the for the prevention, management, and clinicalamelioration of insulin resistance and type 2 diabetes and conditionsgiving rise thereto, to reduce undesirable physiological side effects,for the preservation and functional maintenance of insulin receptors andpancreatic β-cells, and to enhance the therapeutic effectiveness of saidbiguanide therapy, said method comprising administering to said patienta unit dosage form comprising as active ingredients: (a) chromium, (b)L-arginine, (c) vanadium, (d) zinc, and (e) metformin.
 63. A method inaccordance with claim 62 in which said active ingredients are formulatedas a substantially homogeneous tablet or capsule that releases all ofsaid active ingredients into the stomach upon ingestion for contact withgastric fluid.
 64. A method in accordance with claim 63 in which: (a)said chromium is in an amount ranging from about 0.01 mg to about 0.63mg, (b) said L-arginine is in an amount ranging from about 75 mg toabout 3100 mg, (c) said vanadium is in an amount ranging from about 7.5mg to about 375 mg, (d) said zinc is in an amount ranging from about 1.5mg to about 125 mg, and (e) said metformin is in an amount ranging fromabout 150 mg to about 3000 mg.
 65. A method for treating a patient whorequires nocturnal biguanide for the prevention, management and clinicalamelioration of insulin resistance and type 2 diabetes and conditionsgiving rise thereto, to reduce undesirable physiological side effects,and to enhance the therapeutic effectiveness of said biguanide therapy,said unit dosage form comprising as active ingredients: (a) melatonin,(b) L-carnitine, (c) ubiquinone, (d) L-arginine, (e) magnesium, (f)folic acid, and (g) metformin.
 66. A unit dosage form in accordance withclaim 65 in which said active ingredients are formulated as asubstantially homogeneous tablet or capsule that releases all of saidactive ingredients into the stomach upon ingestion for contact withgastric fluid.
 67. A unit dosage form in accordance with claim 66 inwhich: (a) said melatonin is in an amount ranging from about
 0. 15 mg toabout 7.5 mg, (b) said L-carnitine is in an amount ranging from about 90mg to about 2500 mg, (c) said ubiquinone is in an amount ranging fromabout 4.5 mg to about 225 mg, (d) said folic acid is in an amountranging from about 0.03 mg to about 2 mg, (e) said magnesium is in anamount ranging from about 30 mg to about 1000 mg, (f) said L-arginine isin an amount ranging from about 75 mg to about 3100 mg, and (g) saidmetformin is in an amount ranging from about 150 mg to about 3000 mg.68. A method in accordance with claim 56 in which said unit dosage formis a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate-Release Layer Sustained-Release Layer choline 100% ascorbate100% L-carnitine 40-60% balance magnesium 40-60% balance taurine 40-60%balance folic acid 100% metformin 40-60% balance


69. A method in accordance with claim 59 in which said unit dosage formis a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate-Release Layer Sustained-Release Layer D,α-lipoic acid 40-60%balance ubiquinone 100% L-arginine 40-60% balance N-acetyl-cysteine40-60% balance selenium 40-60% balance D,α-tocopherol 100%tetrahydrobiopterin 40-60% balance metformin 40-60% balance


70. A method in accordance with claim 62 in which said unit dosage formis a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate-Release Layer Sustained-Release Layer chromium 40-60% balanceL-arginine 40-60% balance vanadium 40-60% balance zinc 40%-60%  balancemetformin 40%-60%  balance


71. A method in accordance with claim 59 in which said α-lipoic acid isin the form of a member selected from the group consisting of anα-lipoic acid salt of a metal ion selected from the group consisting ofMg²⁺ and Zn²⁺, and a complex of α-lipoic acid, a metal ion selected fromthe group consisting of Mg²⁺ and Zn²⁺, and an anion selected from thegroup consisting of hydroxide, halide, acetate, and ascorbate.
 72. Amethod in accordance with claims 59, 62 or 65 in which said L-arginineis in the form of a member selected from the group consisting ofL-arginine ascorbate, bis-L-arginine ascorbate, L-arginine salt of ametal ion selected from the group consisting of Mg²⁺ and Zn²⁺,bis-L-arginine salt of a metal ion selected from the group consisting ofMg²⁺ and Zn²⁺, and a complex of L-arginine or bis-L-arginine, a metalion selected from the group consisting of Mg²⁺ and Zn²⁺, and an anionselected from the group consisting of hydroxide, halide, acetate, andascorbate.
 73. A method in, accordance with claims 56 or 65 in whichsaid L-carnitine is in the form of a member selected from the groupconsisting of L-carnitine ascorbate, bis-L-carnitine ascorbate,L-carnitine salt of a metal ion selected from the group consisting ofMg²+ and Zn²⁺, bis-L-carnitine salt of a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, and a complex of L-carnitine orbis-L-carnitine, a metal ion selected from the group consisting of Mg²⁺and Zn²⁺, and an anion selected from the group consisting of hydroxide,halide, acetate, and ascorbate.
 74. A method in accordance with claim 56in which said L-taurine is in the form of a member selected from thegroup consisting of L-taurine ascorbate, bis-L-taurine ascorbate,L-taurine salt of a metal ion selected from the group consisting of Mg²⁺and Zn²⁺, bis-L-taurine salt of a metal ion selected from the groupconsisting of Mg²⁺ and Zn²⁺, and a complex of L-taurine orbis-L-taurine, a metal ion selected from the group consisting of Mg²⁺and Zn²⁺, and an anion selected from the group consisting of hydroxide,halide, acetate, and ascorbate.
 75. A method in accordance with claims56 or 65 in which said magnesium is in the form of a member selectedfrom the group consisting of magnesium, magnesium L-arginate, magnesiumL-arginine ascorbate and bis-ascorbate, magnesium α-lipoate, magnesiumα-lipoate ascorbate and bis-ascorbate, magnesium taurate, magnesiumtaurine ascorbate and bis-ascorbate, magnesium L-acetylcysteine,magnesium L-carnitate, magnesium L-carnitine ascorbate andbis-ascorbate, magnesium ascorbate and magnesium bis-ascorbate.
 76. Amethod in accordance with claim 62 in which said zinc is in the form ofa member selected from the group consisting of zinc halide, zincsulfate, zinc L-carnitate, zinc L-carnitate ascorbate and bis-ascorbate,zinc taurate, zinc taurine ascorbate and bis-ascorbate, zinc L-arginate,zinc L-arginine ascorbate and bis-ascorbate, zinc L-carnitate, zincL-carnitine ascorbate and bis-ascorbate, zinc phosphate, zinc acetate,zinc ascorbate, and zinc bis-ascorbate.
 77. A method in accordance withclaim 62 in which said vanadium is in the form of a member selected fromthe group consisting of vanadate, peroxovanadate, vanadyl sulfate salts,and bis(maltolato)oxovanadium(IV).
 78. A method in accordance with claim59 in which said D,α-tocopherol is present in the form of a memberselected from the group consisting of D,α-tocopherol succinate,D,α-tocopherol nicotinate, D,α-tocopherol picolinate, D,α-tocopherolacetate, and tocotrienol.
 79. A method in accordance with claim 59 inwhich said tocotrienol is present in the form of a member selected fromthe group consisting of tocotrienol succinate, tocotrienol nicotinate,tocotrienol picolinate, and tocotrienol acetate.
 80. A method inaccordance with claim 62 in which said chromium is in the form of amember selected from the group consisting of chromium dinicotinate, andchromium tripicolinate.
 81. A method for treating a patient who requiressulfonylurea therapy for the prevention, management, and clinicalamelioration of insulin resistance and type 2 diabetes and conditionsgiving rise thereto, to reduce undesirable physiological side effects,and enhance the therapeutic effectiveness of said sulfonylurea therapyby supporting mitochondrial metabolism, said method comprisingadministering to said patient a unit dosage form comprising as activeingredients: (a) choline, (b) ascorbate (c) L-carnitine, (d) magnesium,(e) taurine, (f) folic acid, and (g) a sulfonylurea or asulfonylurea-like compound.
 82. A method in accordance with claim 81 inwhich said active ingredients are formulated as a substantiallyhomogeneous tablet or capsule that releases all of said activeingredients into the stomach upon ingestion for contact with gastricfluid.
 83. A method in accordance with claim 82 in which: (a) saidcholine is in an amount ranging from about 15 mg to about 250 mg, (b)said ascorbate is in an amount ranging from about 75 mg to about 2500mg, (c) said L-carnitine is in an amount ranging from about 90 mg toabout 2500 mg, (d) said magnesium is in an amount ranging from about 30mg to about 1000 mg, (e) said taurine is in an amount ranging from about75 mg to about 3000 mg, (f) said folic acid is in an amount ranging fromabout 0.03 mg to about 2 mg, and (g) said sulfonylurea or asulfonylurea-like compound is in an amount ranging from about 1 mg toabout 20 mg.
 84. A method for treating a patient who requiressulfonylurea therapy for the for the prevention, management, andclinical amelioration of insulin resistance and type 2 diabetes andconditions giving rise thereto, to reduce undesirable physiological sideeffects, and enhance the therapeutic effectiveness of said sulfonylureatherapy by the preservation of plasma and mitochondrial membraneintegrity, said method comprising administering to said patient a unitdosage form comprising as active ingredients: (a) D,α-lipoic acid, (b)ubiquinone, (c) L-arginine, (d) N-acetyl-cysteine, (e) selenium, (f) amember selected from the group consisting of D,α-tocopherol andtocotrienol, (g) tetrahydrobiopterin, and (h) a sulfonylurea orsulfonylurea-like compound.
 85. A method in accordance with claim 84 inwhich said active ingredients are formulated as a substantiallyhomogeneous tablet or capsule that releases all of said activeingredients into the stomach upon ingestion for contact with gastricfluid.
 86. A method in accordance with claim 85 in which: (a) saidD,α-lipoic acid is in an amount ranging from about 30 mg to about 1500mg, (b) said ubiquinone is in an amount ranging from about 4 mg to about225 mg, (c) said L-arginine is in an amount ranging from about 75 mg toabout 3100 mg, (d) said N-acetyl-cysteine is in an amount ranging fromabout 30 mg to about 1000 mg, (e) said selenium is in an amount rangingfrom about 80 mg to about 3900 mg, (f) said D,α-tocopherol ortocotrienol is in an amount ranging from about 0.02 mg to about 0.75 mg,(g) said tetrahydrobiopterin is in an amount ranging from about 24 mg toabout 3000 mg, and (h) said sulfonylurea or sulfonylurea-like compoundis in an amount ranging from about 1 mg to about 20 mg.
 87. A method fortreating a patient who requires sulfonylurea therapy for the for theprevention, management, and clinical amelioration of insulin resistanceand type 2 diabetes and conditions giving rise thereto, to reduceundesirable physiological side effects, and enhance the therapeuticeffectiveness of said sulfonylurea therapy by the preservation andfunctional maintenance of insulin receptors and pancreatic β-cells, saidmethod comprising administering to said patient a unit dosage formcomprising as active ingredients: (a) chromium, (b) L-arginine, (c)vanadium, (d) zinc, and (e) a sulfonylurea or a sulfonylurea-likecompound.
 88. A method in accordance with claim 87 in which said activeingredients are formulated as a substantially homogeneous tablet orcapsule that releases all of said active ingredients into the stomachupon ingestion for contact with gastric fluid.
 89. A method inaccordance with claim 88 in which: (a) said chromium is in an amountranging from about 0.01 mg to about 0.63 mg, (b) said L-arginine is inan amount ranging from about 75 mg to about 3100 mg, (c) said vanadiumis in an amount ranging from about 7.5 mg to about 375 mg, (d) said zincis in an amount ranging from about 1.5 mg to about 125 mg, and (e) saidsulfonylurea is in an amount ranging from about 1 mg to about 20 mg. 90.A method for treating a patient who requires sulfonylurea specificallyfor nocturnal use as a method for the prevention, management andclinical amelioration of insulin resistance and type 2 diabetes andconditions giving rise thereto, said unit dosage form comprising asactive ingredients: (a) melatonin, (b) L-carnitine, (c) ubiquinone, (d)folic acid, (e) magnesium, (f) L-arginine, and (g) a sulfonylurea orsulfonylurea-like compound.
 91. A method in accordance with claim 25 inwhich said active ingredients are formulated as a substantiallyhomogeneous tablet or capsule that releases all of said activeingredients into the stomach upon ingestion for contact with gastricfluid.
 92. A method in accordance with claim 26 in which: (a) saidmelatonin is in an amount ranging from about 0.15 mg to about 7.5 mg,(b) said L-carnitine is in an amount ranging from about 90 mg to about2500 mg, (c) said ubiquinone is in an amount ranging from about 4.5 mgto about 225 mg, (d) said folic acid is in an amount ranging from about0.03 mg to about 2 mg, (e) said magnesium is in an amount ranging fromabout 30 mg to about 1000 mg, (f) said L-arginine is in an amountranging from about 75 mg to about 3100 mg, and (g) said sulfonylurea orsulfonylurea-like compound is in an amount ranging from about 1 mg toabout 20 mg.
 93. A method in accordance with claim 81 in which said unitdosage form is a bilayer tablet comprising an immediate-release layerand a sustained-release layer, said active ingredients are distributedbetween said immediate-release layer and said sustained-release layer inthe following approximate proportions expressed as relative weightpercents: Immediate-Release Layer Sustained-Release Layer choline 100%ascorbate 100% L-carnitine 40-60% balance magnesium 40-60% balancetaurine 40-60% balance folic acid 100% sulfonylurea or 40-60% balancesulfonylurea-like compound


94. A method in accordance with claim 84 in which said unit dosage formis a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate-Release Layer Sustained-Release Layer D,α-lipoic acid 40-60%balance ubiquinone 100% L-arginine 40-60% balance N-acetyl-cysteine40-60% balance selenium 40-60% balance D,α-tocopherol 100%tetrahydrobiopterin 40-60% balance sulfonylurea or 40-60% balancesulfonylurea-like compound


95. A method in accordance with claim 87 in which said unit dosage formis a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate-Release Layer Sustained-Release Layer chromium 40-60% balanceL-arginine 40-60% balance vanadium 40-60% balance zinc 40%-60%  balancesulfonylurea or 40%-60%  balance sulfonylurea-like compound


96. A method in accordance with claim 87 in which said α-lipoic acid isin the form of a member selected from the group consisting of anα-lipoic acid salt of a metal ion selected from the group consisting ofMg²⁺ and Zn²⁺, and a complex of α-lipoic acid, a metal ion selected fromthe group consisting of Mg²⁺ and Zn²⁺, and an anion selected from thegroup consisting of hydroxide, halide, acetate, and ascorbate.
 97. Amethod in accordance with claims 84 or 87 in which said L-arginine is inthe form of a member selected from the group consisting of L-arginineascorbate, bis-L-arginine ascorbate, L-arginine salt of a metal ionselected from the group consisting of Mg²⁺ and Zn²⁺, bis-L-arginine saltof a metal ion selected from the group consisting of Mg²⁺ and Zn²⁺, anda complex of L-arginine or bis-L-arginine, a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 98. A method inaccordance with claims 81 or 90 in which said L-carnitine is in the formof a member selected from the group consisting of L-carnitine ascorbate,bis-L-carnitine ascorbate, L-carnitine salt of a metal ion selected fromthe group consisting of Mg²⁺ and Zn²⁺, bis-L-carnitine salt of a metalion selected from the group consisting of Mg²⁺ and Zn²⁺, and a complexof L-carnitine or bis-L-carnitine, a metal ion selected from the groupconsisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 99. A method inaccordance with claim 81 in which said L-taurine is in the form of amember selected from the group consisting of L-taurine ascorbate,bis-L-taurine ascorbate, L-taurine salt of a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, bis-L-taurine salt of a metal ionselected from the group consisting of Mg²⁺ and Zn²⁺, and a complex ofL-taurine or bis-L-taurine, a metal ion selected from the groupconsisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 100. A methodin accordance with claims 81 or 90 in which said magnesium is in theform of a member selected from the group consisting of magnesium,magnesium L-arginate, magnesium L-arginine ascorbate and bis-ascorbate,magnesium α-lipoate, magnesium α-lipoate ascorbate and bis-ascorbate,magnesium taurate, magnesium taurine ascorbate and bis-ascorbate,magnesium L-acetylcysteine, magnesium L-carnitate, magnesium L-carnitineascorbate and bis-ascorbate, magnesium ascorbate and magnesiumbis-ascorbate.
 101. A method in accordance with claim 87 in which saidzinc is in the form of a member selected from the group consisting ofzinc halide, zinc sulfate, zinc L-carnitate, zinc L-carnitate ascorbateand bis-ascorbate, zinc taurate, zinc taurine ascorbate andbis-ascorbate, zinc L-arginate, zinc L-arginine ascorbate andbis-ascorbate, zinc L-carnitate, zinc L-carnitine ascorbate andbis-ascorbate, zinc phosphate, zinc acetate, zinc ascorbate, and zincbis-ascorbate.
 102. A method in accordance with claim 87 in which saidvanadium is in the form of a member selected from the group consistingof vanadate, peroxovanadate, vanadyl sulfate salts, andbis(maltolato)oxovanadium(IV).
 103. A method in accordance with claim 84in which said D,α-tocopherol is present in the form of a member selectedfrom the group consisting of D,α-tocopherol succinate, D,α-tocopherolnicotinate, D,α-tocopherol picolinate, D,α-tocopherol acetate, andtocotrienol.
 104. A method in accordance with claim 84 in which saidtocotrienol is present in the form of a member selected from the groupconsisting of tocotrienol succinate, tocotrienol nicotinate, tocotrienolpicolinate, and tocotrienol acetate.
 105. A method in accordance withclaim 87 in which said chromium is in the form of a member selected fromthe group consisting of chromium dinicotinate, and chromiumtripicolinate.
 106. A method for treating a patient who requiressulfonylurea (or a sulfonylurea-like)-biguanide complex therapy for theprevention, management, and clinical amelioration of insulin resistanceand type 2 diabetes and conditions giving rise thereto, to reduceundesirable physiological side effects, and enhance the therapeuticeffectiveness of said combined sulfonylurea-biguanide therapy bysupporting mitochondrial metabolism, said method comprisingadministering to said patient a unit dosage form comprising as activeingredients: (a) choline, (b) ascorbate (c) L-carnitine, (d) magnesium,(e) taurine, (f) folic acid, and (g) a sulfonylurea (or asulfonylurea-like)-biguanide complex.
 107. A method in accordance withclaim 106 in which said active ingredients are formulated as asubstantially homogeneous tablet or capsule that releases all of saidactive ingredients into the stomach upon ingestion for contact withgastric fluid.
 108. A method in accordance with claim 107 in which: (a)said choline is in an amount ranging from about 15 mg to about 250 mg,(b) said ascorbate is in an amount ranging from about 75 mg to about2500 mg, (c) said L-carnitine is in an amount ranging from about 90 mgto about 2500 mg, (d) said magnesium is in an amount ranging from about30 mg to about 1000 mg, (e) said taurine is in an amount ranging fromabout 75 mg to about 3000 mg, (f) said folic acid is in an amountranging from about 0.03 mg to about 2 mg, (g) said sulfonylurea (or asulfonylurea-like)-biguanide complex with a sulfonylurea componentselected from the following group in an amount ranging in milligrams:(for first generation sulfonylureas) Acetohexamide from 150 to about1875, Chlorpropamide from 75 to about 938, Tolazamide from 75 to about1250, Tolbutamide from 300 to about 5000,

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanide component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


109. A method for treating a patient who requires sulfonylurea (or asulfonylurea-like)-biguanide complex therapy for the for the prevention,management, and clinical amelioration of insulin resistance and type 2diabetes and conditions giving rise thereto, to reduce undesirablephysiological side effects, and enhance the therapeutic effectiveness ofsaid combined sulfonylurea-biguanide therapy by the preservation ofplasma and mitochondrial membrane integrity, said method comprisingadministering to said patient a unit dosage form comprising as activeingredients: (a) D,α-lipoic acid, (b) ubiquinone, (c) L-arginine, (d)N-acetyl-cysteine, (e) selenium, (f) a member selected from the groupconsisting of D,α-tocopherol and tocotrienol, (g) tetrahydrobiopterin,and (h) a sulfonylurea (or a sulfonylurea-like)-biguanide complex. 110.A method in accordance with claim 109 in which said active ingredientsare formulated as a substantially homogeneous tablet or capsule thatreleases all of said active ingredients into the stomach upon ingestionfor contact with gastric fluid.
 111. A method in accordance with claim110 in which: (a) said D,α-lipoic acid is in an amount ranging fromabout 75 mg to about 2500 mg, (b) said ubiquinone is in an amountranging from about 0.03 mg to about 2 mg, (c) said L-arginine is in anamount ranging from about 75 mg to about 3100 mg, (d) saidN-acetyl-cysteine is in an amount ranging from about 30 mg to about 1000mg, (e) said selenium is in an amount ranging from about 80 mg to about3900 mg, (f) said a member selected from the group consisting ofD,α-tocopherol and tocotrienol is in an amount ranging from about 0.02mg to about 0.75 mg, (g) said tetrahydrobiopterin is in an amountranging from about 15 mg to about 1600 mg, (h) said sulfonylurea (orsulfonylurea-like)-biguanide complex with a sulfonylurea componentselected from the following group in an amount ranging in milligrams:(for first generation sulfonylureas) Acetohexamide from 150 to about1875, Chlorpropamide from 75 to about 938, Tolazamide from 75 to about1250, Tolbutamide from 300 to about 5000,

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanide component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


112. A method for treating a patient who requires sulfonylurea (or asulfonylurea-like)-biguanide complex therapy for the for the prevention,management, and clinical amelioration of insulin resistance and type 2diabetes and conditions giving rise thereto, to reduce undesirablephysiological side effects, and enhance the therapeutic effectiveness ofsaid combined sulfonylurea-biguanide therapy by the preservation andfunctional maintenance of insulin receptors and pancreatic β-cells, saidmethod comprising administering to said patient a unit dosage formcomprising as active ingredients: (a) chromium, (b) L-arginine, (c)vanadium, (d) zinc, and, (e) a sulfonylurea (orsulfonylurea-like)-biguanide complex.
 113. A method in accordance withclaim 112 in which said active ingredients are formulated as asubstantially homogeneous tablet or capsule that releases all of saidactive ingredients into the stomach upon ingestion for contact withgastric fluid.
 114. A method in accordance with claim 113 in which: (a)said chromium is in an amount ranging from about 0.01 mg to about 0.63mg, (b) said L-arginine is in an amount ranging from about 75 mg toabout 3100 mg, (c) said vanadium is in an amount ranging from about 7.5mg to about 375 mg, (d) said zinc is in an amount ranging from about 1.5mg to about 125 mg, (e) said sulfonylurea (orsulfonylurea-like)-biguanide complex with a sulfonylurea componentselected from the following group in an amount ranging in milligrams:(for first generation sulfonylureas) Acetohexamide from 150 to about1875, Chlorpropamide from 75 to about 938, Tolazamide from 75 to about1250, Tolbutamide from 300 to about 5000,

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanidi component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


115. A method for treating a patient who requires sulfonylurea-(orsulfonylurea-like)-biguanide complex specifically for nocturnal use as amethod for the prevention, management and clinical amelioration ofinsulin resistance and type 2 diabetes and conditions giving risethereto, said unit dosage form comprising as active ingredients: (a)melatonin, (b) L-carnitine, (c) ubiquinone, (d) folic acid, (e)magnesium, (f) L-arginine, and (g) a sulfonylurea (or asulfonylurea-like)-biguanide complex.
 116. A unit dosage form inaccordance with claim 115 in which said active ingredients areformulated as a substantially homogeneous tablet or capsule thatreleases all of said active ingredients into the stomach upon ingestionfor contact with gastric fluid.
 117. A method in accordance with claim116 in which: (a) said melatonin is in an amount ranging from about 0.15mg to about 7.5 mg, (b) said L-carnitine is in an amount ranging fromabout 90 mg to about 2500 mg, (c) said ubiquinone is in an amountranging from about 4.5 mg to about 225 mg, (d) said folic acid is in anamount ranging from about 0.03 mg to about 2 mg, (e) said magnesium isin an amount ranging from about 30 mg to about 1000 mg, (f) saidL-arginine is in an amount ranging from about 75 mg to about 3100 mg,(g) said sulfonylurea (or sulfonylurea-like)-biguanide complex with asulfonylurea component selected from the following group in an amountranging in milligrams: (for first generation sulfonylureas)Acetohexamide from 150 to about 1875, Chlorpropamide from 75 to about938, Tolazamide from 75 to about 1250, Tolbutamide from 300 to about5000.

(for second generation sulfonylureas) Glimepiride from 0.3 to about 20,Glipizide from 1.5 to about 50, Glyburide from 0.45 to about 30,

(for sulfonylurea-like oral hypoglycemic agents) Repaglinide from 0.45to about 30,

and for the biguanide component, metformin, ranging in milligrams,Metformin from 150 to about
 3750.


118. A method in accordance with claim 106 in which said unit dosageform is a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate- Sustained- Release Layer Release Layer choline  100%ascorbate  100% L-carnitine 40-60% balance magnesium 40-60% balancetaurine 40-60% balance folic acid  100% sulfonylurea-biguanide 40-60%balance


119. A method in accordance with claim 109 in which said unit dosageform is a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate- Sustained- Release Layer Release Layer D,α-lipoic acid 40-60%balance ubiquinone  100% L-arginine 40-60% balance N-acetyl-cysteine40-60% balance selenium 40-60% balance D,α-tocopherol  100%tetrahydrobiopterin 40-60% balance sulfonylurea-biguanide 40-60% balance


120. A method in accordance with claim 112 in which said unit dosageform is a bilayer tablet comprising an immediate-release layer and asustained-release layer, said active ingredients are distributed betweensaid immediate-release layer and said sustained-release layer in thefollowing approximate proportions expressed as relative weight percents:Immediate- Sustained- Release Layer Release Layer chromium    40-60%balance L-arginine    40-60% balance vanadium    40-60% balance zinc40%-60% balance sulfonylurea-biguanide 40%-60% balance


121. A method in accordance with claim 109 in which said α-lipoic acidis in the form of a member selected from the group consisting of anα-lipoic acid salt of a metal ion selected from the group consisting ofMg²⁺ and Zn²⁺, and a complex of α-lipoic acid, a metal ion selected fromthe group consisting of Mg²⁺ and Zn²⁺, and an anion selected from thegroup consisting of hydroxide, halide, acetate, and ascorbate.
 122. Amethod in accordance with claims 109 or 112 in which said L-arginine isin the form of a member selected from the group consisting of L-arginineascorbate, bis-L-arginine ascorbate, L-arginine salt of a metal ionselected from the group consisting of Mg²⁺ and Zn²⁺, bis-L-arginine saltof a metal ion selected from the group consisting of Mg²⁺ and Zn²⁺, anda complex of L-arginine or bis-L-arginine, a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 123. A methodin accordance with claim 106 in which said L-carnitine is in the form ofa member selected from the group consisting of L-carnitine ascorbate,bis-L-carnitine ascorbate, L-carnitine salt of a metal ion selected fromthe group consisting of Mg²⁺ and Zn²⁺, bis-L-carnitine salt of a metalion selected from the group consisting of Mg²⁺ and Zn²⁺, and a complexof L-carnitine or bis-L-carnitine, a metal ion selected from the groupconsisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 124. A methodin accordance with claim 106 in which said L-taurine is in the form of amember selected from the group consisting of L-taurine ascorbate,bis-L-taurine ascorbate, L-taurine salt of a metal ion selected from thegroup consisting of Mg²⁺ and Zn²⁺, bis-L-taurine salt of a metal ionselected from the group consisting of Mg²⁺ and Zn²⁺, and a complex ofL-taurine or bis-L-taurine, a metal ion selected from the groupconsisting of Mg²⁺ and Zn²⁺, and an anion selected from the groupconsisting of hydroxide, halide, acetate, and ascorbate.
 125. A methodin accordance with claim 106 in which said magnesium is in the form of amember selected from the group consisting of magnesium, magnesiumL-arginate, magnesium L-arginine ascorbate and bis-ascorbate, magnesiumα-lipoate, magnesium α-lipoate ascorbate and bis-ascorbate, magnesiumtaurate, magnesium taurine ascorbate and bis-ascorbate, magnesiumL-acetylcysteine, magnesium L-carnitate, magnesium L-carnitine ascorbateand bis-ascorbate, magnesium ascorbate and magnesium bis-ascorbate. 126.A method in accordance with claim 112 in which said zinc is in the formof a member selected from the group consisting of zinc halide, zincsulfate, zinc L-carnitate, zinc L-carnitate ascorbate and bis-ascorbate,zinc taurate, zinc taurine ascorbate and bis-ascorbate, zinc L-arginate,zinc L-arginine ascorbate and bis-ascorbate, zinc L-carnitate, zincL-carnitine ascorbate and bis-ascorbate, zinc phosphate, zinc acetate,zinc ascorbate, and zinc bis-ascorbate.
 127. A method in accordance withclaim 112 in which said vanadium is in the form of a member selectedfrom the group consisting of vanadate, peroxovanadate, vanadyl sulfatesalts, and bis(maltolato)oxovanadium(IV).
 128. A method in accordancewith claim 109 in which said D,α-tocopherol is present in the form of amember selected from the group consisting of D,α-tocopherol succinate,D,α-tocopherol nicotinate, D,α-tocopherol picolinate, D,α-tocopherolacetate, and tocotrienol.
 129. A method in accordance with claim 109 inwhich said tocotrienol is present in the form of a member selected fromthe group consisting of tocotrienol succinate, tocotrienol nicotinate,tocotrienol picolinate, and tocotrienol acetate.
 130. A method inaccordance with claim 112 in which said chromium is in the form of amember selected from the group consisting of chromium dinicotinate, andchromium tripicolinate.